




NJ Department of Environmental Protection
Division of Water Monitoring and Standards
Bureau of Freshwater & Biological Monitoring

2021 Cyanobacterial Harmful Algal Bloom (HAB) Freshwater Recreational Response Strategy



April, 2021

Amended February 2022

ACKNOWLEDGEMENTS

The New Jersey Department of Environmental Protection (DEP) wishes to acknowledge the input of the members of the interagency Harmful Algal Bloom (HAB) Workgroup in the development of this Strategy (a listing of the members can be found in Appendix A). Workgroup members represent the following agencies/programs: DEP – Division of Water Monitoring and Standards - Bureau of Freshwater & Biological Monitoring, Bureau of Marine Water Monitoring, Bureau of Environmental Analysis, Restoration and Standards and Director's Office, Water Resource Management Assistant Commissioner's Office, Division of Science and Research, Division of Water Supply and Geoscience, State Park Service, Division of Fish & Wildlife, Office of Quality Assurance, and Water Compliance and Enforcement; New Jersey Department of Health (DOH) – Division of Epidemiology, Environmental and Occupational Health/Consumer, Environmental and Occupational Health Service, and Communicable Disease Service; New Jersey Department of Agriculture - Division of Animal Health.

Contributors to the development of this document include: Victor Poretti (lead), Leslie McGeorge, Tom Miller, Dean Bryson, Alena Baldwin-Brown, Jodie Battaglia, Gloria Post, Rob Newby, Brian Pachkowski, Leigh Lager, Robert Schuster, Chelsea Brook, Kelley Meccia. The authors wish to thank Katrina Angarone, Michele Putnam, Patricia Gardner, Bruce Friedman and Gary Buchanan for their reviews and support in the development of this Strategy.

If there are any questions or comments on the HAB Strategy, please provide them to:
njcyanoabs@dep.nj.gov.

TABLE OF CONTENTS

	Page
1. PURPOSE AND SCOPE.....	5
A. Agency Responsibilities	
2. BACKGROUND.....	13
A. Cyanobacteria	
B. Cyanobacterial Blooms and Toxins	
3. HUMAN HEALTH RECREATIONAL RISK THRESHOLDS.....	14
A. Human and Animal Exposure and Treatment - Cyanobacteria and Toxins	
B. Cyanobacteria and Cyanotoxin Risk Thresholds for Recreational Waters	
C. Recommended Action Levels and Health Advisory Guidance Levels	
4. INVESTIGATION & RESPONSE TO HARMFUL ALGAL BLOOMS IN RECREATIONAL WATERS.....	22
A. Initial HAB Report	
B. Screening	
i. Cyanobacteria Presence and Field Measurements	
ii. Visual Assessment	
iii. Remote Sensing – Satellite, Aircraft and Unmanned Aerial Vehicles	
iv. Continuous Data Monitoring Program	
v. Toxin Presence	
C. Confirmation Analysis	
i. Toxin Analysis Methods	
ii. Chlorophyll ‘a’ and Cell Counts	
D. Response/ Actions Flow Diagram	
E. Communication/ Continued Monitoring	
5. HARMFUL ALGAL BLOOM ADVISORIES.....	32
6. RESEARCH STRATEGY.....	37
7. OUTREACH AND COMMUNICATION.....	38
8. REFERENCES.....	39

Tables

Table 1. Primary Cyanotoxins and their Associated Human Health Effects.....	16
Table 2. Alert Level Summary.....	34

TABLE OF CONTENTS continued

Figures

Figure 1. Example of HAB in a Lake.	13
Figure 2. <i>Dolichospermum</i> sp. cells.....	14
Figure 3. Cyanobacteria Bloom Cell Count and Microcystins Ranges.	19
Figure 4. Linear Regression of Log of Cell Counts versus Log of Microcystin Toxin Concentration in 2017-2020 data.....	20
Figure 5. Quick Reporting Guide.....	23
Figure 6. Automated Plate Reader Used for ELISA.	28
Figure 7. Response Summary.....	30
 APPENDIX A – Interagency HAB Workgroup Members/ Contact Information.....	40
APPENDIX B – HAB Sample Collection Method for DEP BFBM HAB Laboratory.....	45
APPENDIX C – Cyanotoxin Analysis Methods and Specifications.....	47
APPENDIX D - World Health Organization (WHO) and USEPA Recreational HAB Guidance.....	58
 APPENDIX E- Basis for Health Advisory Guidelines.....	59
1. Summary of Updated Exposure Assumptions used in Cyanotoxin Recreational Advisories in New Jersey(microcystins, cylindrospermopsis, anatoxin).....	60
2. Basis for NJDEP Recreational Advisory for Saxitoxin).....	61
3. Background Information on Microcystin “Warning” and “Danger” Threshold Values.....	91

Acronym List

ADDA - cyclic heptapeptide structure of the general composition cyclo(-D-Ala-L-X-D-erythro- β -methylisoAsp-L-Y-Adda-D-iso-Glu-N-methyldehydroAla), where ADDA is the unusual C20 aa 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid and X and Y are variable L-aa.

BFBM - DEP Bureau of Freshwater and Biological Monitoring

CDC - Center for Disease Control, United States Department of Health and Human Services

CDS - DOH Communicable Disease Service

CEHA - DEP County Environmental Health Act program

CEOHS - DOH Consumer, Environmental and Occupational Health Service

DEP – New Jersey Department of Environmental Protection

DoA - New Jersey Department of Agriculture

DOH – New Jersey Department of Health

DSR - DEP Division of Science and Research

DWMS - DEP Division of Water Monitoring and Standards

DWSG -DEP Division of Water Supply and Geoscience

EOH - DOH Environmental and Occupational Health

ELISA - Enzyme-Linked Immuno-Sorbent Assay

HAB - Harmful Algal Bloom

LC-ESI/MS/MS - Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry

LC/MS/MS - Liquid Chromatography/Tandem Mass Spectrometry

LHA - Local Health Authorities

NLA - National Lakes Assessment, USEPA

OHHABS - CDC One Health Harmful Algal Bloom System

qPCR - quantitative Polymerase Chain Reaction

PRB – Public Recreational Bathing facility

UAV – Unmanned Aerial Vehicle

UCMR - Unregulated Contaminant Monitoring Rule, USEPA

USEPA - United States Environmental Protection Agency

USGS - United States Geological Survey

WHO - World Health Organization

WMA - Wildlife Management Area

WRM - DEP Water Resource Management

1. PURPOSE AND SCOPE

The purpose of the New Jersey Cyanobacterial Harmful Algal Bloom (HAB)* Response Strategy (Response Strategy) is to provide a unified statewide approach to respond to cyanobacterial HABs in freshwater recreational waters and sources of drinking water, and to protect the public from risks associated with exposure to cyanobacteria and related toxins. Although the primary focus of the Response Strategy is the protection of human health, it provides some information and recommendations regarding exposure and prevention of potential impacts to domestic animals (pets), livestock, and wildlife, as well. The Response Strategy is designed to identify:

- Entities responsible for response and actions
- Recreational risk thresholds and appropriate responses to protect public health and safety
- Acceptable parameters and methods for assessing risk
- Appropriate monitoring and analysis to identify cyanobacteria, enumerate cells and determine concentrations of cyanotoxins, and
- HAB Alert Levels, recommended advisory language and other related communication mechanisms.

The scope of the Response Strategy is for freshwater lakes, ponds, rivers and streams with potential public access, recreational use, public recreational bathing facilities as defined in N.J.A.C. 8:26, and sources of drinking water. These waterbodies may be owned or operated by state, county, municipal, federal or private entities. As such, coordination of the investigation and response activities will vary depending on ownership.

Direct drinking water related HAB concerns are addressed by the Department of Environmental Protection's (DEP's) Division of Water Supply & Geoscience (DWSG). The DWSG has an emergency protocol in place for responding to and handling HAB/cyanotoxin events that affect a drinking water source. The protocol outlines the communication during a HAB/cyanotoxin event, including the coordination between the Division of Water Monitoring and Standards (DWMS), the Division of Water Supply and Geoscience (DWSG), and the public water system(s). Internal email notifications are sent during all stages of the incident to provide details and keep all relevant staff updated on the incident. Additional parties included on these emails includes NJDEP OEM and Enforcement, and outside State agencies such as the New Jersey Department of Health, Board of Public Utilities, New Jersey Water Supply Authority, and New Jersey Department of Community Affairs, if appropriate.

The DWSG also focuses on working with water systems to be better prepared for HAB/cyanotoxin events. This includes providing guidance on how best to prevent, mitigate, and treat HABs/cyanotoxins as well as having public water systems who are at risk for HABs plan for such events as part of their Cyanotoxin Management Plan. For more information on drinking water and HABs, see the DWSG website: <http://www.nj.gov/dep/watersupply/>.

New Jersey released its first Response Strategy in 2017 and since then has continued to enhance all aspects of its approaches including, response monitoring, testing, notification methods and research. HAB events from 2017-2020 are described at <https://www.state.nj.us/dep/wms/bfbm/CyanoHABHome.html>. In

November of 2019, Governor Phil Murphy announced a Harmful Algal Blooms (HABs) Initiative to comprehensively address these blooms in the State. The Initiative has three main components: to reduce and prevent future harmful algal blooms; to enhance HAB science, and build monitoring, testing and data management response capacity; and to improve communication, including HAB website enhancements and interactive mapping and reporting. Details of this Initiative can be found at:

https://www.state.nj.us/dep/hab/docs/HABs_factsheet_11.14.19rev2.pdf

* For this Response Strategy document, a HAB refers to a cyanobacterial Harmful Algal Bloom.

A. Agency Responsibilities

An interagency HAB Workgroup was formed in 2016, consisting of representatives from the DEP, the New Jersey Department of Health (DOH), and the New Jersey Department of Agriculture (DoA) to discuss and collaborate on HAB issues, including: Response Strategy development, monitoring, laboratory analysis, risk thresholds, advisories, research and communication. Following development and release of the initial version of this Response Strategy in 2017, the Workgroup has met periodically after each HAB season to enhance the Response Strategy based on New Jersey's experience responding to HABs, the State's HAB and water quality data, updated information on HAB science, evaluation of other States' HAB strategies, available federal guidance, and New Jersey HAB partner input. Appendix A contains a list of the members of the Workgroup and their contact information and provides a link to local/county Health Department emergency contact information for this Response Strategy.

The following are the responsibilities of each state agency tasked with contributing to this Response Strategy.

NJ Department of Environmental Protection (DEP)

Division of Water Monitoring and Standards, Bureau of Freshwater and Biological Monitoring, and Director's Office (DWMS/BFBM)

- Develop, maintain and enhance monitoring and analysis capacity for cyanobacteria/cyanotoxins.
- Perform surveillance and screening for freshwater HABs including field sampling, monitoring, and reconnaissance work on lakes, rivers and streams as required.
- Oversee HAB information dissemination on DWMS/BFBM website <https://www.state.nj.us/dep/wms/bfbm/CyanoHABHome.html>, including HAB events and data. Develop and maintain HAB Interactive Mapping and Communication System.
- Provide content for HAB information dissemination and outreach, including production and maintenance of general HAB information, outreach materials and fact sheets on DWMS/BFBM website. Work in cooperation with DWMS Director's Office to provide content for DEP general HAB website <https://www.state.nj.us/dep/hab/>
- Work with other divisions and programs throughout DEP to maintain DEP general HAB website.
- Coordinate with DEP State Park Service, DEP Division of Fish and Wildlife and NJ Department of Health regarding outreach material development and dissemination.
- Notify New York State Department of Environmental Conservation/ Division of Water regarding HABs occurring in waterbodies that span the NY/NJ boarder including, Greenwood Lake, West Milford, Passaic Co.; Lake Tappan (reservoir), River Vale & Old Tappan, Bergen Co.; Potake Pond, Ringwood Boro, Passaic Co.; Ramapo R., Mahwah Twp, Bergen Co., Mahwah R., Mahwah Twp, Bergen Co.; Wallkill R., Wantage Twp., Sussex Co.)

- Coordinate exchange of data and advisory communication with New York State Department of Environmental Conservation/ Division of Water.
- Develop and maintain HAB reporting procedures. Collect and review reports following submissions and determine who should be contacted for follow-up.
- Upon notification of a suspected HAB incident (Algal Bloom), DEP's BFBM will serve as the lead to investigate and coordinate responses consistent with Section 4 of this document, as applicable to the event. Primary activities include completing the initial incident report, performing field activities involving visual assessment and field screening (cyanobacteria and toxin presence), conducting laboratory analysis, and coordinating appropriate response activities.
- Investigation and analysis will be designed to quantify cyanobacteria levels above a cell count of 20,000 cells/ml and toxins above NJ Guidance Levels.
- Coordinate additional field surveillance and monitoring at Public Recreational Bathing facilities (PRB) when Alert level is reached upon a cell count of 40,000 – 80,000 cells/ml.
- Monitor and analyze suspected and confirmed blooms. Depending on waterbody jurisdiction and use, may include direct monitoring and analysis by BFBM and/or coordination and guidance for partner surveillance and monitoring and, on occasion, analysis of blooms.
- Coordinate implementation of Response Strategy with other New Jersey State, local and federal agencies.
- Coordinate investigation and response with appropriate partners. Internal DEP partners include the program areas of Division of Fish and Wildlife, State Parks Service, Water Compliance & Enforcement, Water Supply & Geoscience, and external partners such as county and/or local health and parks departments.
- Develop and maintain Standard Operating Procedures (SOPs) for performing field screening measurements, sampling, and laboratory analyses for HAB response. Develop training for others to use SOPs.
- Coordinate with New Jersey DOH for information dissemination and outreach to local health departments and the public regarding the potential effects of HABs.
- Coordinate with DEP's Communication Center to forward reports of suspected HAB incidents the Center receives to the BFBM.
- Provide analysis results to partners with advisory recommendations based on established New Jersey Health Advisory Guidance Levels, Alert tiers and recreational use.
- Provide analysis results and advisory recommendations to DOH and local health agencies related to Public Recreational Bathing (PRB) facilities to inform DOH and local health agencies of Alert Level actions at PRBs.
- With DEP Division of Science and Research, co-chair HAB Research Committee. Report on recommendations of the Committee, provide guidance and participate in research efforts to meet HAB information needs.
- With DEP Office of Information Technology and other DEP programs, participate in the HAB Detection and Monitoring – Unmanned Aerial Vehicle (UAV) Operations Committee and make recommendations for UAV use in HAB response. Explore uses of BFBM's current and future UAVs in screening for HABs.
- Provide training in proper sample collection and phycocyanin field meter use to partners as needed.

DEP State Park Service

- Provide general HAB outreach materials such as posters and pamphlets to Park users.
- Provide assistance in conducting HAB field surveillance, field screening and sample collection to support HAB response at State Park Lakes.
- Visually monitor State Park waterbodies for HAB development. Physically monitor HABs using equipment such as test strips and phycocyanin field meters when such equipment and training is provided.
- Contact BFBM and DOH when suspected HABs are observed at a public recreational bathing facility (PRB), or in other recreational areas, for sample collection and analysis.
- Post advisories at State Park lakes using guidelines in this document (Section 5). Also, include posts on Parks Facebook page and website.
- After initial response and issuance of advisory, it is the responsibility of State Parks Service to communicate any change in status to BFBM and DOH throughout the HAB event, until the advisory is lifted. Provide outreach to the public about HABs.
- Coordinate with BFBM and DOH on additional field surveillance and monitoring at Public Recreational Bathing facilities when Alert level is reached upon a cell count of 40,000 – 80,000 cells/ml.
- Contribute to the management of State Park lakes for the prevention of HABs. Prepare and implement Lakes Management Plans to minimize HABs.

DEP Division of Science and Research (DSR)

- Provide HAB scientific and technical support concerning human health exposure and impacts.
- Provide scientific support in cyanobacterial identification and enumeration, and toxin analysis.
- Provide technical consultation regarding bloom response.
- Provide scientific basis for revisions of guidelines/thresholds for cyanobacteria and related toxins for recreational risk using the best available science.
- With BFBM and the Research Committee of the HAB Workgroup, research new developments in HAB monitoring, analysis, prediction, treatment and impacts.
- With BFBM, co-chair HAB Research Committee. Report recommendations of Committee and provide guidance.

DEP Division of Water Supply and Geoscience (DWSG)

- Focus on prevention, response, treatment, and follow-up of drinking water contamination as it applies to cyanobacterial HABs and toxins through the development of guidance documents taking into consideration input from surface water stakeholders. Manage water system Cyanotoxin Management Plans which address the key areas of planning, response, and continuity of operations to ensure each water system's ability to handle HAB incidents.
- Coordinate with DWMS/BFBM regarding source water HABs, including reservoirs used for both drinking water and recreational activities. Provide DWMS/BFBM with information on whether source waters are being used for water supply at time of HAB event, and if so, identify if the water body is a direct or indirect source of drinking water.
- Largely external to this Recreational Response Strategy, coordinate appropriate response to HAB events with impacted drinking water system(s), including but not limited to:
 - Discuss with the system the potential for impact based on the location of the bloom in relation to the surface water intake.
 - Timely and appropriate communication of submitted water system cyanotoxin sampling results with relevant agencies.
 - Suggest appropriate alteration(s) of treatment techniques to water systems to effectively inactivate or remove potential cyanotoxins from entering the finished water.
 - Assist with identification and/or approval to use an alternate supply, where feasible.
 - Interact with and report to appropriate emergency response officials as set forth in an incident command structure.
 - If necessary, assistance in preparation of applicable public notification.
- Provide periodic updates on regulatory water system cyanotoxin monitoring data (i.e., Unregulated Contaminant Monitoring Rule 4) at interagency HAB Workgroup meetings.

DEP Division of Fish and Wildlife

- Provide general HAB outreach materials such as posters and pamphlets to fishing community and Wildlife Management Area (WMA) visitors.
- Visually monitor waterbodies during scheduled field sampling activities for suspected HAB development. Contact BFBM when blooms are sighted for sample collection and analysis.
- Post advisories at Wildlife Management Area (WMA) lakes using guidelines in this document (Section 5). Also, include posts on Fish and Wildlife Facebook page and website.
- After initial response and issuance of advisory, communicate any change in status to BFBM throughout the HAB event, until the advisory is lifted.
- Request, as needed, BFBM's assistance with HAB monitoring of fish stocked waterbodies.
- Provide a link to the CyanoHAB Events website (<https://www.state.nj.us/dep/wms/bfbm/cyanoHABevents.html>) on an appropriate DFW web page to provide the fishing public current status of HAB events on NJ waterbodies.
- Report fish kills to BFBM prior to, during or shortly after known HAB events which may be potentially linked to these events.
- When requested, DFW will perform necropsy and/or submit liver tissue samples from fish and wildlife cases with suspected mortality from HABs to an appropriate lab for confirmation of tissue toxins.
- Contribute to the management of WMA lakes for the prevention of HABs and prepare and implement Lakes Management Plans to minimize HABs.

DEP Compliance and Enforcement/ Division of Water and Land Use Enforcement

- Provide assistance in conducting HAB field surveillance, field screening and sample collection to support HAB response.
- With DEP Office of Information Technology, participate in the HAB Detection and Monitoring - UAV Drone Operations Committee and make recommendation for UAV use in HAB response. Provide assistance as needed to BFBM in UAV field applications for HAB screening.

DEP Emergency Management Program

- Maintain the functionality of the DEP Hotline/Communication Center to gather and share incident reports involving a suspected HABs in freshwater.
- Assist with incident management as needed.

New Jersey Department of Health (DOH)

Division of Epidemiology, Environmental and Occupational Health- Consumer, Environmental and Occupational Health Service (CEOHS)

- Enforce DOH regulation, New Jersey State Sanitary Code Chapter IX Public Recreational Bathing N.J.A.C. 8:26.
- Advise and make appropriate recommendations regarding inspected or permitted freshwater, public recreational bathing facilities (PRBs), including New Jersey State Park bathing facilities.
- Maintain and provide to DEP (for response and reporting purposes) a list of all State licensed freshwater PRBs with waterbody names, locations (coordinates, municipalities and counties) and local health department emergency contact information.
- Work with DEP to develop a PRB Notification System that, for the first time, will include freshwater beaches Offer technical assistance and consult with DEP regarding HAB human health-related concerns in freshwaters regardless of bathing designation.
- Coordinate with, and inform, local health departments regarding appropriate response and advisories - Local health authorities license and/or inspect PRBs within their jurisdictions.
- Notify local health authorities of required actions to be taken at PRBs when HAB Notice or Advisories/Beach Closures are warranted.
- Confirm advisories have been issued.
- Coordinate additional field surveillance and monitoring at Public Recreational Bathing, when Alert level is reached at a cell count of 40,000 – 80,000 cells/ml, with BFBM and local health authorities.
- Contribute to development of HAB Alert Levels in consultation with DEP.
- Provide information to the public regarding HAB awareness, including use of DOH websites.
- Provide outreach to the public about the health effects of HABs, in conjunction with DEP, including assistance with distribution of HABs-related outreach materials
https://www.state.nj.us/health/ceohs/documents/phss/hab_resource_list.pdf

Communicable Disease Service (CDS)

- Review and monitor human illness reports to determine if illnesses may be associated with HAB exposure.
- Public Health Veterinarian to review pet (e.g., dog) illness reports to determine if symptoms consistent with exposure to HABs or confirmed to be associated with HAB exposure.
- Maintain the Waterborne Illness webpage: <https://www.nj.gov/health/cd/>, that features HAB-related information and awareness material for the public.
- Provide outreach to the public about the health effects of HABs, in conjunction with DEP, including assistance with distribution of HABs-related outreach materials.

Local Health Authorities (LHA)

- Conduct inspections of PRB's where a suspected HAB has been identified and/or confirmed.
- Enforce DOH regulation, New Jersey State Sanitary Code Chapter IX Public Recreational Bathing N.J.A.C. 8:26.
- Provide confirmation of advisory posting or other actions taken for any PRB which was closed to recreational bathing to CEHOS at prb@doh.nj.gov.
- Coordinate with BFBM and DOH additional field surveillance and monitoring at Public Recreational Bathing facilities when Alert level is reached at a cell count of 40,000 – 80,000 cells/ml.
- Provide information to the public regarding HAB awareness.
- Provide outreach to the public about the health effects of HABs, in conjunction with DEP and DOH including assistance with distribution of HABs-related outreach materials.

New Jersey Department of Agriculture

Division of Animal Health/ New Jersey Animal Emergency Response

- Review and monitor livestock illness reports to determine if illnesses may be associated with HAB exposure.
- Receive and review notifications by DEP of HAB occurrences in waterbodies that may affect livestock.
- Notify BFBM of any reports of potential livestock illnesses which may be related to HABs received by Dept. of Agriculture.
- Notify and issue advisories to livestock owners as appropriate to protect livestock health.
- After initial response and issuing of an advisory, communicate status to livestock owners until the advisory is lifted.

2. BACKGROUND

A. Cyanobacteria

Cyanobacteria are a type of bacteria capable of photosynthesis. Although they are not true algae, they were often referred to as “blue-green algae” in the past. Cyanobacteria can discolor the waters and frequently impart off-tastes and odors to the water in which they grow. Some species can produce toxins (known as cyanotoxins) that can be harmful to the health of humans and animals. Although problems related to cyanobacteria most often occur in freshwaters (lakes and streams), cyanobacteria can also be found in coastal waters.

A cyanobacterial Harmful Algal Bloom (HAB) is the name given to the excessive growth, or “bloom” of cyanobacteria, some of which can produce one or more types of potentially harmful toxins (cyanotoxins). DEP defines a HAB as a density of identified cyanobacterial cells of 20,000 cells/ml or higher. HABs often occur under suitable environmental conditions of light, temperature, nutrient enrichment, and calm water. These blooms can result in a thick coating or mat on the surface of a waterbody, frequently in summer or fall, but blooms can occur year-round. A general overview fact sheet about Cyanobacterial Harmful Algal Blooms (HABs) and a technical fact sheet related to recreational exposure and health effects are available at: <https://www.state.nj.us/dep/hab/outreach-material.html>.

B. Cyanobacterial Blooms and Toxins

Cyanobacterial blooms may vary in species composition, residence time, the cyanotoxins they produce, and the associated risk to human health, pets, livestock and wildlife. The distribution and concentration of blooms may be affected by weather and lake conditions such as rain, wind, and currents. Distributions of HABs can be waterbody-wide, or localized near the shoreline, shallows or areas affected by flows or the influx of nutrients.

Cyanobacteria may maintain a position at a particular depth or may be found throughout the water column where light penetrates (e.g. *Planktothrix*, *Cylindospermopsis*). Some cyanobacteria may migrate vertically to different locations in the photic zone (where light penetrates) throughout the day. Surface accumulations (scum) may develop when cyanobacteria float to the surface during calm, sunny weather and may dissipate within hours as conditions change. Entire cyanobacteria populations may accumulate at 1 or 2 cm below the water surface. Surface accumulations of cyanobacteria may concentrate further when blown by wind to leeward areas like bays, inlets, or near-shore areas (with the direction of the wind). Dense accumulations may extend from the surface to depths of more than one meter.




Figure 1. Example of HAB in a Lake.

3. HUMAN HEALTH RECREATIONAL RISK THRESHOLDS

A. Human Health Impacts from Exposure to Cyanobacteria and Toxins

Exposures to cyanobacteria and cyanotoxins during recreational activities may potentially occur through oral ingestion (swallowing), skin absorption, and inhalation. Oral exposure may occur from accidental or deliberate ingestion of water. Dermal exposure occurs by direct contact of exposed parts of the body during recreational activity in water containing cyanobacteria. Inhalation may occur through the inhalation of contaminated aerosols while recreating. However, such inhalation exposure is much lower than ingestion exposure that can occur from immersion during recreational activities, such as swimming.

Adverse health effects from recreational exposure to cyanobacterial cells and cyanotoxins can range from a mild skin rash to serious illness. Acute illnesses caused by exposure to cyanotoxins have been reported, and exposure to very high levels of toxins is potentially fatal.

Allergic-like reactions (e.g., rhinitis, asthma, eczema, and conjunctivitis), flu-like symptoms, gastroenteritis, respiratory irritation, skin rashes, and eye irritation can occur through primary recreational exposure to cyanobacterial cells. These effects are caused by components of the cells that are present regardless of whether the cells are producing cyanotoxins. Allergic or irritative skin reactions of varying severity have been reported from recreational exposures where the presence of freshwater cyanobacteria, such as *Dolichospermum* (Figure 2), *Aphanizomenon*, *Nodularia*, and *Oscillatoria* endotoxins have been confirmed. Skin and eye irritation, from exposure during swimming, have been related to the cyanobacterial cells and dermal toxins produced by cyanobacteria.

In addition, cyanotoxins such as microcystins and anatoxin-a can cause gastrointestinal illness, liver disease, neurological effects, and skin reactions. While cyanotoxins are not classified as carcinogens by USEPA, studies in laboratory animals and cultured cells suggest that microcystin can cause liver tumors and microcystin and nodularin promote the

growth of existing liver tumors. Recent evaluation of carcinogenesis from microcystin exposure by the International Agency for Research in Cancer has determined that microcystin-LR is possibly carcinogenic to humans (Group 2B) and has been suggested to be a tumor promoter and linked to incidences of human liver and colon cancer. (Note: Nodularin, which is structurally related to microcystin and has a similar mode of toxicity, has been isolated from only one species of cyanobacteria, *Nodularia spumigena*.) (USEPA's HABs website: (<https://www.epa.gov/nutrient-policy-data/cyanobacterial-harmful-algal-blooms-water>))




Figure 2. *Dolichospermum* sp. cells

Anatoxin-a binds to neuronal nicotinic acetylcholine receptors affecting the central nervous system (neurotoxins). There are multiple variants, including anatoxin-a, homoanatoxin-a, and anatoxin-a(s). Although other anatoxin(s) and homo-anatoxins exist, there is currently no toxicity data to definitively determine if they have the same health effects as anatoxin-a. (USEPA's HABs website: ([Cyanobacterial Harmful Algal Blooms \(CyanoHABs\) in Water Bodies | US EPA](#)))

It should be noted that many types of toxins can be produced by HABs, and that most of these toxins cannot be measured by HAB response organizations. DEP, like most such organizations, routinely measures for microcystins – the most common group of cyanotoxins.

Table 1 lists the primary cyanotoxins as well as their associated human health effects

Table 1. Primary Cyanotoxins and their Associated Human Health Effects (USEPA HABs website : <https://www.epa.gov/cyanohabs>)

Cyanotoxin	Acute Health Effects in Humans	Most Common Cyanobacteria Producing the Toxin
Microcystins	Abdominal Pain, Headache, Sore Throat, Vomiting and Nausea, Dry Cough, Diarrhea, Blistering around the Mouth, Pneumonia, Liver Toxicity.	<i>Dolichospermum</i> (previously <i>Anabaena</i>), <i>Fischerella</i> , <i>Gloeotrichia</i> , <i>Nodularia</i> , <i>Nostoc</i> , <i>Oscillatoria</i> , members of <i>Microcystis</i> , and <i>Planktothrix</i>
Cylindrospermopsin	Fever, Headache, Vomiting, Bloody Diarrhea, Liver Inflammation, Kidney Damage	<i>Raphidiopsis</i> (previously <i>Cylindrospermopsis</i>), <i>raciborskii</i> (<i>C. raciborskii</i>), <i>Aphanizomenon flos-aquae</i> , <i>Aphanizomenon gracile</i> , <i>Aphanizomenon ovalisporum</i> , <i>Umezakia natans</i> , <i>Dolichospermum</i> (previously <i>Anabaena</i>) <i>bergii</i> , <i>Dolichospermum lapponica</i> , <i>Dolichospermum planctonica</i> , <i>Lyngbya wollei</i> , <i>Raphidiopsis curvata</i> , and <i>Raphidiopsis mediterranea</i> .
Anatoxin-a group	Tingling, Burning, Numbness, Drowsiness, Incoherent Speech, Salivation, Respiratory Paralysis Leading to Death	<i>Chrysosporum</i> (previously <i>Aphanizomenon</i>) <i>ovalisporum</i> , <i>Cuspidothrix</i> , <i>Raphidiopsis</i> (previously <i>Cylindrospermopsis</i>), <i>Cylindrospermum</i> , <i>Dolichospermum</i> , <i>Microcystis</i> , <i>Oscillatoria</i> , <i>Planktothrix</i> , <i>Phormidium</i> , <i>Dolichospermum</i> (previously <i>Anabaena</i>) <i>flos-aquae</i> , <i>A. lemmermannii</i> , <i>Raphidiopsis mediterranea</i> (strain of <i>Raphidiopsis raciborskii</i>), <i>Tychonema</i> and <i>Worochinia</i>
Saxitoxin	Tingling or numbness around the mouth or digits, headache, dizziness, nausea, vomiting, incoherent speech, shortness of breath, muscular paralysis, Respiratory Paralysis Leading to Death.	<i>Aphanizomenon flos-aquae</i> , <i>Dolichospermum</i> (previously <i>Anabaena</i>) <i>circinalis</i> , <i>Lyngbya wollei</i> , <i>Planktothrix</i> spp. and a Brazilian isolate of <i>Raphidiopsis raciborskii</i> .

B. Human and Animal Exposure and Treatment - Cyanobacteria and Toxins

Currently, New Jersey does not have specific or separate toxicological assessments for livestock or pets. Development of these values may be considered in the future. Pets, livestock, and wildlife have all had well documented adverse health outcomes when exposed to cyanobacteria and cyanotoxins. Pets, particularly dogs, may unknowingly ingest cyanobacteria or their toxins by either directly drinking water or by licking their fur after recreating. Therefore, it is best for pets and livestock to avoid any visible blooms.

The Center for Disease Control (CDC) states that if you or your pet come in contact with a cyanobacteria bloom, you should wash yourself and your pet thoroughly with fresh water. If you swallow water from a waterbody where a harmful algae bloom is present, call your health care provider or a Poison Center. If your pet drinks water from a waterbody where a harmful algae bloom is present, call a veterinarian. Also call a veterinarian if your animal shows any of the following symptoms of cyanobacteria poisoning: loss of appetite, loss of energy, vomiting, stumbling and falling, foaming at the mouth, diarrhea, convulsions, excessive drooling, tremors and seizures, or any other unexplained sickness after being in contact with water. For more information see the CDC website:
<http://www.cdc.gov/habs/materials/factsheets.html>.

C. Cyanobacteria and Cyanotoxin Risk Thresholds for Recreational Waters

In 2019, EPA developed recommended recreational ambient water quality criteria/ swimming advisories for two types of cyanotoxins - microcystins and cylindrospermopsin.
(<https://www.epa.gov/sites/production/files/2019-05/documents/hh-rec-criteria-habs-document-2019.pdf>), while the World Health Organization (WHO) (http://www.who.int/water_sanitation_health/publications/srwe1/en/) (Appendix D), and a number of states have derived their own “action levels” or health advisory guidelines based on cyanobacteria cell counts and/or concentrations of the more toxic and most commonly occurring cyanotoxins.

New Jersey has developed State guidance levels for cyanobacterial cell counts and for four of the most commonly observed cyanotoxins (microcystins, cylindrospermopsin, anatoxin-a, and saxitoxin) discussed below.

DWMS/BFBM’s laboratory has the capability to enumerate and provide taxonomic identification of cyanobacterial cells, it is certified in microcystins analysis, and uses approved methodology to reliably measure other toxins at concentrations below the specified threshold limit.

D. Cyanobacterial and Cyanotoxin Health Advisory Guidance Levels

DEP, with the support of the HAB Workgroup, has developed health advisory guidance levels and a matrix of action levels for the protection of human health from the effects of exposure to different levels of cell counts and toxin concentrations. See Table 2 for this matrix which describes the various health effects risk indices and associated Health Advisory Guidance Levels.

• Alert Levels - Cyanobacterial cell count bases

Exposure to cyanobacteria cells themselves, whether or not the bloom is actively producing cyanotoxins, may cause allergenic and/or irritative effects to a portion of an exposed population. These effects are caused by endotoxins (mainly from components of the cyanobacterial cell wall) rather than cyanotoxins.

It has been established that some sensitive individuals have adverse allergenic/irritative responses from exposure to cyanobacterial cells at concentrations as low as 5,000 cells/ml (USEPA, 2019).

NJ Watch: Health Advisory Guidance Level- DEP defines a HAB as a density of identified cyanobacterial cells of 20,000 cells/ml or higher. This definition is supported in the scientific literature and is widely accepted by many organizations (Loftin et al, 2008).

WHO cyanobacterial cell count guidance indicates that exposure to cyanobacteria in concentrations between 20,000 cells/ml and 100,000 cells/ml can result in a moderate probability of acute health effects (WHO, 2009).

When a HAB is present, based on cyanobacterial cell counts of at least 20,000 cells/ml (but less than 80,000 cells/ml, and with cyanotoxin levels below the NJ advisory guidance levels – see below), Watch advisories will be posted to notify the public that a HAB is present and to protect against the probability of potential allergic and/or irritative health effects from recreational exposure to the cells themselves.

If the cyanobacterial cell count is between 20,000 - 80,000 cells/ml (and toxins are below NJ advisory guidance levels) in an area where primary recreational contact is likely to occur, local authorities will be notified to surveil and monitor the area for changes in the bloom condition and notify the DEP if such changes occur. Frequency will be determined on a case by case basis, based on such factors as recreational use, extent of bloom, resources available, and seasonal variability.

At PRBs, an Alert for more frequent monitoring will occur when the cell count is between 40,000 - 80,000 cells/ml. If the intensity of the bloom increases as determined by visual observations or other screening methods (such as meter phycocyanin measurements or toxin “strip tests” with secondary confirmation), DEP should be notified to perform sampling and laboratory analysis to ensure the cell count has not increased or that toxin production is not above Health Advisory Guidance Levels for primary contact at a PRB which would require a beach closure.

NJ Advisory: Health Advisory Guidance Levels – While exposure to cyanobacterial cells that are not producing toxins can result in the allergenic-like, flu-like and irritative effects discussed above, more serious health effects can result from exposure to cyanotoxins. Blooms may begin producing toxins at any time during an active HAB.

DEP conducted an evaluation of NJ-specific HAB data to determine if there was a level of cyanobacterial cell density that is associated with an appreciable likelihood that a bloom will produce toxins at levels above the NJ toxin thresholds. These data were collected from 2017 to 2020 and included 1,093 paired cell count and microcystin results. This DEP data set was available due to the large number of HAB samples collected over the four-year period during which the NJ HAB Response Strategy was being implemented. All these data were then managed and entered into a new DEP NJ HAB database which became available in early 2020.

The HAB data were evaluated by analyzing the percentage of samples exceeding the NJ advisory guidance level for microcystins (the most common group of cyanotoxins) of 2 µg/L for various ranges of cyanobacteria cell counts. Cell count ranges were used to allow for a sufficient number of samples for statistical analysis within each range. The data shows a substantial increase in the likelihood of toxin levels above the NJ guidelines when cell counts exceeded 80,000 cells/ml (See Figure 3).

Figure 3. Percent of Cyanobacteria Bloom Response Samples Exceeding Microcystin Health Advisory Guidance Level of 2 µg/L in 2017-2020 Data.




Figure 4. Linear Regression of the Log of Cell Count versus Log of Microcystin Toxin Concentration ($\mu\text{g/L}$) in 2017-2020 data.




Figure 4 is the linear regression of the log of the cell counts versus the log of the toxin concentration. The chart is based on data from 2017-2020, where log results for both the cell count and microcystin data was available; 1,093 matching results. A log scale was used to be able to cover the large range in the cell count data. This figure shows that the 2 $\mu\text{g/L}$ microcystin threshold is more likely to be exceeded when the cell count is greater than approximately 80,000 cells/ml. The yellow and red lines are where approximately 80,000 cells/ml and 2 $\mu\text{g/L}$ of microcystin toxin intersect, and shows the greater likelihood of exceeding 2 $\mu\text{g/L}$ of microcystin when the cell density is above 80,000 cells/ml.

Additionally, advanced logistic regressions were also performed on these data to evaluate relationships between the probability of exceeding the microcystin health advisory guidance level of 2 $\mu\text{g/L}$ and cell count. Overall, the probability of exceeding the microcystin health advisory guidance level increased as the cell count (cells per ml) increased for all subsets of the dataset.

Therefore, to ensure the protection of public recreational health, an advisory and beach closures are recommended when cell counts are > 80,000 cells/ml due to the increased probability that toxins in excess of 2 $\mu\text{g/L}$ of microcystins could be produced. This threshold is also protective for the increased risk from the cells themselves at these levels, as well as for the increased probability of toxin production to levels exceeding the health advisory guidance level at any point during the duration of the HAB. It should be noted that many types of toxins can be produced by HABs, and that most of these toxins cannot be measured by HAB response organizations. DEP, like most such organizations, routinely measures for microcystins – the most common group of cyanotoxins.

Health agencies have the authority to close public recreational bathing (PRB) facilities under the New Jersey State Sanitary Code, Chapter IX - Public Recreational Bathing, N.J.A.C. 8:26-8.5 "Criteria for closure of a public recreational bathing facility." Under these criteria, any conditions which pose an immediate health or safety hazard shall be grounds for closure of bathing and swimming activities. The DOH may use Alert Levels and Health Advisory Guidance Levels defined in this Strategy to interpret an immediate health hazard.

- **Health advisory guidance levels for individual cyanotoxins - Basis for Advisory (including Beach Closures), Warning and Danger Action Levels**

The DEP Division of Science and Research (DSR) recently reviewed the basis for health advisory guidance levels for three cyanotoxins (microcystins, cylindrospermopsin, anatoxin-a) that it developed in 2017. In 2021 DSR developed guidance for a fourth toxin, saxitoxin. The basis for these recreational advisory guidance levels, including the toxicological basis (Reference Doses) and exposure assumptions, is provided in Appendix E - Basis for Health Advisory Guidelines. It is important to note that the uncertainties in the risk estimates, as well as the inherent uncertainty in the temporal variability of the toxins in any given waterbody, should be considered when providing advice to the public regarding recreation in affected waterbodies.

Based on the information presented in Appendix E, DEP recommends the following guidance values for recreational exposure to individual cyanotoxins:

- Microcystins (as total including microcystin –LR and other detectable congeners): 2 µg/L
- Cylindrospermopsin: 5 µg/L
- Anatoxin-a: 15 µg/L
- Saxitoxin: 0.6 µg/L

An advisory and/or beach closure will be recommended when toxins are present at or above these levels regardless of cyanobacterial cell concentration. If microcystin levels are present at levels associated with high (≥ 20 µg/L) or very high (≥ 2000 µg/L) toxin levels, additional advice and actions will be warranted as per the Alert Level Summary table (See Section 5, Table 2).

4. INVESTIGATION AND RESPONSE TO HARMFUL ALGAL BLOOMS IN RECREATIONAL WATERS

A. Initial HAB Report

A cyanobacterial bloom may often be visible as a blue-green, green, yellow-green, brown, pink or possibly red discoloration on the water surface. The visible bloom may blow with the wind or move with water flow, and may accumulate in shallow areas, forming very dense scum. Other evidence of a potential cyanobacterial HAB could be discolored or pea-green colored water, parallel streaks, or green dots/globs in the water. It is important to note that some algal blooms are due to common green algae and not cyanobacteria. It is also important to note that cyanobacteria blooms do not always produce cyanotoxins.

If you observe what you think might be a HAB in a pond, lake, or stream, submit the report via smartphone or PC using the [NJDEP HAB Interactive Map Reporting and Communication System \(HAB System\)](#). If a smartphone or PC is not available, call the DEP Hotline (1-877-WARNDEP) to report it.

The NJDEP HAB System will allow the reporting of suspected HABs, as well as facilitate the provision of additional information such as site coordinates and photos. This tool is intended to gather and display reports and sampling for all freshwaters where a HAB is suspected. The reports will be immediately available to DWMS/BFBM staff who will determine the entities and partners who may be available to be contacted for follow-up. Partners could include: local health departments, state and local park authorities, DEP's Division of Fish and Wildlife personnel for Wildlife Management Areas, DEP's Water Compliance and Enforcement program, academia, Water Suppliers with surface water supplies, USGS, Rutgers Cooperative Extension, lake associations, watershed associations, DEP Watershed Ambassadors, and volunteers.

If follow-up is with a government entity concerning a public water body, DWMS/BFBM will coordinate any possible response monitoring and analysis, as requested. If the report relates to a drinking water source, the DEP DWSG will be contacted. See section 4.E. for communication actions.

Upon initial reporting of a suspected HAB, one or more of the following field screenings (See Section B below) will be performed by a qualified organization to verify whether a potential HAB is present. If field screenings verify a HAB may be present, a sample will be collected for further confirmatory analysis.

Figure 5. Quick Reporting Guide You can help!

If you observe what you think might be a HAB in a pond, lake, or stream, a suspected Harmful Algal Bloom report, can be submitted by smartphone or PC using the [NJDEP HAB Interactive Map Reporting and Communication System](#). The HAB System will be used to gather initial information such as: location coordinates, photos, known recreational activities, and extent of the waterbody. This information will be used to inform DEP to initiate appropriate response actions. Once the DEP completes the investigation of the suspected HAB, results and any recommendations for public notices or advisories will be communicated through the HAB System. All information and HAB data will be accessible by clicking the location on the interactive map in the HAB System. If a smart phone or computer is not available, reports may also be submitted to the DEP Hotline at 1-877-WARNDEP (927-6337) - If reporting by phone, please note the exact location of the suspected HAB along with any details (e.g., date/time, bloom appearance and color, and if known, whether a swimming beach is nearby or whether the waterbody is a drinking water source like a reservoir).



B. Screening

Upon receiving a report of a suspected HAB, several screening procedures may be performed to inform continued response and confirmation actions.

i. Cyanobacteria Presence and Field Measurements

The presence of phycocyanin pigment (unique to cyanobacteria) can be determined using a handheld field fluorometer (phycocyanin meter). If a phycocyanin meter is not available, a sample may be collected for laboratory analyses. See Appendix B for the sample collection procedure for HABs. If using a non-DEP lab, assure samples are collected in amber glass bottles or amber plastic bottles made of polyethylene terephthalate glycol (PETG) or High-Density Polyethylene (HDPE), refrigerated, and analyzed within 24 hours. Exact sample size, collection materials, holding times, and preservation should be confirmed with the laboratory. The laboratory will provide all collection procedures and preservation to assure compliance with the minimum requirements of the analytical method.

ii. Visual Assessment

A visual assessment is an important part of the NJDEP HAB System. When public reports are received, usually the same or next day, the System requests information on size, extent, and visual information using example photos available in the System. Many times, a determination can be made simply based on a supplied photo. When samplers visit the waterbody, additional visual information and measurements are input into the system.

iii. Remote Sensing – Satellite Imagery, Aircraft Flight Reconnaissance and Unmanned Aerial Vehicles (UAVs)

While discrete laboratory analyses (cell identification and enumeration, and toxin analyses) serve as the definitive determination of whether results exceed NJ Health Advisory Guidance levels, remote

sensing data provides useful screening information on the spatial extent and relative cell density a bloom. Remote sensing is also a valuable tool to assess HAB trends (i.e., whether the HAB is increasing or dissipating).

Satellite imagery. Satellite imagery, such as the USEPA's Cyanobacteria Assessment Network Application (CyAN app) https://cfpub.epa.gov/si/si_public_record_Report.cfm?Lab=NERL&dirEntryId=346902. The CyAN app provides weekly satellite data to identify the concentration, location, and time series of cyanobacterial blooms in fresh and coastal waters of the United States. Monitoring this application may be used to inform decisions on staff deployment for other response actions such as field screening and sampling. Due to resolution limitations, satellite imagery is limited to the approximately seven largest lakes in the State (Wanaque Reservoir, Union Lake, Greenwood Lake, Boonton Reservoir, Lake Hopatcong, Lake Tappan, Round Valley Reservoir).

Aircraft Flight Reconnaissance.

The DEP has developed aircraft remote sensing capabilities for general cyanobacteria detection and tracking. A hyper-spectral sensor is used to detect wavelengths of light specific to the cyanobacteria pigment phycocyanin in a waterbody. This advanced monitoring method provides immediate feedback on the presence and relative cyanobacteria cell counts and can serve as a screening method to target waters for sample collection.

Unmanned Aerial Vehicles (UAVs)

DEP is also working on the development and use of UAVs for HAB screening through photography and remote sensing for phycocyanin. UAV surveillance can be used for smaller lakes than the satellite remote sensing.

iv. Continuous Data Monitoring Program

Continuous monitors may be deployed at waterbodies with recurring HABs or having recreational, drinking water, or ecological significance. Phycocyanin, as well as other water quality measurements, are monitored for the status of an existing HAB or for conditions that may predict the onset of a HAB (e.g. changes in pH or dissolved oxygen). Data from these continuous monitors will inform the deployment of staff for on-site measurements and sampling. Continuous monitoring data can be found here: <http://njdep.rutgers.edu/continuous/>

v. Toxin Presence

A microcystins test strip reading is considered a semi-quantitative analysis and can be used to identify the presence of the total microcystin toxins (including –LR and other detectable congeners). Test strips for cylindrospermopsin and anatoxin–a are also available. Microcystins test strip results will be interpreted, per the manufacturer’s instructions (Appendix C) in the following manner:

Microcystins Test Strip Interpretation

- Control line not present/ Test line not present: invalid result
- Control line present/ Test line not present: concentration result is >10 µg/L (ppb)
- Control line present- Moderate intensity/Test line present: concentration result is between 0 and 10 µg/L (ppb)
- If at any time, microcystin strip test results indicate the presence of microcystin, water samples will be collected for microcystin analysis in the laboratory.

It should be cautioned that the absence of microcystins does not indicate the absence of all toxins, such as cylindrospermopsin and anatoxin-a. If any other screening indicates the presence of a potential HAB, then laboratory analysis may be performed for other toxins.

If cyanobacteria cell density or toxin concentration is estimated to be above NJ Health Advisory Guidance levels using any of these screening methods, cell identification, enumeration and toxins will be analyzed per below.

C. Confirmation Laboratory Analysis

The following cyanotoxins will be analyzed to confirm presence if the initial screening indicates the presence of a HAB. Descriptions below are from USEPA Cyanobacteria website:

[\(Cyanobacterial Harmful Algal Blooms \(CyanoHABs\) in Water Bodies | US EPA](#)

New Jersey data show that Microcystins are the most common toxin found and can routinely be produced at levels above recreational health risk. Because other toxins are rarely detected and have not been found above threshold levels unless very high cell counts are present, Microcystins are analyzed at all times while Cylindrospermopsin, Anatoxin-a, and Saxitoxin are only analyzed under certain criteria:

- Suspected HAB is at a Drinking Water source
- People or animal illness was reported, and/ or
- High levels of cell concentration is measured (approx. >150Kcells/ml)

Microcystins

Microcystins are a group of at least more than 200 toxin variants which share a cyclic heptapeptide structure and primarily affect the liver (hepatotoxin). Microcystins are the most widespread cyanobacterial toxins and can bioaccumulate in common aquatic vertebrates and invertebrates such as fish, mussels, and zooplankton. Microcystins are produced by *Dolichospermum* (previously *Anabaena*), *Fischerella*, *Gloeotrichia*, *Nodularia*, *Nostoc*, *Oscillatoria*, members of *Microcystis*, and *Planktothrix*.

Cylindrospermopsin

Cylindrospermopsin is usually produced by *Raphidiopsis* (previously *Cylindrospermopsis*), *raciborskii* (*C. raciborskii*), *Aphanizomenon flos-aquae*, *Aphanizomenon gracile*, *Aphanizomenon ovalisporum*, *Umezakia natans*, *Dolichospermum* (previously *Anabaena*) *bergii*, *Dolichospermum lapponica*, *Dolichospermum planctonica*, *Lyngbya wollei*, *Raphidiopsis curvata*, and *Raphidiopsis mediterranea*. The primary toxic effect of this toxin is irreversible damage to the liver. It also appears to have a progressive effect on several other vital organs. Effects of poisoning in humans include hepatoenteritis and renal insufficiency.

Anatoxin-a

Anatoxin-a binds to neuronal nicotinic acetylcholine receptors affecting the central nervous system (neurotoxins). There are multiple variants, including anatoxin-a, homoanatoxin-a, and anatoxin-a(s). Although other anatoxin(s) and homo-anatoxins exist, there is currently no toxicity data to definitively determine if they have the same health effects as anatoxin-a. These toxins are mainly associated with the cyanobacterial genera *Chrysosporum* (*Aphanizomenon*) *ovalisporum*, *Cuspidothrix*, *Raphidiopsis* (previously *Cylindrospermopsis*), *Cylindrospermum*, *Dolichospermum*, *Microcystis*, *Oscillatoria*, *Planktothrix*, *Phormidium*, *Dolichospermum* (previously *Anabaena*) *flos-aquae*, *A. lemmermannii*, *Raphidiopsis mediterranea* (strain of *Raphidiopsis raciborskii*), *Tychonema* and *Woronichinia*. (USEPA's HABs website:

Saxitoxin

Saxitoxin is a potent neurotoxin that blocks the flow of sodium in the nerve cells leading to numbness, paralysis and death. Saxitoxins are also representative of a large toxin family referred to as the Paralytic Shellfish Poisoning (PSP) toxins. When toxigenic marine dinoflagellates are consumed by shellfish, toxins concentrate and are delivered to consumers of the shellfish. These toxins have been reported also in freshwater cyanobacteria including *Aphanizomenon flos-aquae*, *Dolichospermum* (previously *Anabaena*) *circinalis*, *Lyngbya wollei*, *Planktothrix* spp. and a Brazilian isolate of *Raphidiopsis raciborskii*.

..

i. Toxin Analysis Methods

Samples analyzed by DWMS/BFBM laboratory will use a microtiter plate Enzyme-Linked Immuno-Sorbent Assay (ELISA), EPA method 546, using an automated plate reader (Figure 6) and ABRAXIS kits (Sample Collection Reference Guide Methods in Appendix B and C respectively). The DEP Office of Quality Assurance, Laboratory Certification Program offers certification for this method. This method was utilized by the USEPA as part of the National Lakes Assessment (NLA). Quality Assurance/ Quality Control (QA/QC) procedures are outlined in: *USEPA. 2009 (Final). Survey of the Nation's Lakes: Integrated Quality Assurance Project Plan. EPA/841-B-07-003. U.S. Environmental Protection Agency, Office of Water and Office of Research and Development, Washington, DC.* (<https://www.epa.gov/national-aquatic-resource-surveys/nla>).

Analysis levels (note levels are significantly below NJ Health Advisory Guidelines)

- Microcystins (> 80 variants)
 - Method – ELISA (EPA [Method 546](#))
 - Detection limit = 0.10 µg/L
 - Reporting level = 0.15 µg/L
- Cylindrospermopsin
 - Method - ELISA.
 - Detection limit = 0.04 µg/L
 - Reporting level = 0.05 µg/L
- Anatoxin-a
 - Method – ELISA
 - Detection limit = 0.10 µg/L
 - Reporting level = 0.15 µg/L
- Saxitoxin
 - Method – ELISA
 - Detection limit = 0.015 µg/L
 - Reporting level = 0.02 µg/L




Figure 7. Automated Plate Reader Used for ELISA

For detection of cyanotoxins in drinking water, EPA developed [Method 544](#), a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for six microcystins and nodularin (combined intracellular and extracellular), and [Method 545](#), a LC-ESI/MS/MS method for the determination of cylindrospermopsin and anatoxin-a. These methods, as well as Method 546 above are published in EPA's "Revisions to the Unregulated Contaminant Monitoring Rule (UCMR 4) for Public Water Systems and Announcement of Public Meeting" on December 20, 2016 (81 FR 92666). UCMR 4 includes Assessment Monitoring for a total of 30 chemical contaminants, including the cyanotoxins referred to here. Additional information regarding UCMR4, the applicable water systems involved, and the timeframe and frequency of sampling can be found here: <https://www.epa.gov/dwucmr/fourth-unregulated-contaminant-monitoring-rule>.

- ii. **Cyanobacteria Identification and Enumeration**
Standard phytoplankton identification guides are used for taxa identification. Cyanobacteria cell concentrations are determined using direct counts on a Hemocytometer. The majority of cyanobacteria form in colonies or "natural units". Individual cells in these "natural units" are enumerated and counts are reported as cells/ml. All cyanobacteria taxa are identified and the dominant taxa, i.e. most abundant, is noted and posted with the data on the interactive map.
- iii. **Chlorophyll 'a' and cell count estimation**
Algal concentrations in the water column, although not typical, may be estimated through Chlorophyll 'a' analysis. Chlorophyll "a" is contained in both green algae and cyanobacteria, both of which may be present in a bloom community at varying ratios. As a conservative estimate of possible health risk, it is assumed that higher concentrations of Chlorophyll 'a' increase the potential of higher cyanobacteria densities. Chlorophyll 'a' analysis (EPA


Method 445.0) and/ or cell counts can be performed as an additional screening method or measure of relative abundance. WHO guidance for Chlorophyll 'a' and cell counts for moderate risk are Chlorophyll 'a' > 10 µg/l and cell counts > 20,000 – 100,000 cells/ml (Appendix D). WHO report is available at: http://www.who.int/water_sanitation_health/publications/srwe1/en/.

E. Response/ Actions

Depending on the waterbody and its use, a variety of actions may be taken by DWMS/BFBM to communicate risk to the proper authority and the public. (Figure 7 summarizes the response flow)

- DEP DWSG will be alerted for HABs in a waterbody that is a direct source for drinking water.
- If reported at a State Park bathing beach, the specific State Park Superintendent and DOH will be notified.
- If reported at a Public Recreational Bathing facility (PRB), other than a State Park, the appropriate local health department and DOH will be notified. DOH will convey recommended actions to local health departments.
- If reported at a State Park recreational water that is not a bathing beach, the specific State Park Superintendent will be notified.
- If reported at a Wildlife Management Area, Fish and Wildlife will be contacted.
- For drinking water sources and State-owned recreational waterbodies, there will be joint communication and coordination regarding actions among DEP divisions.
- If the report concerns a potential HAB at another public water body, county/ local health agency and others (e.g., park commissions), as appropriate, will be notified with joint guidance from DEP and DOH.
- If HAB poses a risk to livestock, appropriate NJ Department of Agriculture staff will be notified.
- BFBM will perform situational awareness in accordance with established internal DEP protocols.
- DEP will make every effort to respond to reported suspected HABs as soon as possible. In the event that resources are limited, the response actions will be prioritized based on potential risk to public health.
 1. Drinking water sources.
 2. Bathing beaches (PRBs).
 3. Recreational waters without bathing beaches.
 4. Waterbodies with a protective alert already in place.
 5. Waterbodies not covered in the above.

Figure 7. HAB Response Summary:



F. Communication/ Continued Monitoring

A tiered approach will be used for notices and advisories based on analysis results from response and continued monitoring. If levels are above NJ Health Advisory Guidance for toxins and/or cell concentrations, it is recommended that advisories be posted or PRB closures implemented (See Section 5). Situational awareness in accordance with established internal DEP protocols will be initiated. After initial HAB confirmation and actions, subsequent monitoring may be necessary until the risk level subsides or the HAB dissipates. Monitoring design, including parameters, area of study, sample depth, frequency, and responsible entity will be determined on a case by-case basis. The monitoring design will consider the source of the HAB and potential for any exposure risks downstream of the originally reported waterbody including, but not limited to: downstream drinking water sources, recreational and swimming areas, and livestock exposure. If monitoring is performed by DWMS/BFBM, results and/or additional information will continue to be communicated to responsible authorities.

After initial response and issuing of an advisory, it is the responsibility of the resource's authority (e.g., Division of Fish and Wildlife, local health department) to communicate any substantial changes in status such as increased discoloration or dissipation of the HAB to DWMS throughout the HAB event, until the advisory is lifted. An agreed upon surveillance frequency which will consider recreational use, HAB extent, and other factors will be employed. Screening or visual observations which indicate a potential increase in cell counts or toxin production may result in additional DWMS/BFBM response and monitoring.

5. CYANOBACTERIAL HARMFUL ALGAL BLOOM ADVISORIES

The tiered Alert levels are based on the recommended NJ Health Advisory Guidance Levels for Recreational Exposure. The tiered Alerts are intended to be protective for the exposures most likely to occur from recreational activities. Two categories of recreational activity are defined per the USEPA (2004) Water Quality Standards for Coastal and Great Lakes Recreation Waters. Proposed Rule as follows: "Primary contact recreation is typically defined by States and Territories to encompass activities that could be expected to result in the ingestion of, or immersion in, water, such as swimming, water skiing, surfing, kayaking, or any other activity where immersion in the water is likely." Secondary contact recreation consists of the following activities that may result in incidental contact with water, but not full body immersion in, nor ingestion of, water: wading, fishing, hunting, power boating, canoeing, sailing (ORSANCO, 2018).

When posting advisories, it is recommended to err on the side of caution to avoid unnecessary risk to the public. These advisories may be modified on a site-specific basis as appropriate to reflect the nature and extent of a specific HAB occurrence.

DEP has developed Alert Levels (Watch, Alert, Advisory, Warning and Danger) based on cyanobacterial cell concentrations and cyanotoxin levels in a bloom that can be used to provide tiered advice for recreational exposure to HABs and their toxins. These tiered Alert Levels are based on DSR's evaluation of potential health effects at elevated microcystin concentrations, as well as Warning and Danger (or similar) guidelines from WHO and other states. More detail on the basis for the tiered Alert levels is found in Appendix E.

Watch

A Watch should be used if a HAB is strongly suspected based on visual, photographic or other screening measures such as phycocyanin measurements, or if laboratory analysis results confirm that cyanobacteria are present, and cell concentrations are >20,000 cells/ml and < 80,000 cells/ml and toxins are below Health Advisory Guidelines. While there is no recommendation suggesting the need to limit recreational activities, caution should be used and contact with visible blooms should be avoided. Precautionary beach closures may be put into place by a local health department/authority or a PRB owner/operator if visual or other clear evidence of a HAB is present until confirmation analysis is performed. Additionally, a cell concentration >40,000 cells/ml and < 80,000 cells/ml at PRBs initiates an Alert for additional monitoring as per below:

Alert Tier for Public Recreational Bathing Facilities (PRB)

An Alert applies to PRBs only. An Alert should be used if laboratory analysis results confirm that cyanobacteria are present, and the cell concentration is > 40,000 cells/ml and < 80,000 cells/ml, and toxins are below Health Advisory Guidelines. An Alert initiates actions by the DEP or partners to monitor the waterbody more closely for changes in the HABs appearance. Such changes may indicate an increase in cell concentrations or toxin production warranting the collection of additional samples. The Watch advice remains in effect. No limits in recreational

activities are suggested; however, caution should be used and contact with visible blooms should be avoided. Precautionary beach closures may be put into place by the local health department or authority or the PRB facility owners/operators if visual or other clear evidence of a HAB is present.

Advisory

An Advisory should be used if a HAB is confirmed through laboratory analysis within the health advisory guidance levels range for cell concentration of > 80,000 cells/ml or above any health advisory guidance level for measured toxins.

Public Recreational Bathing Beaches (PRBs)

Upon confirmation analysis*, PRBs will be closed under the authority of DOH regulation, New Jersey State Sanitary Code Chapter IX Public Recreational Bathing N.J.A.C. 8:26.

DOH will communicate advisory recommendations to local health departments and confirm PRB Closures have been carried out appropriately.

*If there is compelling evidence at a PRB (e.g, field measurements using a fluorometer), the local authority may close the PRB until confirmation analysis is performed.

Areas with no PRBs

An Advisory may be posted at public access points in waterbodies, or sections of waterbodies, where a PRB is not present, but other recreation or use may occur. At these areas, primary contact recreation is not advised. While there is no recommendation against secondary recreational activities, caution should be used and contact with visible blooms should be avoided

Warning*

A Warning should be issued if a HAB is confirmed through laboratory analysis with microcystins toxin levels of >20 µg/L and <2000 µg/L. PRBs will be closed and Warning signs posted as above. At these areas, primary contact recreation is not advised. Secondary contact recreation may not be recommended if additional evidence (e.g., animal or human adverse health effects reports) exists.

Danger*

A Danger posting will be considered if microcystins toxin levels are > 2000 µg/l and there is a significant increased risk to public health. A Danger notification will prohibit all primary and secondary contact recreation activity for the waterbody. A waterbody closure, or partial closure, may be considered after evaluating all aspects of the HAB event, including but not limited to recreational uses, size and extent of bloom and monitoring data.

*The intent of these tiers is to advise against secondary recreation when a HAB poses an imminent threat to public health and safety, or if the HABs results in the confirmed injury/death of wildlife, pets or livestock. Therefore, other evidence, such as reported health effects, may be used to recommend the posting of these tiers.

Recommended Alert Levels:

Table 2. Summary of Alert Levels, Criteria, and Recommended Recreational Activities.

HAB ALERT LEVEL	CRITERIA	RECOMMENDATIONS
NONE	HAB report investigated and no HAB found	None
WATCH <i>Suspected or confirmed HAB with potential for allergenic and irritative health effects</i>	Suspected HAB based on visual assessment or screening test OR Lab confirmed cell counts between 20k – 40k cells/mL AND No known toxins above public health thresholds	Public Bathing Beaches Open (dependent upon local health authority evaluation and assessment) Waterbody Accessible: <ul style="list-style-type: none"> Use caution during primary contact (e.g. swimming) and secondary (e.g. non-contact boating) recreational activities Do not ingest water (people/pets/livestock) Do not consume fish
ALERT <i>Confirmed HAB that requires greater observation due to increasing potential for toxin production</i> PUBLIC BATHING BEACHES INCREASE MONITORING	Lab confirmed cell counts between 40k – 80k cells/mL AND No known toxins above public health threshold	WATCH remains in effect. Public Bathing Beaches Open (dependent upon local health authority evaluation and assessment) and should observe and report changing bloom conditions Waterbody Accessible: <ul style="list-style-type: none"> Use caution during primary contact (e.g. swimming) and secondary (e.g. non-contact boating) recreational activities Do not ingest water (people/pets/livestock) Do not consume fish
ADVISORY <i>Confirmed HAB with <u>moderate risk of adverse health effects</u> and increased potential for toxins above public health thresholds</i>	Lab testing for toxins exceeds public health thresholds OR Lab confirmed cell counts above 80K cells/mL OR Field measurement evidence indicating HAB present and above guidance thresholds (e.g. phycocyanin readings)	Public Bathing Beaches Closed Waterbody Remains Accessible: <ul style="list-style-type: none"> Avoid primary contact recreation (e.g. swimming) Use caution for secondary contact recreation (e.g. boating without water contact) Do not ingest water (people/pets/livestock) Do not consume fish
WARNING <i>Confirmed HAB with <u>high risk of adverse health effects</u> due to high toxin levels</i>	Toxin (microcystin) 20 - 2000 µg/l AND/OR Additional evidence, including, expanding bloom, increasing toxin levels (i.e. duration, spatial extent or negative human or animal health impacts) indicates that additional recommendations are warranted	Public Bathing Beaches Closed Waterbody Remains Accessible: <ul style="list-style-type: none"> Avoid primary contact recreation (e.g. swimming) May recommend against secondary contact recreation (e.g. boating without water contact) with additional evidence Do not ingest water (people/pets/livestock) Do not consume fish
DANGER <i>Confirmed HAB with <u>very high risk of adverse health effects</u> due to very high toxin levels</i>	Toxin (microcystin) > 2000 µg/l AND/OR Additional evidence, including, expanding bloom, increasing toxin levels (i.e. duration, spatial extent or negative human or animal health impacts) indicates that additional recommendations are warranted	Closure of Public Bathing Beaches Possible closure of all or portions of waterbody and possible restrictions access to shoreline. Avoid primary contact recreation (e.g. swimming) May recommend against secondary contact recreation with additional evidence Do not ingest water (people/pets/livestock) Do not consume fish

WHO (2003) states that a ***relatively low probability of adverse health effects from cyanobacteria*** is due to the irritative or allergenic effects of cyanobacterial components and exists at a cyanobacterial cell concentration of 20,000 cyanobacterial cells/ml; these effects are not due to cyanotoxin toxicity. In studies of individuals with recreational exposure to cyanobacterial blooms, health outcomes were related to cyanobacterial density and duration of exposure, and less than 30% of individuals were affected at a cell concentration of 20,000 cells/ml. WHO (2003) further states that a **moderate probability of adverse health effects** occurs at higher concentrations of cyanobacterial cells, and the probability of irritative symptoms is elevated. Additionally, cyanotoxins may reach concentrations with potential health impacts at higher cell concentrations. (WHO, 2003).

Public Bathing Beaches will be closed under the authority of NJDOH regulation, New Jersey State Sanitary Code Chapter IX Public Recreational Bathing N.J.A.C. 8:26. If there is compelling evidence at a PRB from visual surveillance or through field measurements (e.g., phycocyanin meter), the local health department/authority has the authority to close the PRB until confirmation analysis is performed.

NOTE: A printable version of HAB signs can be found on the web page below:

<https://www.state.nj.us/dep/hab/alert-tiers-signs.html>

Guidance for lifting and/or changing advisories and/or re-opening bathing beaches.

If the above advisories are posted or result in a PRB closure, the following guidance for lifting advisories and/or re-opening is recommended:

Watch/Alert

- Continue field surveillance for substantial changes in bloom conditions. If changes occur, perform laboratory analysis to confirm that levels remain below thresholds. Analysis frequency to be determined on a case-by-case basis.

Watch should remain in effect until HAB has visually dissipated and laboratory analysis confirms that levels remain below thresholds, or until analysis confirms that the HAB has worsened, and exceeds the Advisory Level or higher Alert Level.

Advisory/ Beach Closure

- **Public recreational bathing facility**
 - If HAB is present with cell count or toxin levels quantified at or above the health advisory guidance levels, the PRB closure should not be lifted until:
 - With no phycocyanin field measurements - two (2) subsequent lab analyses are below cell count and toxin thresholds, or
 - If phycocyanin measurements show levels are below thresholds for 5 consecutive days, then only one laboratory analysis with cell count and toxin results below thresholds is necessary.
 - When advisory is lifted, and/ or PRB is re-opened, the DOH recommends continued frequent surveillance of the waterbody and documentation of findings (visual and/ or phycocyanin). Follow-up laboratory analysis is required when bloom appearance changes or phycocyanin measurements increase.
 - If a HAB re-occurs (visual and/ or phycocyanin), then automatic closure of the PRB until

thorough testing is conducted and no cell count or toxin levels are detected above thresholds.

- Any re-opening of PRBs will be communicated by DOH to the local health department. If at any time after re-opening a HAB has re-occurred based on visual observations or phycocyanin measurements, the PRB should be closed immediately and sampling/ analysis initiated.
- **Areas with no PRBs**
- If HAB is present with cell counts or toxin levels quantified at or above the health advisory guidance levels, the Advisory should not be lifted until one subsequent analysis is below thresholds.
- When Advisory is lifted, continue surveillance of the waterbody using the suggested screening procedures in Section 4.B, and document findings. If a HAB re-occurs, then follow-up laboratory analysis is required.

Warning and Danger

Actions performed as above Advisory tier. However, additional monitoring and analysis may be necessary depending on the severity of the HAB and its impact on the waterbody use, and the frequency of such additional monitoring will be determined on a case by case basis. Such analyses may indicate the downgrading of advice to lower level Alert tiers, as well.

6. RESEARCH STRATEGY

DEP's DSR and DWMS/BFBM co-chair the HAB Research Committee which provides technical consultation regarding HAB bloom response, implements portions of the Science Agenda component of the Governor's Harmful Algal Blooms (HABs) Initiative, and conducts literature-based evaluations and applied research on the following topics:

- New developments in HAB screening, monitoring and laboratory analysis
- Downstream fate and transport of cyanobacteria and toxins
- Factors that contribute to toxin production
- Risks of consumption of fish from waters where HABs are present, including commonly caught game fish.

Literature research will include keeping abreast of HAB monitoring and response strategies established by other states, current USEPA guidance, and studies reported by United States Geological Survey, academic researchers, and others.

A cyanobacterial HAB research and information needs plan will be developed. It may include applied research related to:

- Technology
 - Investigation of the application of new analyses, monitoring equipment and surveillance equipment, such as:
 - Use of continuous monitoring meters with telemetry for real time monitoring of conditions.
 - Use of satellite imagery, monitoring aerial unmanned vehicles, and other aircraft-based sensor technology to monitor cyanobacterial blooms.
 - Flow cytometer and Luminex Assays as potential monitoring methods.
 - Molecular PCR and qPCR techniques for identification and quantification of cyanobacteria and toxin production potential.
- Pilot Studies
 - Coordination with academia and other local agencies to develop enhanced monitoring and detection techniques.
- Predictive Tools/Prevention
 - In consultation with the HAB prevention and mitigation Expert Team formed in response to the Governor's Harmful Algal Blooms (HABs) Initiative, use of water quality data, bathymetry, weather/ climate, land use and other information to predict possible HAB events and/or prevent such events through lake management.
- Treatment
 - In consultation with the HAB prevention and mitigation Expert Team formed in response Governor's Harmful Algal Blooms (HABs) Initiative, build on existing efforts to develop a database of treatment technologies.
 - Evaluate effective treatment for prevention and elimination of HABs (communities and toxins).

New information and enhancements will be added to the DWMS HABs website and/ or this Strategy as it becomes available.

7. OUTREACH and COMMUNICATION

DEP will continue its efforts to provide up-to-date and easily accessible information, both within the Department, to other State and local agencies, as well as to the public. Communication mechanisms which continue to be pursued include, but are not limited to:

- Implementation of “improve communication” component of the Governor’s Harmful Algal Blooms (HABs) Initiative.
 - Continue to enhance the HAB website to include updated scientific information and other information related to HABs and public health risk
 - Continue to enhance interactive HAB mapping and communication system so that data is easily accessible and downloadable.
- Continue development of new and revision of existing fact sheets and other outreach material (e.g., general information posters and post cards) for intra-Departmental, other government agency, partners and public use.
- Continue maintaining and enhancing both overall DEP HAB website (<https://www.nj.gov/dep/hab/>) as well as BFBM CyanoHAB website (<https://www.state.nj.us/dep/wms/bfbm/CyanoHABHome.html>)
- Continue making all outreach material available for download at: <https://www.state.nj.us/dep/hab/outreach-material.html>. Outreach material will include, but is not limited to:
- Continue to update DEP HAB Fact Sheets as new information becomes available
 - Cyanobacterial Harmful Algal Blooms (HABs)
 - Cyanobacteria Harmful Algal Blooms (HABs) and Cyanotoxins: Recreational Exposure and Health Effects
 - Harmful Algal Blooms and Pets
- Continue to refine physical signage to be used in response to suspected or confirmed HABs.
- Continue communication/ coordination on HABs, and development of surveillance and monitoring partnerships with the members of the New Jersey Water Monitoring Council (NJWMC) which serves as a statewide body to promote and facilitate the coordination, collaboration and communication of scientifically sound, ambient water quality and quantity information to support effective water resource management.
- Continue communication/coordination with county and local health departments through avenues such as the County Environmental Health Act (CEHA) program and the Cooperative Coastal Monitoring Program (CCMP).
- Continue training and information exchange for DEP programs, partners and the public, such as in-person training, webinars, videos, web- based training, and HAB Summits.
- Continue to develop meter loan program for partners for the purpose of screening and monitoring HABs.
- Continue working with State Park Service and Division of Fish and Wildlife to provide and enhance, where necessary, information that would be accessible at New Jersey State Parks and Wildlife Management Areas. Items include physical signage, informational material, increased information on individual park and wildlife management area websites, etc.
- Continue to enhance various additional platforms for communicating HABs information, including social media and listservs.
- Investigate use of the Center for Disease Control’s One Health Harmful Algal Bloom System (OHHABS). The One Health Harmful Algal Bloom System (OHHABS) is a voluntary reporting system available to state and territorial public health departments and their designated

environmental health or animal health partners. It collects data on individual human and animal cases of illnesses from HAB-associated exposures, as well as environmental data about HABs. The goal of OHHABS is to collect information to support the understanding and prevention of HABs and HAB-associated illnesses. DOH is the lead in exploring State participation in this effort.

8. References

1. NJDEP. Division of Science, Research and Environmental Health. Recommended NJ Action Level and Health Advisory Guidelines for Recreational Exposure to Microcystin-LR, Cylindrospermopsin, and Anatoxin –A. 2017.
2. ORSANCO. Ohio River Valley Residents' River-Based Recreation and Consumption of Freshwater Fish. 2018. <http://www.orsanco.org/wp-content/uploads/2018/07/Ohio-River-Valley-Residents-River-Based-Recreation-and-Consumption-of-Fresh-Water-Fish.pdf>
3. USEPA. Developing a Cyanobacteria Monitoring & Bloom Watch Program | EPA & Minnesota Sea Grant. November 9, 2016.
4. USEPA. 40 CFR Part 131 [OW–2004–0010; FRL–7785–6] RIN 2040–AE63 Water Quality Standards for Coastal and Great Lakes Recreation Waters.
5. USEPA's HABs website: <https://www.epa.gov/nutrient-policy-data/cyanobacterial-harmful-algal-blooms-water>
6. USEPA. Recommended Human Health Recreational Ambient Water Quality Criteria or Swimming Advisories for Microcystins and Cylindrospermopsin. EPA 822-P-19-001. U.S. Environmental Protection Agency, Office of Water and Office of Research and Development, Washington, DC. 2019.
7. USEPA. (Final). Survey of the Nation's Lakes: Integrated Quality Assurance Project Plan. EPA/841-B-07-003. U.S. Environmental Protection Agency, Office of Water and Office of Research and Development, Washington, DC. 2009.
8. USEPA. Recommendations for Public Water Systems to Manage Cyanotoxins in Drinking Water. Office of Water (4606M). EPA 815-R-15-010. June 2015.
9. USGS. Graham, J.L., Dubrovsky, N.M., and Eberts, S.M., 2016, Cyanobacterial harmful algal blooms and U.S. Geological Survey science capabilities: U.S. Geological Survey Open-File Report 2016–1174, 12 p., <https://pubs.er.usgs.gov/publication/ofr20161174>.
10. USGS. Loftin, K. A., Ziegler, A. C., and Meyer, M. T. 2008. Guidelines for design and sampling for cyanobacterial toxin and taste-and-odor studies in lakes and reservoirs. U.S. Department of the Interior, U.S. Geological Survey
11. World Health Organization. Guidelines for Safe Recreational Water Environments. 2003. http://www.who.int/water_sanitation_health/publications/srwe1/en/.

Links to information websites including CDC, EPA, WHO can be found at the DWMS HAB webpage: <https://www.state.nj.us/dep/hab/>.

Appendix A

Workgroup Members and Workgroup Agency Contact Information

New Jersey Harmful Algal Bloom (HAB) Workgroup

DEP DWMS

Victor Poretti
Tom Miller
Dean Bryson
Alena Baldwin-Brown
Johannus Franken
Mike Kusmiesz
Bob Schuster
Ismail Sukkar
Rachel White
Aynan Zaman
Bruce Friedman
Tracy Fay
Chris Kunz

DEP DSR

Robert Newby
Gloria Post
Nick Procopio

DEP WRM
Monique Girona
Chelsea Brook

DEP Water Supply and Geoscience

Matthew Wilson
Kelley Meccia
Christian Haviland

Joseph McNally

DEP State Park Service

Blanca Chevrestt, Northern Region
Jonathan Luk, Central Region
Dave Robbins, Southern Region
Jenny Felton, Spruce Run
Lauren Rojewski, Spruce Run
Josh Osowski, Regional Superintendent
Northern Region Office

DEP Fish and Wildlife

Lisa Barno, Freshwater Fisheries
Jan Lovy, Office of Fish and Wildlife
Health and Forensics
Nicole Lewis, Office of Fish and Wildlife
Health and Forensics

DEP Office of Quality Assurance

Melissa Hornsby

DOH Division of Epidemiology, Environmental and Occupational Health/Consumer, Environmental and Occupational Health Service (CEOHS)

Loel Muetter
Danielle Clemons
Gary Centifonti

DOH Division of Epidemiology, Environmental and Occupational Health/ Communicable Disease Service (CDS)

Deepam Thomas
Rebecca Greeley
Barbara Carothers

Department of Agriculture/ Division of Animal Health

Manoel Tamassia
Sebastian Reist

Workgroup Agency Contact Information

DEP

DEP HAB Main Page: <https://www.state.nj.us/dep/hab/>

DEP HAB Reporting System:

<https://survey123.arcgis.com/share/993bfe45dc494666af762b5397c12b9c>

DEP HAB Interactive Map for data and Alerts:

<https://njdep.maps.arcgis.com/apps/opsdashboard/index.html#/49190166531d4e5a811c9a91e4a41677>

DEP Hotline - 877-WARN-DEP (877-927-6337) <http://www.nj.gov/dep/warndep.htm>
<https://www.state.nj.us/dep/hab/>

DEP Division of Water Monitoring and Standards

<http://www.nj.gov/dep/wms/>

njcyanoabs@dep.nj.gov

DEP Bureau of Freshwater and Biological Monitoring (BFBM) HABs 609 -292-0427

<http://www.state.nj.us/dep/wms/bfbm/CyanoHABHome.html>

DEP Division of Science and Research

609-940-4080

<http://www.nj.gov/dep/dsr/>

DEP Division of Water Supply and Geoscience

609-292-7219

watersupply@dep.nj.gov

<http://www.nj.gov/dep/watersupply/>

DEP Division of Fish & Wildlife

609-292-2965

<http://www.nj.gov/dep/fgw/>

DEP State Park Service

<http://www.nj.gov/dep/parksandforests/>

Southern Region 609-704-1951

Jurisdiction: Wharton State Forest, Atsion State Park, Bass River State Forest, Belleplain State Forest, Parvin State Park

Central Region 908-236-2043

Jurisdiction: Cheesequake State Park, Round Valley Recreation Area, Spruce Run Recreation Area

Northern Region 973-786-5210

Jurisdiction: High Point State Park, Hopatcong State Park, Ringwood State Park, Stokes State Forest, Swartwood State Park, Wawayanda State Park

DEP Compliance and Enforcement/ Division of Water and Land Use Enforcement

<http://www.nj.gov/dep/enforcement/dwlue.html>

609-984-2011

Bureau of Water Compliance & Enforcement-Northern

973-656-4099

Jurisdiction: Counties of Bergen, Essex, Hudson, Hunterdon, Morris, Passaic, Somerset, Sussex, and Warren

Bureau of Water Compliance & Enforcement-Central

609-292-3010

Jurisdiction: Counties of Mercer, Middlesex, Monmouth, Ocean, and Union

Bureau of Water Compliance & Enforcement-Southern

856-614-3655

Jurisdiction: Counties of Atlantic, Burlington, Camden, Cape May, Cumberland, Gloucester, and Salem

DEP Office of Quality Assurance

(609) 292-3950

<http://www.nj.gov/dep/enforcement/oqa.html>

New Jersey Department of Health (DOH)

AFTER HOURS EMERGENCY CONTACT

609-392-2020

NJDOH Public Health and Food Protection Program (PHFPP):

<http://www.nj.gov/health/ceohs/sanitation-safety/environmental/>

609-826-4935

Consumer, Environmental and Occupational Health Service

<http://www.nj.gov/health/ceohs/index.shtml>

Public Recreational Bathing Project

<http://www.nj.gov/health/ceohs/sanitation-safety/environmental/>

Local Health Department Directory

<http://nj.gov/health/lh/directory/lhdselectcounty.shtml>

New Jersey Department of Agriculture

Division of Animal Health/ New Jersey Animal Emergency Response

609-671-6400

<http://www.nj.gov/agriculture/divisions/ah/>

Local and County Health Department Notification List:

<http://nj.gov/health/lh/directory/lhdselectcounty.shtml>

In New Jersey, every municipality is required to be served by a local health department that meets the requirements of state public health laws and regulations. The local health departments listed in this directory are recognized by the New Jersey Department of Health as the provider of public health services for those municipalities within their jurisdiction.

Should you have questions about available public health services or concerns about health conditions within a particular municipality, please use this directory to obtain important information about how to contact the local health department. In cases where a municipality is temporarily without the services of a local health department, you will be provided with contact information for that municipality's administrative offices.

To begin your search, select a county or municipality from the link above. You may also print the [Directory of Local Health Departments in New Jersey](#) which includes 24 hour emergency contacts for each jurisdiction.

APPENDIX B – HAB Sample Collection Method

Harmful Algae Bloom (HAB) Sample Collection Division of Water Monitoring and Standards/ Bureau of Freshwater and Biological Monitoring (BFBM)

HAB Field Collection Procedure For DEP BFBM Laboratory Analyses

OBJECTIVE

Harmful Algal Blooms, “HABs”, is the name given to the excessive growth, or “blooms”, of algae and algae-like bacteria which can be harmful to people and animals. These “blooms” often result in a thick coating or “mat” on the surface of a body of freshwater, often most frequently in the summer or fall. Algae-like bacteria which occur primarily in freshwater, or cyanobacteria can form HABs that may produce chemicals which can be toxic to humans, pets, livestock or wildlife. These chemicals are called cyanotoxins.

Cyanotoxins can be produced by a wide variety of planktonic (i.e., free living in the water column) cyanobacteria. One of the most commonly occurring types of cyanobacteria is Microcystis which can produce a common group of toxins called microcystins, as well other toxins. Microcystins may cause adverse health effects to humans and animals, if ingested, if contacted by skin or mucous membranes, or if inhaled. Other types of cyanotoxins, include anatoxin and cylindrospermopsin.

The procedure for field sample collection provided below is for analyses at DEP’s BFBM HAB laboratory. If collecting water samples for analyses at another laboratory, that facility should be contacted for their specific field sample collection procedures.

SAMPLING PROCEDURES for ANALYSIS AT DEP’s BFBM HAB LABORATORY

Equipment and Supplies

- Protective gloves
- 500 ml bottles
- BFBM labels
- Cooler with ice.

Notifications

- A Harmful Algal Bloom report, can be submitted by smartphone or PC using the [NJDEP HAB Reporting and Communication System](#). The HAB Reporting and Communication System will be used to gather initial information such as: location coordinates, photos, known activities, and extent over the waterbody. This information will be used to inform DEP to initiate appropriate response actions. Once the DEP completes the investigation of the suspected HAB, results and recommendations for public notices or advisories will be communicated through the HAB

System. All information and data will be accessible to the public by clicking the location on the interactive map in the HAB System. If a smart phone or computer are not available, reports may also be submitted to the DEP Hotline at 1-877-WARNDEP (927-6337).

- Upon receipt of report, BFBM will contact partner to coordinate sampling and to assure the correct measurements are recorded and necessary sampling supplies are in hand.
- BFBM will coordinate appropriate lab analysis.

Sample Collection/ Analysis/ Actions

- Protective gloves should be worn during sample collection and analysis. Avoid contact with water; if wading, boots should be worn.

Samples for BFBM analysis may include: cyanobacterial IDs, cell counts, toxin analyses (microcystins, anatoxin, cylindrospermopsin, and/ or saxitoxin) and/or chlorophyll a)

- Collect samples at designated locations, filling one (1) 500 ml amber glass bottle for lab analysis at BFBM. Brown plastic bottles made of polyethylene terephthalate glycol (PETG) or High Density Polyethylene (HDPE), wrapped in foil may be used as an alternative to glass.
- Samples should be collected just below the surface so mouth of bottle is immersed approximately 3-6 inches. (make sure algae is represented in sample)
- Fill out label with permanent marker and place on sample bottle.
- Refrigerate samples, or place in cooler with ice.
- Contact BFBM to arrange for sample pickup/ delivery within 24 hours. Contact info below.
- Based on lab analysis, BFBM will recommend and coordinate advisories, and continued monitoring and analysis as needed.

BFBM Contacts (609) 292-0427

Victor Poretti, Section Chief

Dean Bryson, Supervisor

Johannus Franken, Field Project Officer

Tom Miller, Lab Project Officer

Chris Kunz, Supervisor

APPENDIX C - Cyanotoxin Analysis Methods and Specifications

Importance of Microcystins/Nodularins Determination

Most of the world's population relies on surface freshwaters as its primary source for drinking water. The drinking water industry is constantly challenged with surface water contaminants that must be removed to protect human health. Toxic cyanobacterial blooms are an emerging issue worldwide due to increased source water nutrient pollution caused by eutrophication. Microcystins and Nodularins are cyclic toxin peptides. Microcystins (of which there are many structural variants, or congeners) have been found in fresh water throughout the world. To date, approximately 80 variants of Microcystin have been isolated. The most common variant is Microcystin-LR. Other common Microcystin variants include YR, RR, and LW. These toxins are produced by many types of cyanobacteria (blue-green algae), including *Microcystis*, *Anabaena*, *Oscillatoria*, *Nostoc*, *Anabaenopsis*, and terrestrial *Hapalosiphon*. Nodularins are produced by the genus *Nodularia* and they are found in marine and brackish water.

Acute poisoning of humans and animals constitutes the most obvious problem from toxic cyanobacterial blooms, and in several cases has led to death. Human and animal exposure to these toxins occurs most frequently through the ingestion of water, through drinking or during recreational activities in which water is swallowed. These toxins mediate their toxicity by inhibiting liver function and are potent inhibitors of the serine/threonine protein phosphatases, and therefore they may act as tumor promoters.

To protect consumers from adverse health effects caused by these toxins, the World Health Organization (WHO) has proposed a provisional upper limit for Microcystin-LR of 1.0 ppb (µg/L) in drinking water. For recreational bathing waters, the WHO has established the following guidelines:

- Relatively low risk of exposure effect at 4 ng/mL (ppb)
- Moderate probability of exposure effect at 20 ng/mL
- High probability of exposure effect – scums

The U.S. Environmental Protection Agency (EPA) has also established guidelines for Microcystins in drinking water:

- For children below school age, 0.3 µg/L (ppb)
- For all other age groups, 1.6 µg/L (ppb)

Performance Data

Test sensitivity: The Abraxis Microcystins Strip Test for Recreational Water will detect Microcystins and Nodularins at 1 ng/mL or higher. At this level, the test line exhibits moderate intensity. At levels greater than 10 ng/mL, the test line is not visible. When compared with samples of known Microcystins concentration, it is possible to obtain a semi-quantitative result.

Selectivity: The assay exhibits very good cross-reactivity with all Microcystin cyclic peptide toxin congeners tested to date.

Cell Lysing: When comparing samples lysed using the QuikLysTM reagents and the 3 cycle freeze/thaw method, average recovery obtained was 94%, SD = 16.7%.

Samples: A sample correlation between the Abraxis Strip Test and ELISA methods showed a good correlation.

General Limited Warranty/Disclaimer: Abraxis, Inc. warrants the products manufactured by the Company, against defects and workmanship when used in accordance with the applicable instructions for a period not to extend beyond the product's printed expiration date. Abraxis, Inc. makes no other warranty, expressed or implied. There is no warranty of merchantability or fitness for a particular purpose. The ETV verifies the performance of commercial ready technologies under specific criteria, testing conditions, and quality assurance. ETV does not imply approval or certification of this product, nor does it make any explicit or implied warranties or guarantees as to product performance. www.epa.gov/etv

For ordering or technical assistance contact:

Abraxis, Inc.
124 Railroad Drive
Warrameter, PA 18974
Tel: (215) 357-3911
Fax: (215) 357-5232
Email: info@abraxiskits.com
WEB: www.abraxiskits.com



R071216

Microcystins Strip Test

Immunochromatographic Strip Test for the Detection
of Microcystins and Nodularins in Recreational Water at 10 ppb



Product No. 520023 (5 Test), 520022 (20 Test)

1. General Description

The Abraxis Microcystins Strip Test for Recreational Water is a rapid immunochromatographic test, designed solely for the use in the qualitative screening of Microcystins and Nodularins in recreational water (freshwater samples only; please see the Brackish or Sea Water Sample Preparation technical bulletin for information on the screening of marine water samples). A rapid cell lysis step (QuikLysTM) performed prior to testing is required to measure total Microcystins (dissolved, or free, plus cell-bound). The Abraxis Microcystins Strip Test provides only preliminary qualitative test results. If necessary, positive samples can be confirmed by ELISA, HPLC or other conventional methods.

* Patent Pending

2. Safety Instructions

Discard samples according to local, state and federal regulations.

3. Storage and Stability

The Microcystins Strip Kit should be stored between 4-30°C. The test strips, test vials and water samples to be analyzed should be at room temperature before use.

4. Test Principle

The test is based on the recognition of Microcystins, Nodularins, and their congeners by specific antibodies. The toxin conjugate competes for antibody binding sites with Microcystins/Nodularins that may be present in the water sample. The test device consists of a vial containing specific antibodies for Microcystins and Nodularins labeled with a gold colloid and a membrane strip to which a conjugate of the toxin is attached. A control line, produced by a different antibody/antigen reaction, is also present on the membrane strip. The control line is not influenced by the presence or absence of Microcystins in the water sample and, therefore, should be present in all reactions.

In the absence of toxin in the water sample, the colloidal gold labeled antibody complex moves with the water sample by capillary action to contact the immobilized Microcystins conjugate. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of two visible lines of similar intensity indicates a negative test result, meaning the test did not detect the toxin at or above the cut-off point established for the toxin. If Microcystins are present in the water sample, they compete with the immobilized toxin conjugate in the test area for the antibody binding sites on the colloidal gold labeled complex. If a sufficient amount of toxin is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the toxin conjugate, therefore preventing the development of a colored line. If a colored line is not visible in the test line region, or if the test line is lighter than the control line, Microcystins are present at a level > 2.5 ppb. Semi-quantitative results in the range of 0-10 ppb can be obtained by comparing the sample test strip appearance to the appearance of test strips from solutions of known Microcystins concentrations (control solutions). Microcystins controls are available through Abraxis (PN 422011).

5. Limitations of the Microcystins Strip Test, Possible Test Interference

Numerous organic and inorganic compounds commonly found in water samples have been tested and found not to interfere with this test. However, due to the high variability of compounds that might be found in water samples, test interferences caused by matrix effects can't be completely excluded.

Mistakes in handling the test can also cause errors. Possible sources for such errors include:

Inadequate storage conditions of the test strip, too long or too short incubation times, extreme temperatures during the test performance (lower than 10°C or higher than 30°C).

The test is designed for use with freshwater recreational waters. The use of the test with brackish or seawater samples will produce inaccurate results. Please see the Brackish or Sea Water Sample Preparation technical bulletin for information on the preparation and screening of marine water samples using the Microcystins Strip Test for Finished Drinking Water. The Microcystins Strip Test provides only a preliminary qualitative test result. Use another more quantitative analytical method such as ELISA or instrumental analysis to obtain a confirmed quantitative analytical result. Apply good judgement to any test result, particularly when preliminary positive results are observed.

6. Warnings and Precautions

- The Microcystins Strip Test for Recreational Water is for the screening of freshwater recreational water samples for total Microcystins (free and cell-bound). Please see the Bradish or Sea Water Sample Preparation technical bulletin for the preparation and screening of marine water samples using the Microcystins Strip Test for Finished Drinking Water.
- Use of the Microcystins Test Strips **without** the QuikLysTM reagents will adversely affect the performance of the test, producing inaccurate results. To test samples without using QuikLysTM reagents for cell lysis, such as when testing for free Microcystins only or when testing samples which have been previously lysed (such as those which have undergone the freeze/thaw method), please use the Abraxs Microcystins Strip Test for Finished Drinking Water at 1 ppb, PN520016 (5 Test) or PN 520017 (20 Test).
- Use only the Microcystins test strips and QuikLysTM reagents from one kit lot, as they have been adjusted in combination.
- All reagents and samples should be allowed to reach room temperature before testing.
- Prior to use, ensure that the product has not expired by verifying that the date of use is prior to the expiration date on the label.
- For test strips packaged in a desiccated vial, the vial should be kept completely closed except for opening to remove test strips. When re-closing, snap lid firmly.
- Avoid cross-contamination of water samples by using a new sample vial and disposable pipette for each sample.
- Samples containing unusually large amounts of algal blooms or very thick algal scums should be diluted 1:1 with deionized or distilled water prior to lysis; an overly viscous sample may not allow for uniform cell lysis or proper capillary flow up the test strip. Diluted samples will have a cut-off of 20 ppb.
- Use reasonable judgment when interpreting the test results.
- Results should be interpreted within 5-10 minutes after completion of the test.

7. Sample Collection and Handling

- Collect water samples in glass or polyethylene terephthalate (PETG) containers only. The use of other types of plastic containers may result in adsorptive loss of Microcystins, producing inaccurate (falsely low) results.
- Samples can be stored refrigerated for up to 5 days. If samples must be held for greater than 5 days, samples should be stored frozen.

A. Materials Provided

1. Microcystins test strips in a desiccated container
2. Sample collection vials
3. Lysis vials
4. Graduated disposable pipettes (calibrated at 1 mL)
5. Forceps
6. Reagent papers
7. Conical test vials
8. Disposable transfer pipettes
9. User's guide

B. Additional Materials (not provided with the test)

1. Timer
2. Microcystins Check Samples, Abraxs PN 42011, for the preparation of control solutions which can be analyzed with samples, to obtain semi-quantitative sample results (see section C, Assay Controls, below).

C. Controls

It is a good laboratory practice to use positive and negative controls to ensure proper test performance. Water samples containing known quantities of Microcystins (positive and negative controls) should be analyzed with each lot of test strips to provide a reference for line intensity to be expected.

D. Test Preparation

1. Allow the reagents and water sample to reach room temperature before use.
2. Remove the number of test strips required from the package. The remaining strips are stored in the tightly closed desiccated container.

E. Procedure

When analyzing for total Microcystins (dissolved, or free, and cell-bound), which may be present in recreational waters, a sample lysis is necessary before analysis. The Abraxs QuikLysTM reagents provide a rapid option for cell lysis.

1. Using a new graduated disposable pipette for each sample, draw the sample to the 1 mL line (graduation mark slightly below bubble) and add 1 mL of sample to the lysis vial.
2. Cap the vial and shake for 2 minutes, then allow the sample in the vial to incubate at room temperature for 8 minutes, to begin the cell lysis.
3. Using the forceps provided, add 1 reagent paper to the lysis vial.


4. Cap the vial and shake for 2 minutes, then allow the sample in the vial to incubate at room temperature for 8 minutes.
5. Label conical test vials for each sample to be tested.
6. Using a new disposable transfer pipette for each sample, transfer 7 drops (approximately 200 μ L) of the previously lysed water sample (Steps 1-4 above) to the appropriately labeled conical test vial.
7. Close the conical test vial and shake for 30 seconds. Examine the vial to ensure all dried reagents are completely dissolved (dried reagents will dissolve, turning the sample purple).
8. Insert test strip (arrow down) into the conical vial.
9. Allow the test to develop for 10 minutes.
10. Remove the test strip. Lay the strip flat and allow to continue developing for 5 minutes.
11. Read the results visually as explained below in section F, Interpretation of Results.

F. Interpretation of Results

Sample concentrations are determined by comparison of the intensity of the test line to the intensity of the control line on the same test strip. Although control line intensity may vary, a visible control line must be present for results to be considered valid. Test strips with a test line which is darker than or of equal intensity to the control line indicates a result which is below the limit of detection of the test. Test strips with a test line which is lighter than the control line indicates a result which is <10 ppb. Test strips with no test line visible (only the control line is visible) indicates a result which is ≥ 10 ppb. Results should be determined within 5-10 minutes after completion of the strip test procedure. Determination made using strips which have dried for more or less than the required time may be inaccurate, as line intensities may vary with drying time.

Control Line	Test Line	Interpretation
No control line present	No test line present	Invalid result
Control line present	No test line present	> 10 ng/mL (ppb)
Control line present	Moderate to equal intensity test line present	Between 0 and 10 ng/mL (ppb)

The appearance of test strips may also be compared to the illustration below to determine approximate sample concentration ranges. Please note that the illustration is intended for the demonstration of test line to control line intensity only. Results should not be determined by comparing the intensity of test lines from test strips to the test line intensity of the illustration, as the overall intensity of test strips may vary slightly with different lots of reagents. To obtain semi-quantitative results in the range of 0-10 ppb, solutions of known Microcystins concentration (control solutions) must be tested concurrently with samples. Sample test line intensities can then be compared with control solution test line intensities, yielding approximate sample concentrations. Do not use strips run previously to determine semi-quantitative sample concentrations, as test line intensities may vary once strips are completely dry.



Alternately, test strips can also be interpreted using the AbraxScan test strip reader (PN 475025), which provides objective determination of line intensities for consistent interpretation of results as well as a digital photographic record of all test strips.

G. Additional Analysis

If necessary, positive samples can be confirmed by ELISA, HPLC or other conventional methods. These services are available from commercial analytical laboratories such as Green Water Labs (www.greenwaterlabs.com).

H. References

- (1) Ill. J. Fischer, I. Garthwaite, C.O. Miles, K.M. Ross, J.B. Aggrey, A.R. Chamberlain, N.A. Townes, and D.R. Diebih, Congener Independent Immunoassay for Microcystins and Nodularins. Environ. Sci. Technol. 35, 2002, 4949-4956.
- (2) Worldwide Patenting PCT WO 01/18059 A2.
- (3) U.S. Patent Number 6,967,240.

Importance of Microcystins/Nodularins Determination

Most of the world's population relies on surface freshwaters as its primary source for drinking water. The drinking water industry is constantly challenged with surface water contaminants that must be removed to protect human health. Toxic cyanobacterial blooms are an emerging issue worldwide due to increased source water nutrient pollution caused by eutrophication. Microcystins and Nodularins are cyclic toxin peptides. Microcystins (of which there are many structural variants, or congeners) have been found in fresh water throughout the world. To date, approximately 80 variants of Microcystin have been isolated. The most common variant is Microcystin-LR. Other common Microcystin variants include YR, RR, and LW. These toxins are produced by many types of cyanobacteria (blue-green algae), including *Microcystis*, *Anabaena*, *Oscillatoria*, *Nostoc*, *Anabaenopsis*, and terrestrial *Hepatosiphon*. Nodularins are produced by the genus *Nodularia* and are found in marine and brackish water.

Acute poisoning of humans and animals constitutes the most obvious problem from toxic cyanobacterial blooms, and in several cases has led to death. Human and animal exposure to these toxins occurs most frequently through ingestion of water, through drinking or during recreational activities in which water is swallowed. These toxins mediate their toxicity by inhibiting liver function and are potent inhibitors of the serine/threonine protein phosphatases, and therefore may act as tumor promoters.



To protect consumers from adverse health effects caused by these toxins, the World Health Organization (WHO) has proposed a provisional upper limit for Microcystin-LR of 1.0 ppb ($\mu\text{g/L}$) in drinking water.

Performance Data

Test sensitivity: The detection limit for this assay, based on MC-LR, is 0.10 ppb ($\mu\text{g/L}$).

Test reproducibility: Coefficients of variation (CVs) for standards: <10% for samples: <15%.

Selectivity*: The assay exhibits very good cross-reactivity with all cyanobacterial cyclic peptide toxin congeners tested to date (see cross-reactivity illustration below).



Samples: Sample correlation between HPLC, PPA, and ELISA methods showed a good correlation (see ELISA and PPA correlation above).

References

- (1) W. J. Fischer, I. Gathwaite, C.O. Miles, K.M. Ross, J.B. Aggen, A.R. Chamberlin, N.A. Taverner, and D.R. Dietrich, Congener-independent Immunoassay for Microcystins and Nodularins. *Environ. Sci. Technol.* 35, 2001, 4849-4858.
- (2) Worldwide Patenting PCT WO 01/18059 A2.
- (3) U.S. Patent Number 6,967,240.

General Limited Warranty/Disclaimer: Abraxis LLC warrants the products manufactured by the Company, against defects and workmanship when used in accordance with the applicable instructions for a period not to extend beyond the product's printed expiration date. Abraxis LLC makes no other warranty, expressed or implied. There is no warranty of merchantability or fitness for a particular purpose. The ETV verifies the performance of commercial ready technologies under specific criteria, testing conditions, and quality assurance. The ETV does not imply approval or certification of this product, nor does it make any explicit or implied warranties or guarantees as to product performance. www.epa.gov/etv.

For ordering or technical assistance contact:

Abraxis LLC
54 Steamwhistle Drive
Warminster, PA 18974
Tel.: (215) 351-3911
Fax: (215) 351-3422
Email: info@abraxiskits.com
WEB: www.abraxiskits.com



RD1131504

Microcystins-ADDA ELISA (Microtiter Plate)

Enzyme-Linked Immunosorbent Assay for the Congener-Independent* Determination of Microcystins and Nodularins in Water Samples



Product No. 520011OH

1. General Description

The Abraxis Microcystins-ADDA ELISA is an immunoassay for the quantitative and sensitive congener-independent* detection of Microcystins and Nodularins in water samples. This test is suitable for the quantitative and/or qualitative detection of Microcystins and Nodularins in water samples [please refer to the appropriate technical bulletins for sample collection, handling, and treatment of drinking (treated and untreated) and recreational water samples]. If necessary, positive samples can be confirmed by HPLC, protein phosphatase assay, or other conventional methods.

2. Safety Instructions

The standard solutions in the test kit contain small amounts of Microcystins. The substrate solution contains tetramethylbenzidine (TMB) and the stop solution contains diluted sulfuric acid. Avoid contact of the TMB and stopping solution with skin and mucous membranes. If these reagents come in contact with skin, wash with water.

3. Storage and Stability

The Microcystins-ADDA ELISA kit should be stored in the refrigerator (4–8°C). The solutions must be allowed to reach room temperature (20–25°C) before use. Reagents may be used until the expiration date on the box. Consult state, local, and federal regulations for proper disposal of all reagents.

4. Test Principle

The test is an indirect competitive ELISA for the congener-independent detection of Microcystins and Nodularins. It is based on the recognition of Microcystins, Nodularins, and their congeners by specific antibodies. Toxin, when present in a sample, and a Microcystine-protein analogue immobilized on the plate compete for the binding sites of the anti-Microcystins/Nodularins antibodies in solution. The plate is then washed and a second antibody-HRP label is added. After a second washing step and addition of the substrate solution, a color signal is generated. The intensity of the blue color is inversely proportional to the concentration of Microcystins present in the sample. The color reaction is stopped after a specified time and the color is evaluated using an ELISA reader. The concentrations of the samples are determined by interpolation using the standard curve constructed with each run.

5. Limitations of the Microcystins-ADDA ELISA, Possible Test Interference

Numerous organic and inorganic compounds commonly found in water samples have been tested and found not to interfere with this test. However, due to the high variability of compounds that may be found in water samples, test interferences caused by matrix effects cannot be completely excluded.

Samples containing methanol must be diluted to a concentration < 5% methanol to avoid matrix effects.

Seawater samples must be diluted to a concentration $\leq 2.5\%$ to avoid matrix effects. Alternately, if a lower detection limit is required, interfering compounds can be removed from seawater or brackish water samples prior to analysis. Please see the Microcystins in Brackish Water or Seawater Sample Preparation for the Microcystins-ADDA ELISA Technical Bulletin (available upon request).

No matrix effects have been observed with samples which have been treated with sodium thiosulfate at concentrations $\leq 1 \text{ mg/mL}$ or ascorbic acid at concentrations $\leq 1 \text{ mg/mL}$.

Mistakes in handling the test can cause errors. Possible sources for such errors include: inadequate storage conditions of the test kit, incorrect pipetting sequence or inaccurate volumes of the reagents, too long or too short incubation times during the immune and/or substrate reaction, and extreme temperatures during the test performance (lower than 10°C or higher than 30°C).

As with any analytical technique (GC, HPLC, etc.), positive results requiring regulatory action should be confirmed by an alternative method.

A. Materials Provided

1. Microtiter plate (12 X 8 strips) coated with an analog of Microcystins conjugated to a protein
2. Standards (6): 0, 0.15, 0.40, 1.0, 2.0, 5.0 ppb
3. Control: 0.75 \pm 0.185 ppb, prepared from a secondary source, for use as a Quality Control Standard (QCS)
4. Low Calibration Range Check (LCRC): 0.40 \pm 0.16 ppb
5. Sample Diluent, for use as a Laboratory Reagent Blank (LRB) and for dilution of samples above the range of the standard curve
6. Antibody Solution
7. Anti-Sheep-HRP Conjugate Solution
8. Wash Solution (5X) Concentrate, must be diluted prior to use, see Test Preparation (Section E)
9. Substrate (Color) Solution (TMB)
10. Stop Solution

B. Additional Materials (not delivered with the test kit)

1. Micro-pipettes with disposable plastic tips (20-200 μ L)
2. Multi-channel pipette (50-300 μ L), stepper pipette (50-300 μ L), or electronic repeating pipette with disposable plastic tips
3. Deionized or distilled water
4. Container with 500 mL capacity (for 1X diluted wash solution; see Test Preparation, Section E)
5. Graduated cylinder
6. Paper towels or equivalent absorbent material
7. Timer
8. Tape or parafilm
9. Microtiter plate reader (wavelength 450 nm)
10. Microtiter plate washer (optional)

C. Sample Collection and Handling

Collect water samples in **glass** or **PETG** containers and test within 24 hours. Use of other types of plastic collection and/or storage containers may result in adsorptive loss of Microcystins, producing inaccurate (falsely low) results. Drinking water samples should be treated with sodium thiosulfate immediately after collection (refer to appropriate technical bulletin). If samples must be held for longer periods (up to 5 days), samples should be stored refrigerated. For storage periods greater than 5 days, samples should be stored frozen.

If total Microcystins concentration (free and cell bound) is required, an appropriate cell lysing procedure (freeze and thaw, QuikLysTM, etc.) must be performed prior to analysis. *Note: The use of sonication in cell lysing can negatively affect toxin concentrations, producing falsely low sample results. Please see the appropriate sample preparation technical bulletin for additional information on cell lysis.*

Samples may be filtered prior to analysis using glass fiber filters (Environmental Express 1.2 μ m syringe filters (Environmental Express part number SF012G) are recommended). If determining total Microcystins concentration, samples should be lysed prior to filtration to prevent the removal of cell-bound Microcystins, which would cause inaccurate (falsely low) results. *Note: The use of alternate filter types (non-glass fiber filters) may produce falsely low sample results, as Microcystins may bind to the filter material, removing it from the sample.*

D. Notes and Precautions

Micro-pipetting equipment and pipette tips for pipetting the standards and the samples are necessary.

The use of a multi-channel pipette, stepping pipette, or electronic repeating pipette is recommended for the addition of the antibody, enzyme conjugate, substrate, and stop solutions in order to equalize the incubation periods on the entire microtiter plate.

To avoid drift and obtain accurate results, the addition of the antibody, conjugate, color, and stop solutions should be performed in less than 2 minutes for each reagent. If additions to the entire microtiter plate cannot be completed in less than 2 minutes, run size should be decreased to the number of rows which can be pipetted in less than 2 minutes.


Please use only the reagents and standards from one kit lot in one test, as they have been adjusted in combination.

E. Test Preparation

1. Allow the reagents and samples to reach ambient temperature before use.
2. Remove the number of microtiter plate strips required from the resealable pouch. The remaining strips are stored in the pouch with the desiccant (tightly sealed).
3. The standards, control, low calibration range check (LCRC), sample diluent (LRB), antibody, enzyme conjugate, substrate, and stop solutions are ready to use and do not require any further dilutions.
4. Dilute the Wash Solution (5X) Concentrate at a ratio of 1:5 with deionized or distilled water. If using the entire bottle (100 mL), add to 400 mL of deionized or distilled water and mix thoroughly.

F. Working Scheme

The microtiter plate consists of 12 strips of 8 wells, which can be used individually for the test. The standards must be run with each test. Never use the values of standards which have been determined in a test performed previously.



Std 0-Std5: Standards
Contr.: Control (QCS)
LCRC: Low Calibration Range Check
LRB: Laboratory Reagent Blank
Samp1, Samp2, etc: Samples

G. Assay Procedure

1. Add **50 μ L of the standard solutions, control, LCRC, LRB, or samples** into the wells of the test strips according to the working scheme given. Analysis in duplicate or triplicate is recommended.
2. Add **50 μ L of the antibody solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate the strips for **90 minutes** at room temperature.
3. Remove the covering and decant the contents of the wells into a sink. Wash the strips **three times** using the 1X wash buffer solution. Please use at least a volume of **250 μ L of wash buffer** for each well and each washing step. Remaining buffer in the wells should be removed by patting the plate dry on a stack of paper towels.
4. Add **100 μ L of the enzyme conjugate solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate the strips for **30 minutes** at room temperature.
5. Remove the covering and decant the contents of the wells into a sink. Wash the strips **three times** using the 1X wash buffer solution. Please use at least a volume of **250 μ L of wash buffer** for each well and each washing step. Remaining buffer in the wells should be removed by patting the plate dry on a stack of paper towels.
6. Add **100 μ L of substrate (color) solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate the strips for **20-30 minutes** at room temperature. Protect the strips from sunlight.
7. Add **50 μ L of stop solution** to the wells in the same sequence as for the substrate (color) solution using a multi-channel pipette or a stepping pipette.
8. Read the absorbance at 450 nm using a microplate ELISA photometer within 15 minutes after the addition of the stopping solution.

H. Evaluation

The evaluation of the ELISA can be performed using commercial ELISA evaluation programs such as 4-Parameter (preferred) or LogItLog. For a manual evaluation, calculate the mean absorbance value for each of the standards. Calculate the %B/B₀ for each standard by dividing the mean absorbance value for each standard by the Zero Standard (Standard 0) mean absorbance. Construct a standard curve by plotting the %B/B₀ for each standard on the vertical linear (y) axis versus the corresponding Microcystins concentration on the horizontal logarithmic (x) axis on graph paper. %B/B₀ for the control (QCS), LCRC, LRB, and samples will then yield levels in ppb of Microcystins by interpolation using the standard curve. Results can also be determined using a spreadsheet macro available from Abraxis upon request.

The concentrations of the samples are determined using the standard curve run with each test. Samples showing a lower concentration of Microcystins than standard 1 (0.15 ppb) should be reported as containing < 0.15 ppb of Microcystins. Samples showing a higher concentration than standard 5 (5.0 ppb) must be diluted to obtain accurate results. The concentration of the positive control (QCS) provided should be 0.75 \pm 0.185 ppb; the LCRC should be 0.40 \pm 0.16 ppb.

Semi-quantitative results can be derived by simple comparison of the sample absorbances to the absorbances of the calibrators. Samples with lower absorbances than a calibrator will have concentrations of Microcystins greater than that calibrator. Samples which have higher absorbances than a calibrator will have concentrations of Microcystins less than that calibrator.

Importance of Cylindrospermopsin Determination

Most of the world's population relies on surface freshwaters as its primary source for drinking water. The drinking water industry is constantly challenged with surface water contaminants that must be removed to protect human health. Toxic cyanobacterial blooms are an emerging issue worldwide due to increased source water nutrient pollution caused by eutrophication. Cylindrospermopsin is a toxin produced by several different strains of cyanobacteria (blue-green algae) and has been found in fresh water throughout the world. Certain strains of *Cylindrospermopsis raciborskii* (found in Australia, Hungary, and the United States), *Umezakia natans* (found in Japan), and *Aphanizomenon ovalisporum* (found in Australia and Israel) have been found to produce Cylindrospermopsin. The production of Cylindrospermopsin seems to be strain specific rather than species specific.

Acute poisoning of humans and animals constitutes the most obvious problem from toxic cyanobacterial blooms, and in several cases has led to death. Human exposure to Cylindrospermopsin can occur through ingestion of contaminated water or food (fish) or during recreational activities in which water is swallowed. Dermal contact with Cylindrospermopsin may occur during showering or bathing, or during recreational activities such as swimming or boating. These toxins mediate their toxicity by inhibiting liver function and are potent inhibitors of protein synthesis and glutathione, leading to cell death.

To protect against adverse health effects, the U.S. Environmental Protection Agency (EPA) has established guidelines for Cylindrospermopsin in drinking water:

- For children pre-school age and younger (less than six years old), 0.7 µg/L (ppb)
- For school-age children and adults, 3.0 µg/L (ppb)


Performance Data

Test sensitivity: The detection limit for this assay is 0.040 ppb (µg/L).

Test reproducibility: Coefficients of variation (CVs) for standards: <10% for samples: <15%.

Specificity: This ELISA recognizes Cylindrospermopsin and related compounds with varying degrees:
Cylindrospermopsin 100%
Deoxy-Cylindrospermopsin 112%

Standard Curve:



Samples: A sample correlation between the ELISA and HPLC methods showed a good correlation.

Recovery

Four (4) groundwater samples were spiked with various levels of Cylindrospermopsin and assayed using the Abraxis Cylindrospermopsin Assay.

Spiked Level (ppb)	Mean (ppb)	Std Dev (ppb)	Recovery (%)
0.1	0.101	0.019	101
0.25	0.269	0.026	108
0.5	0.514	0.038	103
1.0	0.982	0.113	98
Average			103

Precision

Control	1	2	3
Replicates	3	3	3
Days	3	3	3
n	9	9	9
Mean (ppb)	0.198	0.501	1.01
% CV (within assay)	8.2	4.3	5.2
% CV (between assay)	6.3	5.3	4.9

General Limited Warranty: Abraxis LLC warrants the products manufactured by the Company, against defects and workmanship when used in accordance with the applicable instructions for a period not to extend beyond the product's printed expiration date. **Abraxis LLC makes no other warranty, expressed or implied. There is no warranty of merchantability or fitness for a particular purpose.**

For ordering or technical assistance contact:

Abraxis LLC
124 Railroad Drive
Warrington, PA 18974
Tel: (215) 357-3911
Fax: (215) 357-5232
Email: info@abraxiskits.com
WEB: www.abraxiskits.com

RO50415

Cylindrospermopsin ELISA (Microtiter Plate)

Enzyme-Linked Immunosorbent Assay for the Determination of
Cylindrospermopsin in Water Samples



Product No. 522011

1. General Description

The Abraxis Cylindrospermopsin ELISA is an immunoassay for the quantitative and sensitive detection of Cylindrospermopsin in water samples. No additional sample preparation is required prior to analysis. If necessary, positive samples can be confirmed by HPLC or other conventional methods.

2. Safety Instructions

The standard solutions in the test kit contain small amounts of Cylindrospermopsin. The substrate solution contains tetramethylbenzidine (TMB) and the stop solution contains diluted sulfuric acid. Avoid contact of the TMB and stopping solution with skin and mucous membranes. If these reagents come in contact with skin, wash with water.

3. Storage and Stability

The Cylindrospermopsin ELISA kit should be stored in the refrigerator (4-8°C). The solutions must be allowed to reach room temperature (20-25°C) before use. Reagents may be used until the expiration date on the box. Consult state, local, and federal regulations for proper disposal of all reagents.

4. Test Principle

The test is a direct competitive ELISA for the detection of Cylindrospermopsin. It is based on the recognition of Cylindrospermopsin by specific antibodies. Cylindrospermopsin, when present in a sample, and a Cylindrospermopsin-HRP analogue compete for the binding sites of rabbit anti-Cylindrospermopsin antibodies in solution. The anti-Cylindrospermopsin antibodies are then bound by a second antibody (post anti-rabbit) immobilized on the wells of the microtiter plate. After a washing step and addition of the substrate solution, a color signal is generated. The intensity of the blue color is inversely proportional to the concentration of Cylindrospermopsin present in the sample. The color reaction is stopped after a specified time and the color is evaluated using an ELISA reader. The concentrations of the samples are determined by interpolation using the standard curve constructed with each run.

5. Limitations of the Cylindrospermopsin ELISA, Possible Test Interference

Numerous organic and inorganic compounds commonly found in water samples have been tested and found not to interfere with this test. However, due to the high variability of compounds that may be found in water samples, test interferences caused by matrix effects cannot be completely excluded.

The presence of the following substances were found to have no significant effect on the Cylindrospermopsin assay results: aluminum oxide, calcium chloride, calcium sulfate, manganese sulfate, magnesium sulfate, magnesium chlorides, sodium chloride, potassium phosphate, and sodium thiosulfate up to 10,000 ppm; sodium nitrate and zinc sulfate up to 1,000 ppm; humic acid and ferric sulfate up to 100 ppm; copper chloride up to 10 ppm; Lugol's solution up to 0.01%.

Samples containing methanol must be diluted to a concentration ≤ 20% methanol to avoid matrix effects.

Seawater samples must also be diluted to a concentration ≤ 20% to avoid matrix effects. Alternately, if a lower detection limit is required, interfering compounds can be removed from seawater or brackish water samples prior to analysis. Please see the Cylindrospermopsin in Brackish Water or Seawater Sample Preparation Technical Bulletin (available upon request).

No matrix effects have been observed with samples which have been treated with sodium thiosulfate at concentrations up to and including 1 mg/mL. Please see Sample Collection and Handling (Section C) for additional information on sample collection, preservation, and storage.

Mistakes in handling the test can cause errors. Possible sources for such errors include: inadequate storage conditions of the test kit, incorrect pipetting sequence or inaccurate volumes of the reagents, too long or too short incubation times during the immune and/or substrate reaction, and extreme temperatures during the test performance (lower than 10°C or higher than 30°C).

As with any analytical technique (GC, HPLC, etc.), positive results requiring regulatory action should be confirmed by an alternative method.

A. Materials Provided

1. Microtiter plate (12 X 8 strips) coated with a second antibody (goat anti-rabbit)
2. Standards (7): 0, 0.05, 0.10, 0.25, 0.50, 1.0, 2.0 ppb
3. Control: 0.75 ± 0.15 ppb, prepared from a secondary source, for use as a Quality Control Standard (QCS)
4. Sample Diluent, for use as a Laboratory Reagent Blank (LRB) and for dilution of samples above the range of the standard curve
5. Cyindrospermopsin-HRP Conjugate Solution
6. Antibody Solution (rabbit anti-Cyindrospermopsin)
7. Wash Solution (5X) Concentrate, must be diluted before use, see Test Preparation (Section E)
8. Substrate (Color) Solution (TMB)
9. Stop Solution

B. Additional Materials (not delivered with the test kit)

1. Micro-pipettes with disposable plastic tips (20-200 μ L)
2. Multi-channel pipette (50-300 μ L), stepper pipette (50-300 μ L), or electronic repeating pipette with disposable plastic tips
3. Deionized or distilled water
4. Container with 500 mL capacity (for 1X diluted wash solution, see Test Preparation, Section E)
5. Graduated cylinder
6. Paper towels or equivalent absorbent material
7. Timer
8. Tape or parafilm
9. Microtiter plate reader (wavelength 450)
10. Microtiter plate washer (optional)

C. Sample Collection and Handling

Water samples should be collected in glass, polyethylene terephthalate glycol (PETG), high density polyethylene (HDPE), polycarbonate (PC), polypropylene (PP), or polystyrene (PS) containers. Samples can be stored refrigerated for up to 5 days. If samples must be held for greater than 5 days, samples should be stored frozen.

Finished (treated) drinking water samples must be preserved (quenched) with sodium thiosulfate immediately after collection to remove residual chlorine. Samples can be quenched with sodium thiosulfate at concentrations up to and including 1 mg/mL. The quenching of residual chlorine is necessary for treated water samples only. Raw (untreated) drinking water samples (samples not treated with chlorine) do not require additional reagents at the time of collection.

D. Notes and Precautions

Micro-pipetting equipment and pipette tips for pipetting the standards and the samples are necessary.

The use of a multi-channel pipette, stepping pipette, or electronic repeating pipette is recommended for the addition of the antibody, enzyme conjugate, substrate, and stop solutions in order to equalize the incubation periods on the entire microtiter plate.

To avoid drift and obtain accurate results, the addition of the antibody, conjugate, color, and stop solutions should be performed in less than 2 minutes for each reagent. If additions to the entire microtiter plate cannot be completed in less than 2 minutes, run size should be decreased to the number of rows which can be pipetted in less than 2 minutes.

Please use only the reagents and standards from one package lot in one test, as they have been adjusted in combination.

E. Test Preparation

1. Allow the reagents and samples to reach ambient temperature before use.
2. Remove the number of microtiter plate strips required from the resealable pouch. The remaining strips are stored in the pouch with the desiccant (tightly closed).
3. The standards, control, sample diluent (LRB), antibody, enzyme conjugate, substrate, and stop solutions are ready to use and do not require any further dilutions.
4. Dilute the Wash Solution (5X) Concentrate at a ratio of 1:5 with deionized or distilled water. If using the entire bottle (100 mL), add to 400 mL of deionized or distilled water and mix thoroughly.
5. The stop solution must be handled with care as it contains diluted H_2SO_4 .

F. Working Scheme

The microtiter plate consists of 12 strips of 8 wells, which can be used individually for the test. The standards must be run with each test. Never use the values of standards which have been determined in a test performed previously.

	1	2	3	4	5	6	7	8	9	10	11	12
A	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
B	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
C	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
D	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
E	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
F	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
G	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				
H	Stand	Stand	Stand	Stand	Stand	Stand	Stand	Stand				

Sd0-Sd6: Standards

Contr.: Control (QCS)

LRB: Laboratory Reagent Blank

Samp1, Samp2, etc.: Samples

G. Assay Procedure

1. Add **50 μ L of the standard solutions, control (QCS), LRB, or samples** into the wells of the test strips according to the working scheme given. Analysis in duplicate or triplicate is recommended.
2. Add **50 μ L of the enzyme conjugate solution** to the individual wells successively using a multi-channel pipette or a stepping pipette.
3. Add **50 μ L of the antibody solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate the strips for **45 minutes** at room temperature.
4. Remove the covering and decant the contents of the wells into a sink. Wash the strips **four times** using the 1X wash buffer solution. Please use at least a volume of **250 μ L of wash buffer** for each well and each washing step. Remaining buffer in the wells should be removed by patting the plate dry on a stack of paper towels.
5. Add **100 μ L of substrate (color) solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate the strips for **30-45 minutes** at room temperature. Protect the strips from sunlight.
6. Add **100 μ L of stop solution** to the wells in the same sequence as for the substrate (color) solution using a multi-channel pipette or a stepping pipette.
7. Read the absorbance at 450 nm using a microplate ELISA photometer within 15 minutes after the addition of the stopping solution.

H. Evaluation

The evaluation of the ELISA can be performed using commercial ELISA evaluation programs such as 4-Parameter (preferred) or Logit/Log. For a manual evaluation, calculate the mean absorbance value for each of the standards. Calculate the %B/B₀ for each standard by dividing the mean absorbance value for each standard by the Zero Standard (Standard 0) mean absorbance. Construct a standard curve by plotting the %B/B₀ for each standard on the vertical linear (y) axis versus the corresponding Cyindrospermopsin concentration on the horizontal logarithmic (x) axis on graph paper. %B/B₀ for the control (QCS), LRB, and samples will then yield levels in ppb of Cyindrospermopsin by interpolation using the standard curve. Results can also be determined by using a spreadsheet macro available from Abraxis upon request.

The concentrations of the samples are determined using the standard curve run with each test. Samples showing a lower concentration of Cyindrospermopsin than standard 1 (0.05 ppb) should be reported as containing < 0.05 ppb of Cyindrospermopsin. Samples showing a higher concentration than standard 6 (2.0 ppb) must be diluted to obtain accurate results. The concentration of the positive control (QCS) provided should be 0.75 ± 0.15 ppb.

Semi-quantitative results can be derived by simple comparison of the sample absorbances to the absorbances of the calibrators. Samples with lower absorbances than a calibrator will have concentrations of Cyindrospermopsin greater than that calibrator. Samples which have higher absorbances than a calibrator will have concentrations of Cyindrospermopsin less than that calibrator.

I. References

- (1) Cyindrospermopsin, Review of Toxicological Literature. Prepared by Integrated Laboratory Systems for Scott Masten, National Institute of Health Sciences, RTP, NC. Contract Number N01-ES-65402, December 2000.

Importance of Anatoxin-a Determination

Anatoxin-a is an alkaloid neurotoxin produced by some species of cyanobacteria (blue-green algae). It is one of the most toxic of the cyanobacterial toxins. In humans and other animals, the skeletal neuromuscular junction constitutes a primary target for Anatoxin-a (Anatoxin-a can also cross the blood-brain barrier). The neuromuscular junction is specialized for the rapid transmission of neuronal information from the pre-synaptic nerve terminal to the post-synaptic muscle fiber. This transmission is mediated by the synchronous release of the neurotransmitter acetylcholine (ACh), which activates nicotinic acetylcholine receptors (nAChRs) in the muscle endplate, triggering a series of events that lead to muscle contraction. Most ACh molecules are hydrolyzed by acetylcholinesterases, which are highly concentrated at the neuromuscular junction. Anatoxin-a functions as an agonist of nAChRs, like ACh, but is about 20 times more potent. Unlike ACh, it is not degraded by acetylcholinesterases and produces sustained depolarization of the muscle endplate, causing over stimulation of the muscles, leading to muscle fatigue and ultimately paralysis. Symptoms begin within 5 minutes of ingestion of Anatoxin-a and progress rapidly, resulting in cyanosis, convulsions, cardiac arrhythmia, and respiratory paralysis, which ultimately results in death due to suffocation.

Humans and other animals may be exposed to Anatoxin-a through ingestion of contaminated water, through drinking or during recreational activities in which water is swallowed. Due to the potential for serious harm and even death, many countries are expanding monitoring programs to include Anatoxin-a and are establishing regulations regarding the amount of Anatoxin-a in drinking and recreational waters. New Zealand is among those taking regulatory action, establishing a 6.0 µg/L provisional maximum acceptable value (MAV) for Anatoxin-a.

The Abraxis Anatoxin-a ELISA Assay can be performed in less than 90 minutes. Only a few milliliters of sample are required.

Performance Data

Test sensitivity: The detection limit, based on Anatoxin-a, (90% B/B) is approximately 0.1 ppb (µg/L). The middle of the test (50% B/B) is approximately 1.38 ng/mL. Determinations closer to the middle of the calibration curve give the most accurate results.


Test reproducibility: Intra and inter assay: < 10%

Recoveries:	Level (ppb)	% Recovery
	0.25	103.3
	0.50	98.0
	1.50	104.4
	3.00	103.1

Specificity: Cross-reactivity of the Abraxis Anatoxin-a Plate Kit for various congeners:

(+)Anatoxin-a	100.0%
Homoanatoxin-a	124.8%
(-)Anatoxin-a	0.3%

Standard Curve:



For demonstration purposes only. Not for use in sample interpretation.

General Limited Warranty: Abraxis, Inc. warrants the products manufactured by the Company, against defects and workmanship when used in accordance with the applicable instructions for a period not to extend beyond the product's printed expiration date. Abraxis makes no other warranty, expressed or implied. There is no warranty of merchantability or fitness for a particular purpose.

*The monoclonal antibody and enzyme conjugate included in the Abraxis Anatoxin-a ELISA have been licensed (Patent Application P201531661) from the Spanish National Research Council (CSIC) and the University of Valencia (UVES).

For ordering or technical assistance contact: Abraxis, Inc.
124 Railroad Drive
Warrminster, PA 18974
Tel: (215) 357-5911
Fax: (215) 357-5232
Email: info@abraxiskits.com
WEB: www.abraxiskits.com

R053116

Anatoxin-a ELISA Microtiter Plate

Enzyme-Linked Immunosorbent Assay for the Determination of
Anatoxin-a* in Water Samples
Product No. 520060



1. General Description

The Abraxis Anatoxin-a ELISA Plate Kit is an immunoassay for the quantitative and sensitive screening of Anatoxin-a in water samples. This test is suitable for the quantitative and/or qualitative screening of Anatoxin-a in drinking and recreational water samples (please refer to Sample Collection and Handling, section C). Samples requiring regulatory action should be confirmed by HPLC, GC/MS, or other conventional methods.

2. Safety Instructions

The standard solutions in the test kit contain small amounts of Anatoxin-a. In addition, the substrate solution contains tetramethylbenzidine and the stop solution contains diluted sulfuric acid. Avoid contact of these solutions with skin and mucous membranes. If these reagents come in contact with skin, wash thoroughly with water.

3. Storage and Stability

The Anatoxin-a ELISA Kit should be stored in the refrigerator (4-8°C). The solutions must be allowed to reach room temperature (20-25°C) before use. Reagents may be used until the expiration date on the box. Consult state, local, and federal regulations for proper disposal of all reagents.

4. Test Principle

The test is a direct competitive ELISA based on the recognition of Anatoxin-a by a monoclonal antibody. Anatoxin-a, when present in a sample, and an Anatoxin-a-enzyme conjugate compete for the binding sites of mouse anti-Anatoxin-a antibodies in solution. The Anatoxin-a antibodies are then bound by a second antibody (anti-mouse) immobilized on the microtiter plate. After a washing step and addition of the substrate solution, a color signal is generated. The intensity of the blue color is inversely proportional to the concentration of Anatoxin-a present in the sample. The color reaction is stopped after a specified time and the color is evaluated using an ELISA reader. The concentrations of the samples are determined by interpolation using the standard curve constructed with each run.

5. Limitations of the Anatoxin-a ELISA, Possible Test Interference

Although many organic and inorganic compounds commonly found in samples have been tested and found not to interfere with this test, due to the high variability of compounds that might be found in water samples, test interferences caused by matrix effects cannot be completely excluded.

Immediately upon collection, fresh water samples must be preserved with the provided Sample Diluent (10X) Concentrate to prevent degradation of Anatoxin-a (please refer to Sample Collection and Handling, section C).

Anatoxin-a will degrade when exposed to natural and artificial light and/or high pH conditions. Samples that have been exposed to natural or artificial light and/or treated with reagents that raise the natural sample pH may produce results that are falsely low. Samples should be adjusted to between pH 5 and pH 7 and protected from light.

Samples containing methanol must be diluted to a concentration < 2.5% methanol to avoid matrix effects.

Seawater samples up to 37 parts per thousand were tested and no matrix effects were detected. Average recovery of spiked seawater samples was 104%.

Anatoxin-a is an intracellular, as well as extracellular, toxin. Therefore, to measure total Anatoxin-a, cell lysing will be required. Once the sample is preserved, three freeze/thaw cycles are recommended for cell lysing.

No matrix effects have been observed with samples that have been treated with ascorbic acid at concentrations ≤ 1 mg/mL. **Sodium thiosulfate should not be used to treat samples, as sodium thiosulfate will degrade Anatoxin-a, producing inaccurate (falsely low) results.**

Mistakes in handling the test can also cause errors. Possible sources for such errors include: inadequate storage conditions of the test kit, incorrect pipetting sequence or inaccurate volumes of the reagents, too long or too short incubation times during the immune and/or substrate reaction, exposure to direct or indirect sunlight during the substrate reaction, or extreme temperatures (lower than 10°C or higher than 30°C) during the test performance.

As with any analytical technique (GC, HPLC, etc.), positive results requiring regulatory action should be confirmed by an alternative method.

A. Reagents and Materials Provided

1. Microtiter plate coated with a secondary antibody (anti-mouse), in a resealable aluminum pouch
2. Lyophilized Anatoxin-a-HRP Enzyme Conjugate, 3 vials
3. Conjugate Diluent, 12 mL
4. Lyophilized Anti-Anatoxin-a Antibody, 3 vials
5. Antibody Diluent, 12 mL
6. Empty clear and amber HDPE bottles for combining reconstituted Enzyme Conjugate and Antibody (if necessary)
7. (+)Anatoxin-a Standards (6): 0, 0.15, 0.40, 1.0, 2.5, 5.0 ppb, 1 mL each
8. Control at 0.75 \pm 0.185 ppb, 1 mL
9. Sample Diluent (10X) Concentrate, 2 X 25 mL
10. Wash Solution (5X) Concentrate, 100 mL, must be diluted before use, see Test Preparation (Section D)
11. Color (Substrate) Solution (TMB), 12 mL
12. Stop Solution, 12 mL (handle with care)

B. Additional Materials (not delivered with the test kit)

1. Micro-pipettes with disposable plastic tips (10-200 and 200-1000 μ L)
2. Multi-channel pipette (10-300 μ L), stepper pipette (10-300 μ L), or electronic repeating pipette with disposable plastic tips (capable of delivering 50-300 μ L)
3. Microtiter plate washer (optional)
4. Microtiter plate reader (wave length 450 nm)
5. Deionized or distilled water
6. Container with 500 mL capacity (for diluted 1X Wash Solution, see Test Preparation, Section D)
7. Paper towels or equivalent absorbent material
8. Timer

C. Sample Collection and Handling

Collect water samples in amber glass sample containers. Drinking water samples should be treated with ascorbic acid (up to 1 mg/mL) immediately after collection to remove residual chlorine. *Do not use sodium thiosulfate. Sodium thiosulfate will degrade Anatoxin-a.*

Immediately upon collection, fresh water samples must be preserved using the Sample Diluent (10X) Concentrate (1 mL of 10X Sample Diluent Concentrate per 9 mL of water sample), to prevent degradation of Anatoxin-a. Samples should be adjusted to between pH 5 and pH 7 and protected from exposure to natural and artificial light, as exposure to light and/or high pH will cause degradation of Anatoxin-a. Store samples refrigerated (up to 28 days). For storage periods greater than 28 days, samples should be stored frozen. Seawater samples do not need to be preserved but the same pH and storage conditions should be applied.

Anatoxin-a is an intracellular, as well as extracellular, toxin. Therefore, to measure total Anatoxin-a, cell lysing will be required. Once the sample is preserved, three freeze/thaw cycles are recommended for cell lysing. This procedure using the three freeze/thaw cycles will not degrade Anatoxin-a.

Preserved fresh water or seawater samples may be filtered following cell lysing and prior to analysis using any of the following syringe filters: Environmental Express 0.2 mm PES (PN SF020E), Pall Acrodisc® 0.2 mm PVDF (PN 4450), Supor® membrane syringe filters (PN 4612), or Environmental Express 1.2 mm Glass Fiber (PN SF012G). *Note: Fresh water samples must be preserved (and lysed) prior to filtration or Anatoxin-a may bind to the filter, removing it from the sample, and producing falsely low sample results.*

D. Test Preparation

Micro-pipetting equipment and pipette tips for pipetting the standards and the samples are necessary. A multi-channel pipette or a stepping pipette is recommended for adding the enzyme conjugate, antibody, substrate, and stop solutions in order to equalize the incubation periods across the entire microtiter plate. Please only use the reagents and standards from one package lot in one test, as they have been adjusted in combination.

1. Allow the microtiter plate, reagents, and samples to reach room temperature before use.
2. The enzyme conjugate and antibody need to be reconstituted prior to use. Add 3 mL of the appropriate diluent to the appropriate vial and vortex well. Let sit for at least 10 minutes and re-vortex prior to use. ***If more than one vial is required for testing, combine the reconstituted enzyme conjugate vials in the amber HDPE bottle and the reconstituted antibody vials in the clear HDPE bottle prior to use.*** The solutions are stable for up to 2 weeks if stored at 4-8°C and up to 1 month if stored frozen.
3. Remove the number of microtiter plate strips required from the foil bag. The remaining strips are stored in the foil bag and zip-locked closed.
4. The standard solutions, substrate and stop solutions are ready to use and do not require any further dilutions.
5. Dilute the Wash Solution (5X) Concentrate at a ratio of 1:5. If using the entire bottle (100 mL) add to 400 mL of deionized or distilled water.
6. Dilute the Sample Diluent (10X) Concentrate at a ratio of 1:10 with deionized or distilled water (i.e. 1 mL of Sample Diluent (10X) Concentrate into 9 mL of deionized water) as needed for sample dilutions.
7. The stop solution must be handled with care as it contains diluted H₂SO₄.
8. After analysis, store the remaining kit components in the refrigerator (4-8°C).

E. Working Scheme

The microtiter plate consists of 12 strips of 8 wells, which can be used individually for the test. The standards must be run with each test. Never use the values of standards which have been determined in a test performed previously.

	1	2	3	4	5	6	7	8	9	10	11	12
A	Stand Std1	Stand										
B	Stand Std2	Stand										
C	Stand Std3	Stand										
D	Stand Std4	Stand										
E	Stand Std5	Stand										
F	Stand Std6	Stand										
G	Stand Std7	Stand										
H	Stand Std8	Stand										

Std 0-Std5: Standards

Contr.: Control

Samp1, Samp2, etc: Samples

F. Assay Procedure

1. Add **50 μ L** of the **standard solutions, control, or samples** into the wells of the test strips according to the working scheme given. Analysis in duplicate or triplicate is recommended.
2. Add **50 μ L** of the **reconstituted enzyme conjugate solution** to the individual wells successively using a multi-channel pipette or a stepping pipette.
3. Add **50 μ L** of the **reconstituted antibody solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 60 seconds. Be careful not to spill the contents. Incubate the strips for **60 minutes** at room temperature.
4. Remove the covering and decant the contents of the wells into a sink. Wash the strips **four times** using the 1X wash buffer solution. Please use at least a volume of **250 μ L** of wash buffer for each well and each washing step. Remaining buffer in the wells should be removed by patting the plate dry on a stack of paper towels.
5. Add **100 μ L** of **substrate (color) solution** to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate the strips for **20-30 minutes** at room temperature. Protect the strips from sunlight.
6. Add **100 μ L** of **stop solution** to the wells in the same sequence as for the substrate (color) solution using a multi-channel pipette or a stepping pipette.
7. Read the absorbance at 450 nm using a microtiter plate ELISA photometer within 15 minutes after the addition of the stopping solution.

G. Evaluation

The evaluation of the ELISA can be performed using commercial ELISA evaluation programs (4-Parameter (preferred) or Logit/Log). For a manual evaluation, calculate the mean absorbance value for each of the standards. Calculate the %B/B₀ for each standard by dividing the mean absorbance value for each standard by the Zero Standard (Standard 0) mean absorbance. Construct a standard curve by plotting the %B/B₀ for each standard on a vertical linear (y) axis versus the corresponding Anatoxin-a concentration on horizontal logarithmic (x) axis on graph paper. %B/B₀ for the control and samples will then yield levels in ppb of Anatoxin-a by interpolation using the standard curve. Results can also be determined using a spreadsheet macro available from Abraxis upon request.

Results for fresh water samples which have been preserved with Sample Diluent (10X) Concentrate as described in Sample Collection and Handling (section C) must be multiplied by a factor of 1.1 to account for the initial dilution.

The concentrations of the samples are determined using the standard curve run with each test. Samples showing a lower concentration of Anatoxin-a than standard 1 (0.15 ppb) should be reported as containing < 0.15 ppb of Anatoxin-a (< 0.165 ppb for preserved water samples). Samples showing a higher concentration than standard 5 (5.0 ppb) should be reported as containing > 5.0 ppb of Anatoxin-a (> 5.5 ppb for preserved water samples) or must be diluted using 1X Sample Diluent and re-analyzed to obtain accurate results. The concentration of the positive control provided should be 0.75 \pm 0.185 ppb.

Semi-quantitative results can be derived by simple comparison of the sample absorbances to the absorbances of the calibrators. Samples with lower absorbances than a calibrator will have concentrations of Anatoxin-a greater than that calibrator. Samples which have higher absorbances than a calibrator will have concentrations of Anatoxin-a less than that calibrator.

As with any analytical technique (GC, HPLC, etc.), positive results requiring regulatory action should be confirmed by an alternative method.

Importance of Saxitoxin Determination

Saxitoxin is one of the "paralytic shellfish poisons" (PSP), produced by several marine dinoflagellates and fresh water algae. Contamination of shellfish with saxitoxin has been associated with harmful algal blooms throughout the world.


In man, PSP causes dose-dependent perioral numbness or tingling sensations and progressive muscular paralysis, which can result in death through respiratory arrest. The maximum tolerance levels established by the EU and FDA are 40-80 µg per 100 g edible portion of fresh, frozen, or tinned shellfish.

The Saxitoxin ELISA allows the determination of 42 samples in duplicate determination. Only a few milliliters of sample are required. The test can be performed in about 1 hour.

Performance Data

Test sensitivity:

The detection limit for Saxitoxin is 0.015 ng/mL (mean of 6 blank determinations minus 3 SD). The middle of the test (50% B/B₀) is at approximately 0.09 ng/mL. Determinations closer to the middle of the calibration curve give the most accurate results.



Test reproducibility: Coefficients of variation (CVs) for standards: <10%, CVs for samples: <15%.

Selectivity: This ELISA recognizes Saxitoxin and other PSP toxins with varying degrees:

Cross-reactivities:	Saxitoxin (STX)	100% (per definition)
	Decarbamoyl STX	29%
	GTX 2 & 3	23%
	GTX-SB	23%
	Lyngbyatoxin	13%
	Sulf. GTX 1 & 2	2.0%
	Decarbamoyl GTX 2 & 3	1.4%
	Neosaxitoxin	1.3%
	Decarbamoyl Neo STX	0.6%
	GTX 1 & 4	<0.2%

Cross-reactivities with other classes of algal toxins have not been observed.

Samples: Drinking water, ground water, and surface water were tested for matrix effects in the ELISA. No matrix effects were determined.

General Limited Warranty: Eurofins Abraxis warrants the products manufactured by the Company, against defects and workmanship when used in accordance with the applicable instructions for a period not to extend beyond the product's printed expiration date. Eurofins Abraxis makes no other warranty, expressed or implied. There is no warranty of merchantability or fitness for a particular purpose.

For ordering or technical assistance contact:

Eurofins Abraxis
124 Railroad Drive
Warminster, PA 18974
Tel.: (215) 357-3911
Fax: (215) 357-5232
Email: info.EU@eurofins.com
WEB: www.abraxiskits.com

This product is for research use only

Rev10/2020

Saxitoxin (PSP) ELISA, Microtiter Plate

Abraxis

Enzyme-Linked Immunosorbent Assay for the Determination of Saxitoxin (PSP) in Water and Contaminated Samples

Product No. 522558

1. General Description

The Saxitoxin ELISA is an immunoassay for the quantitative and sensitive detection of Saxitoxin. Saxitoxin is one of the toxins associated with paralytic shellfish poisoning (PSP). This test is suitable for the quantitative and/or qualitative detection of Saxitoxin in water samples (please refer to the appropriate technical bulletins for freshwater and seawater samples) as well as other contaminated samples. For shellfish samples, a sample preparation is required. If necessary, positive samples can be confirmed by HPLC, GC/MS, or other conventional methods.

2. Safety Instructions

The standard solutions in the test kit contain small amounts of Saxitoxin. In addition, the substrate solution contains tetramethylbenzidine and the stop solution contains diluted sulfuric acid. Avoid contact of stopping solution with skin and mucous membranes. If these reagents come in contact with the skin, wash with water.

3. Storage and Stability

The Saxitoxin ELISA Kit should be stored in the refrigerator (2-8°C). The solutions must be allowed to reach room temperature (20-25°C) before use. Reagents may be used until the last day of the month as indicated by the expiration date on the box.

4. Test Principle

The test is a direct competitive ELISA based on the recognition of Saxitoxin by specific antibodies. Saxitoxin, when present in a sample, and a saxitoxin-enzyme conjugate compete for the binding sites of rabbit anti-saxitoxin antibodies in solution. The saxitoxin antibodies are then bound by a second antibody (anti-rabbit) immobilized on the microtiter plate. After a washing step and addition of the substrate solution, a color signal is produced. The intensity of the blue color is inversely proportional to the concentration of the Saxitoxin present in the sample. The color reaction is stopped after a specified time and the color is evaluated using an ELISA plate reader. The concentrations of the samples are determined by interpolation using the standard curve constructed with each run.

5. Limitations of the Saxitoxin ELISA, Possible Test Interference

Numerous organic and inorganic compounds commonly found in samples have been tested and found not to interfere with this test. However, due to the high variability of compounds that might be found in samples, test interferences caused by matrix effects can not be completely excluded.

Samples containing methanol must be diluted to a concentration < 20% methanol to avoid matrix effects.

Mistakes in handling the test can also cause errors. Possible sources for such errors can be: Inadequate storage conditions of the test kit, wrong pipetting sequence or inaccurate volumes of the reagents, too long or too short incubation times during the immune and/or substrate reaction, extreme temperatures during the test performance (lower than 10°C or higher than 30°C).

The Eurofins Abraxis Saxitoxin ELISA Kit provides screening results. As with any analytical technique (GC/MS, HPLC, etc.), positive samples requiring some action should be confirmed by an alternative method.

Working Instructions

A. Materials Provided

1. Microtiter plate coated with a second antibody (anti-rabbit)
2. Standards (6) and Control: 0, 0.02, 0.05, 0.1, 0.2, 0.4 ng/mL, 1.5 mL each
3. Control at 0.075 ± 0.015 ppb, 1.5 mL
4. Antibody Solution (rabbit anti-Saxitoxin), 6 mL
5. Saxitoxin-HRP Conjugate Solution, 6 mL
6. Sample Diluent (10X) Concentrate, 2 X 25 mL, must be diluted prior to use for shellfish or freshwater sample dilutions, see Test Preparation (Section E)
7. Wash Buffer (5X) Concentrate, 100 mL, must be diluted before use, see Test Preparation (Section E)
8. Substrate (Color) Solution (TMB), 12 mL
9. Stop Solution, 12 mL

B. Additional Materials (not delivered with the test kit)

1. Micro-pipettes with disposable plastic tips (10-200, and 200-1000 μL)
2. Multi-channel pipette (10-300 μL), stepper pipette with plastic tips (10-300 μL), or electronic repeating pipette with disposable plastic tips
3. Deionized or distilled water
4. Container with 500 mL capacity (for diluted 1X Wash Buffer, see Test Preparation, Section E)
5. Microtiter plate washer (optional)
6. Microtiter plate reader (wave length 450 nm)
7. Shaker for microtiter plates (optional)
8. Materials and reagents for sample preparation
9. Seawater Matrix Saxitoxin Standards (please contact Eurofins Abraxis)

C. Sample Preparation (Mussels and other shellfish)

NOTE: If a 100 g sample is needed for regulatory purposes, extraction solution volume should be adjusted accordingly.

1. Remove mussels from shells, wash with deionized water and homogenize.
2. Mix 10 g of homogenized mussels with 10 mL of 0.1M HCl and boil for 5 minutes while stirring.
3. Allow to cool. Centrifuge for 10 minutes at approximately 3500 g.
4. Collect supernatant. Adjust pH to < pH 4.0 with 5 N HCl.
5. Remove 10 μL and dilute in 10 mL of 1X Sample Diluent (this will be a 1:1,000 dilution). Vortex.
6. Analyze as sample (Assay Procedure, step 1).

The STX concentration in the samples is determined by multiplying the ELISA result for the diluted extract by a factor of 2,000. Highly contaminated samples (those outside of the calibration range of the assay), must be diluted further and re-analyzed. We recommend further dilutions of 1:10 with 1X Sample Diluent. The dilution factor will then be 20,000. Samples with low levels of contamination of STX or samples that contain STX congeners with low cross-reactivity (see chart) can be detected in the assay by diluting samples 1:250 before analysis. The assay has low cross-reactivity against GTX 1 & 4, therefore food samples containing these congeners at low concentrations might be underestimated by this ELISA.

D. Alternative Sample Preparation (Mussels and other shellfish)

1. Remove mussels from shells, wash with deionized water and homogenize using a Polytron or equivalent.
2. Mix 1.0 g of homogenized mussels with 6 mL of methanol/DI water (80/20) using a Polytron or equivalent.
3. Centrifuge the mixture for 10 minutes at 3000 g. Collect supernatant.
4. Add 2 mL methanol/deionized water (80/20) to the mussel tissue residue. Re-centrifuge the mixture for 10 minutes. Add supernatant to first portion.
5. Bring the volume of the collected supernatant to 10 mL with methanol/deionized water (80/20). Filter extract through a 0.45 μm filter (Millex HV, Millipore or equivalent).
6. Remove 10 μL and dilute to 1.0 mL with 1X Sample Diluent (1:100 dilution). Vortex. Analyze as sample (Assay Procedure, step 1).

The STX concentration in the samples is determined by multiplying the ELISA result by a factor of 1,000.

E. Test Preparation

Micro-pipetting equipment and disposable pipette tips for pipetting the standards and the samples are necessary. We recommend using a multi-channel pipette or a stepping pipette for adding the antibody, conjugate, substrate and stop solutions in order to equalize the incubation periods of the standard solutions and the samples on the entire microtiter plate. Please use only the reagents and standards from one package lot in one test, as they have been adjusted in combination.

1. Adjust the microtiter plate and the reagents to room temperature before use.
2. Remove the number of microtiter plate strips required from the foil bag. The remaining strips are stored in the foil bag and zip-locked closed. Store the remaining kit in the refrigerator (2-8°C).
3. The standard solutions, enzyme conjugate, antibody, substrate and stop solutions are ready to use and do not require any further dilutions.
4. Dilute the 5X Wash Buffer Concentrate at a ratio of 1:5. If using the entire bottle (100 mL) add to 400 mL of deionized or distilled water.
5. Dilute the 10X Sample Diluent Concentrate at a ratio of 1:10 with deionized or distilled water (i.e. 1 mL of 10X Sample Diluent Concentrate into 9 mL of deionized water) as needed for sample dilutions.
6. The Stop Solution must be handled with care as it contains diluted H_2SO_4 .
7. Freshwater samples must be preserved immediately upon collection to prevent loss of saxitoxin from the samples. Please refer to the Saxitoxin in Freshwater Sample Preparation Bulletin for details.
8. Seawater samples must be analyzed using Seawater Matrix Saxitoxin Standards (available separately, please contact Eurofins Abraxis) and an alternate Assay Procedure. Please refer to the Saxitoxin in Seawater Sample Analysis Bulletin for details.

F. Working Scheme

The microtiter plate consists of 12 strips of 8 wells, which can be used individually for the test. The standards must be run with each test. Never use the values of standards which have been determined in a test performed previously.

Std 0-Std 5: Standards
0; 0.02; 0.05; 0.10; 0.20; 0.40 ppb

Sam1, Sam2, etc.: Samples

	1	2	3	4	5	6	7	8	9	10	11	12
A	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
B	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
C	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
D	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
E	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
F	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
G	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						
H	Std 0	Std 1	Std 2	Std 3	Std 4	Std 5						

G. Assay Procedure

1. Add 50 μL of the standards, control, samples (preserved freshwater), or sample extracts (shellfish) into the wells of the test strips according to the working scheme given. We recommend using duplicates or triplicates.
2. Add 50 μL of enzyme conjugate solution to the individual wells successively using a multi-channel, stepping, or electronic repeating pipette.
3. Add 50 μL of antibody solution to the individual wells successively using a multi-channel, stepping, or electronic repeating pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 to 60 seconds. Be careful not to spill the contents.
4. Incubate the strips for 30 minutes at room temperature.
5. Decant the contents of the wells into an appropriate waste container. Wash the strips four times using the diluted wash buffer. Please use a volume of at least 250 μL of 1X wash buffer for each well and each washing step. Remaining buffer in the wells should be removed by patting the inverted plate dry on a stack of paper towels.
6. Add 100 μL of substrate (color) solution to the wells successively using a multi-channel, stepping, or electronic repeating pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 to 60 seconds. Be careful not to spill the contents. Incubate the strips for 30 minutes at room temperature, protected from direct sunlight.
7. Add 100 μL of stop solution to the wells in the same sequence as for the substrate (color) solution using a multi-channel, stepping, or electronic repeating pipette.
8. Read the absorbance at 450 nm using a microplate ELISA photometer within 15 minutes after the addition of the stopping solution.

H. Evaluation

The evaluation of the ELISA can be performed using commercial ELISA evaluation programs (4-Parameter (preferred) or Logit/Log). For a manual evaluation, calculate the mean absorbance value for each of the standards. Calculate the %B/B₀ for each standard by dividing the mean absorbance value for each standard by the Zero Standard (Standard 0) mean absorbance. Construct a standard curve by plotting the %B/B₀ for each standard on a vertical linear (y) axis versus the corresponding Saxitoxin concentration on horizontal logarithmic (x) axis on graph paper. %B/B₀ for the control and samples will then yield levels in ppb of Saxitoxin by interpolation using the standard curve.

The concentrations of the samples are determined using the standard curve run with each test. Samples showing lower concentrations of Saxitoxin than standard 1 (0.02 ng/mL) are considered as negative. Samples showing a higher concentration than standard 5 (0.4 ng/mL) must be diluted further to obtain accurate results. Results must be multiplied by the appropriate dilution factor for the sample extract (see Sample Preparation, Sections C and D) or preserved freshwater sample (see Saxitoxin in Freshwater Sample Preparation technical bulletin).

As with any analytical technique (GC/MS, HPLC, etc.), samples requiring regulatory action should be confirmed by an alternative method.

APPENDIX D

World Health Organization (WHO) and USEPA Recreational HAB Guidance

The World Health Organization (WHO) established guidelines for cyanobacteria in their *Guidelines for Safe Recreational Water Environments*. 2003.

http://www.who.int/water_sanitation_health/publications/srwe1/en/.

For recreational waters, the World Health Organization (WHO) concluded that a single guideline value for cyanobacteria or cyanotoxins is not appropriate. Due to the variety of possible exposures through recreational activities (contact, ingestion and inhalation), it was necessary to differentiate between the chiefly irritative symptoms caused by cyanobacterial substances and the more severe health effects due to exposure to high concentrations of known cyanotoxins, particularly microcystins. (WHO, 2003). WHO provided a series of recreational guidance/action levels for cyanobacteria, microcystins and chlorophyll a.

In 2019, USEPA released two final recreational cyanotoxin values in *Recommended Human Health Recreational Ambient Water Quality Criteria or Swimming Advisories for Microcystins and Cylindrospermopsin* (USEPA, 2019). Although USEPA did not recommend specific recreational numeric criteria or swimming advisory values for cyanobacterial cell counts and/or biomass, the Agency indicated that, together with microscopic identification, these measures can be informative in making public health decisions and/or in prompting toxin analysis. The Recreational Criteria /Swimming Advisory document also included the information that it has been established that some sensitive individuals have adverse allergenic/irritative responses from exposure to cyanobacterial cells at concentrations as low as 5,000 cells/ml (USEPA, 2019).

The USEPA 2019 HAB Recreational Criteria/Swimming Advisory document summarizes the 2003 WHO HAB guidance in the table below:

WHO (2003) Recreational Guidance/Action Levels for Cyanobacteria, Chlorophyll <i>a</i> , and Microcystin			
Relative Probability of Acute Health Effects	Cyanobacteria (cells/mL)	Chlorophyll <i>a</i> (µg/L)	Estimated Microcystin Levels (µg/L) ^a
Low	< 20,000	< 10	< 10
Moderate	20,000–100,000	10–50	10–20
High	>100,000–10,000,000	50–5,000	20–2,000
Very High	> 10,000,000	> 5,000	> 2,000

APPENDIX E

Basis for Health Advisory Guidelines

- 1. Summary of Updated Exposure Assumptions used in Cyanotoxin
Recreational Advisories in New Jersey**
- 2. Basis for NJDEP Recreational Advisory for Saxitoxin**
- 3. Background Information on Microcystin
“Warning” and “Danger” Threshold Values**

Summary of Updated Exposure Assumptions used in Cyanotoxin Recreational Advisories in New Jersey

Division of Science and Research

March 2021

The cyanotoxin recreational advisory values were updated in 2021 using revised exposure assumptions to provide better protection for children based on the most recent science. See page 21 for threshold values. NJDEP recreational criteria for cyanotoxins are based on exposure through incidental water ingestion by children while swimming. The amount of water ingested by children is used because they swallow more water while swimming than adults. Exposure parameters used to develop recreational advisories include volume of water (L/hour) incidentally swallowed each day and body weight (kg). The NJDEP recreational criteria for cyanotoxins have been updated to use recent information on the amount of water that children ingest each day while swimming. This information became available after the earlier NJDEP criteria were developed in 2017.

A recent USEPA (2019) evaluation found that incidental ingestion rates (volume of water ingested per hour of swimming; L/h) is highest in children age 6-10 years. This evaluation was based on data from 10 times more participants than the study used as the basis for exposure assumptions in the earlier NJDEP recreational advisories. Information from the USEPA (2011) Exposure Factors Handbook shows that children age 5-11 spend more time in the water than younger children, older children, or adults. The information on amount of water swallowed per hour and the number of hours per day spent in the water was combined by USEPA (2019) to determine that the 90th percentile for daily incidental water ingestion by children in this age group is 0.21 L/day.

The daily ingestion rate of 0.21 L/day is used as the basis for the updated NJDEP recreational advisories. It is somewhat higher than the value of 0.12 L/day used in the earlier 2017 NJDEP recreational advisories. The earlier value was based on professional judgement regarding the amount of time children spend in the water each day, while the current value is based on a recent scientific study that evaluated this question. Both the earlier and current NJDEP recreational advisories are based on a body weight of 31.8 kg, which is the mean body weight for children 6 - <11 years of age from the USEPA (2011) Exposure Factors Handbook.

Citations

USEPA (2011). Exposure Factors Handbook 2011 Edition (Final). U.S. Environmental Protection Agency. Washington, DC, EPA/600/R-09/052F.

USEPA (2019). Recommended Human Health Recreational Ambient Water Quality Criteria or Swimming Advisories for Microcystins and Cylindrospermopsin.

Basis for NJDEP Recreational Advisory for Saxitoxin

Brian Pachkowski, Ph.D.
Division of Science and Research
February 2021

Executive summary

Saxitoxin (STX) is a member and the representative molecule of a class (i.e., the saxitoxins) of over 50 structurally related analogues produced by cyanobacteria in freshwater environments. During cyanobacteria harmful algal bloom (cyanoHAB) events, humans can be exposed to STX and its analogues through recreational activities (e.g., incidental ingestion of water during swimming). The Division of Science and Research developed the scientific basis of the NJDEP recreational advisory for STX. The short-term oral reference dose (RfD) and recreational advisory derived here are intended to be protective for oral exposure on multiple days of swimming during the swimming season, for the more sensitive sub-population of children.

Neurotoxicity is the major health effect in humans and laboratory animals, particularly following acute oral exposure. The ability of STX to cause other health effects (e.g., systemic, developmental, reproductive, or immune toxicity) after either acute or prolonged exposure is generally unknown, as such effects have not been as thoroughly studied.

The limited number of studies in laboratory animals that demonstrate the ability of STX to cause neurotoxicity were judged not appropriate for the derivation of a short-term STX RfD (e.g., inadequate study design or data reporting, potential co-exposure to other bacterial toxins, assessment of only sub-clinical endpoints). A number of assessments have reviewed case reports of paralytic shellfish poisoning (PSP) in humans, which is caused by STX and its analogues. Of these assessments, Arnich and Thébault (2018) is deemed most scientifically appropriate for deriving a short-term RfD and recreational guidance value for STX, because of the systematic review approach used to identify and assess relevant data, subsequent statistical modeling of PSP data, and peer-review.

In modeling the human PSP data, Arnich and Thébault (2018) derived a point of departure (POD) of 0.37 µg STX/kg. A composite uncertainty factor of 100, which accounts for human variability (factor of 3), the use of acute PSP exposure data for the derivation of a short-term RfD (factor of 3), and database deficiencies (factor of 10 for lack of developmental, reproductive, and immune studies), was applied to the POD yielding a short-term STX RfD of 0.0037 µg/kg/day.

Based on the assumed body weight of a child (31.8 kg) and the daily incidental ingestion rate of swimming water (0.21 L/day) from the USEPA (2019), an STX recreational guidance value of 0.6 µg/L is derived.

The USEPA does not have an RfD or recreational exposure guidance value for STX. However, five US states (CO, OH, OR, PA, WA) have recreational water guideline levels for STX. All are based on the same principal study (EFSA, 2009) and critical effect (PSP in humans). Using 0.5 µg/kg/day as a POD, these states applied additional UFs (e.g., for human variability or database

limitations) to derive acute or short-term RfDs. The states used these RfDs and relevant exposure factors to derive their recreational values, which range from 0.8 to 75 µg/L. Of these values, only the OH EPA and PA DEP value of 0.8 µg/L is close to the NJDEP value, while the other states' values (4 to 75 µg/L) are higher.

In summary, an STX recreational guidance value of 0.6 µg/L was derived and is recommended for use during New Jersey cyanoHAB events.

Introduction

At the request of the New Jersey Department of Environmental Protection's (NJDEP) Bureau of Freshwater and Biological Monitoring, the scientific basis of the NJDEP recreational advisory for saxitoxin (STX) was developed by the Division of Science and Research (DSR).

Recreational advisories for cyanotoxins are intended to be protective for children's swimming exposures during cyanobacteria harmful algal bloom (cyanoHAB) events, since children are the sensitive sub-population for swimming exposures. In New Jersey, cyanoHABs may persist for several months during the swimming season, and the recreational advisories are intended to protect for repeated daily exposures during the duration of a cyanoHAB event (USEPA, 2019; NJDEP, 2020).

These recreational advisories (µg/L) are based on both toxicity and exposure considerations:

- Toxicity is considered through a short-term Reference Dose (RfD; µg/kg/day), which is the daily oral dose that is not expected to result in adverse health effects from short-term exposures.
- The exposure pathway of concern is incidental ingestion of water by children while swimming. The exposure factors used are the amount of water swallowed per day by a child during swimming (L/day) and the child's body weight (kg).

The bases for both the STX short-term RfD and the exposure assumptions used to develop the advisory are discussed below.

Document development process

Literature searches were conducted by the Department's Environmental Research Library on April 2019 and February 2020 to identify resources to inform the derivation of an RfD for a recreational guidance value for STX. These searches were supplemented by relevant literature identified in the reference sections of authoritative sources (e.g., government and health agency reports) and review articles. In addition to internal NJDEP review, the scientific basis of the NJDEP RfD for STX described herein underwent review by three external peer-reviewers.

Background information relevant to health effects of STX

STX is a member and the representative molecule of a class (i.e., the saxitoxins) of over 50 structurally related analogues (e.g., neosaxitoxin, gonyautoxins). These naturally occurring toxins are hydrophilic and not volatile (Testai et al., 2016; Vilariño et al., 2018; WHO, 2020). STX is considered to be heat (even at 100°C) and acid stable but is unstable under alkaline conditions (EFSA, 2009). In the environment, STX has been shown to persist for up to 2 months in water (WHO, 2020). However, in laboratory experiments, some bacteria have been shown to degrade STX and its analogues within a short period of time (< 3 days) and transform one analogue to another (Donovan et al., 2008; Smith et al., 2001). Further in-depth information regarding the structure and chemical and physical properties of STX can be found elsewhere (WHO, 2020).

Occurrence and human exposure to STX

In freshwater environments, cyanobacteria produce STX and its analogues, whereas dinoflagellates generally produce these toxins in marine environments and brackish waters (WHO, 2020).

The oral route is the main route of human exposure to STX. During cyanoHAB events in freshwater, humans can be exposed to STX and its analogues through recreational activities (e.g., incidental ingestion of water during swimming) and/or drinking water, particularly where drinking water treatment is insufficient or non-existent (WHO, 2020). Additionally, the consumption of marine shellfish contaminated with STX and its analogues (i.e., from feeding on toxin-producing prey) is a well-known route of human oral exposure (Testai et al., 2016).

Although not volatile, inhalation exposure could potentially occur if STX was present in aerosols (e.g., resulting from the wake of a boat) (WHO, 2020). While dermal exposure to STX may occur during recreational activities, dermal absorption is unlikely (WHO, 2020). STX does not appear to irritate or sensitize the eye or skin (except for tingling or numbness of the lips) (WHO, 2020).

Toxicokinetics of STX

Information on the human toxicokinetics (i.e., absorption, distribution, metabolism, and excretion) of STX has largely been ascertained following episodes of human ingestion of shellfish contaminated with STX and its analogues. Toxicokinetic studies in other mammalian models (e.g., cats) are reviewed elsewhere (EFSA, 2009; WHO, 2020).

The absorption of STX and its analogues at the point of contact (i.e., lips, mouth, tongue) and the gastrointestinal tract is efficient, as symptoms occur minutes to hours following oral exposure in humans (EFSA, 2009; WHO, 2020).

STX and its analogues are distributed throughout the human body. Post-mortem analyses of individuals who had died from paralytic shellfish poisoning (PSP), which is caused by STX and its analogues (EFSA, 2009), demonstrated that these toxins were present in the adrenal glands, bile, brain, cerebrospinal fluid, heart, kidneys, liver, lungs, pancreas, spleen, and thyroid gland

(Vilariño et al., 2018). Following intraperitoneal exposure in pregnant mice, STX was reported to cross the placental barrier and reach the fetal brain (Lima-Filho et al., 2020).

The human metabolism of STX has not been clearly elucidated. However, post-mortem analyses of PSP victims suggest that STX and its analogues undergo metabolism, as toxin profiles of the victims' gastric contents differ from the profile in other specimens (e.g., urine, liver, kidneys) (Vilariño et al., 2018). Using human liver microsomes, *in vitro* investigations suggest that STX can undergo N-oxidation and glucuronidation reactions (WHO, 2020). The N-oxidation of STX leads to the formation of neosaxitoxin, which itself is capable of producing toxicity (Testai et al., 2016). In addition to oxidation, other metabolic reactions (e.g., hydrolysis, sulfation) lead to other STX biotransformation products (WHO, 2020).

Urine is the major route of elimination for STX and its analogues in humans, although these toxins have also been detected in bile suggesting a fecal route of elimination (WHO, 2020). STX appears to be eliminated from the human body relatively rapidly. Based on individuals recovering from PSP, STX and its analogues were cleared from the serum to undetectable levels within 24 hours of exposure, and a human serum half-life of less than 10 hours was estimated (Gessner et al., 1997). A urinary human half-life of 20.4 hours has also been reported (Wharton et al., 2017). This relatively short half-life is supported by studies in laboratory rats that reported half-lives between 12 and 18 hours following intravenous injection with either STX or a reduced derivative, saxitoxinol (EFSA, 2009).

Human and laboratory animal health effects of STX

As reviewed below, neurotoxicity is the major health effect in humans and laboratory animals (e.g., rodents) following acute oral exposure to STX (EFSA, 2009). Due to a lack of information, the human and laboratory animal health effects from chronic oral exposure to STX are not definitively known. Health effect studies in other species (e.g., zebrafish) are reviewed elsewhere (O'Neill et al., 2016; Testai et al., 2016).

Acute effects in humans

The acute human health effects of STX have been identified from observations in individuals who consumed shellfish contaminated with STX and its analogues, which lead to PSP (EFSA, 2009). Because of their causative role in PSP, STX and its analogues have been called paralytic shellfish toxins (Vilariño et al., 2018). PSP is a collection of acute neurological symptoms of various severities: mild (e.g., tingling or numbness around the mouth or digits, headache, dizziness, nausea, vomiting); moderate (e.g., numbness and weakness in extremities, ataxia, incoherent speech, shortness of breath); and severe (e.g., muscular paralysis, respiratory difficulties). Death can also result from respiratory paralysis (WHO, 2020). No antidote is available for PSP (Testai et al., 2016). No data were identified on whether acute STX exposure causes effects other than neurotoxicity (e.g., systemic, developmental, reproductive, or immune effects) in humans (WHO, 2020).

Acute effects in animals

As discussed below in the "Derivation of an STX RfD" section, a limited database exists for the acute effects of oral STX exposure in laboratory animals. In general, such studies have focused

on and confirmed the neurotoxicity of STX. Aside from neurotoxicity, the potential for STX to cause overt acute toxicity has not been evaluated.

Chronic effects in humans

No studies have been identified that investigated human health effects from chronic exposure to STX (WHO, 2020). However, there is speculation that low dose STX exposure during different stages of human development may cause long-term, permanent effects. For example, STX exposure during neurogenesis may affect neurodevelopment, since STX interacts with ion channels on neuronal cells and may thereby inhibit the cellular electrical activity that occurs during neurodevelopment (O'Neill et al., 2016).

Subchronic and chronic effects in animals

There are limited chronic data (i.e., those with at least 90 days of exposure) regarding the effects of STX in laboratory animals. However, as reviewed below, subchronic (~30 days) studies in rats exposed to drinking water containing cyanobacterial cultures producing STX and its analogues confirm the neurotoxicity of STX. With the exception of biochemical changes in the liver that were evaluated in one study, these studies did not assess toxicological endpoints other than neurotoxicity.

The study with the longest duration of exposure involved male rats exposed to neosaxitoxin, which is an analogue and metabolite of STX, for 12 weeks via daily subcutaneous injection (Zepeda et al., 2014). Only rats in the high dose group (6 µg/kg/day) exhibited signs of toxicity, including increases in total and direct bilirubin, gamma-glutamyltransferase, and serum glutamic oxaloacetic transaminase, which indicate impaired liver function. These effects were reversible following cessation of exposure. No other signs of toxicity were observed in terms of body weight, food intake, hematological and biochemical parameters, and organ weight and histopathology (heart, kidney, liver, lung, spleen, and stomach).

Mode of action

The neurotoxicity of STX results from its ability to bind to voltage-gated sodium channels (VGSCs) on neuronal cells (EFSA, 2009; O'Neill et al., 2016; WHO, 2020). Specifically, STX binds to site 1 of the α -subunit of the VGSCs found on the outside of these cells. In doing so, STX blocks these channels thereby preventing sodium ions from moving across the neuronal cell membrane. Blocking the movement of sodium ions prevents the generation of action potentials along neuronal axons and the transmission of nerve impulses to muscles. A progressive loss of neuromuscular function occurs resulting in paralytic symptoms that may ultimately lead to death by respiratory arrest. This mode of action is believed to be consistent for most, if not all, of the different STX analogues (Testai et al., 2016).

Humans have 10 different isoforms or variations of the α -subunit of VGSCs (O'Neill et al., 2016; WHO, 2020). The distribution of these isoforms can vary throughout the human body (i.e., some may occur predominantly in the central or peripheral nervous systems) and their expression can vary during development. Additionally, each isoform may have a different sensitivity toward STX. Such differences in distribution, expression, and sensitivity may be an explanation for why some individuals are more susceptible to STX.

In addition to causing toxicity by binding to VGSCs, STX is reported to bind to calcium and potassium channels. Inhibition of these channels, which may result in toxicity, appears to occur with much higher STX doses compared to the inhibition of VGSCs (O'Neill et al., 2016; WHO, 2020). In an *in vitro* mouse model, effects on cellular proliferation and differentiation is suggestive of STX binding to voltage-gated calcium channels, which may have implications for neurodevelopment (Lima-Filho et al., 2020). Oxidative stress may also result from STX exposure; however, this may be more relevant to longer durations of STX exposure (O'Neill et al., 2016; WHO, 2020).

STX recreational values used by other states

As of August 2020, the USEPA does not have a toxicity value (e.g., RfD) or recreational exposure guidance value for STX. However, five US states (CO, OH, OR, PA, WA) are reported by USEPA (2019) to have recreational water guideline levels for STX. While all are based on the same principal study (EFSA, 2009), these recreational values range from 0.8 to 75 µg/L (Appendix A).

As reviewed in detail in the “Human epidemiology studies” section below, the EFSA (2009) assessment summarized human case reports (including > 500 individuals) of paralytic shellfish poisoning (PSP), for which STX and its analogues were the causative toxins (EFSA, 2009). EFSA (2009) estimated a lowest-observed-adverse-effect-level (LOAEL) of 1.5 µg STX equivalents/kg/day (or µg STX eq/kg/day)¹.

EFSA (2009) applied an uncertainty factor (UF) of 3 to the LOAEL of 1.5 µg/kg/day to estimate a no-observed-adverse-effect level (NOAEL) of 0.5 µg /kg/day. Using 0.5 µg /kg/day as a point of departure (POD), the states listed above then applied additional UFs (e.g., for human variability or database limitations) to derive acute or short-term RfDs. The states used these RfDs and relevant exposure factors (e.g., body weight, incidental water ingestion) to derive their recreational values (Appendix A).

Derivation of an STX RfD

As stated above, NJDEP recreational advisories for cyanotoxins including STX are intended to be protective for children’s swimming exposures during cyanoHAB events, which may persist for several months during the swimming season (USEPA, 2019; NJDEP, 2020). The STX RfD derived herein is intended to be protective for exposure on multiple days of swimming during the swimming season, for the more sensitive sub-population of children. Accordingly, laboratory

¹ The most commonly used method of expressing the amount of STX in shellfish implicated in PSP is the mouse bioassay. This assay provides a measure of the total of all STX analogues present within a sample (i.e., this approach can neither qualitatively differentiate among the different STX analogue structures nor provide a quantitative measurement for each individual analogue). Therefore, measurements of STX-group toxins are collective measures of all STX analogues in a sample and have by convention been expressed as STX equivalents (eq) (EFSA 2009; FAO, 2011).

animal and human studies investigating the effects of less than sub-chronic² exposure to STX were considered for deriving the short-term RfD.

In addition to studies identified through literature searches, studies reviewed herein include those cited as the basis of recreational guidance values for other states.

Animal toxicology studies

A limited number of studies in laboratory animals exposed to STX were identified. Studies identified primarily involve either acute or subchronic exposure. Studies in which isolated (i.e., pure) STX was administered orally, either by drinking water or diet, are reviewed below as the potential basis for derivation of an STX RfD. Studies in which laboratory animals were exposed to STX along with its analogues are reviewed as supporting data useful for informing results from pure STX exposures. Reviews of available studies of STX using other routes of exposure (e.g., intravenous or intraperitoneal), which are less relevant than oral studies for recreational exposure through incidental ingestion of water, are reviewed elsewhere (Testai et al., 2016; WHO, 2020). Except for neurotoxicity, there is a lack of standard systemic toxicity studies assessing endpoints such as organ weight and histopathology and clinical chemistry. Additionally, the lack of chronic (i.e., > 90 days of exposure), developmental, and reproductive studies, as well as studies focused on genotoxicity and carcinogenicity, identified for this assessment and in recent reviews (Testai et al., 2016; WHO, 2020) gives an indication of the limited extent of the laboratory animal database for STX.

Two oral mouse studies of pure STX, both acute in duration (i.e., a single exposure), were identified (Munday et al. 2013; Finch et al. 2018). Studies by Ramos et al. (2014) and Diehl et al. (2016) reported on the short-term (i.e., repeated dosing up to ~30 days) exposure of rats to drinking water containing cyanobacterial cultures producing STX and its analogues.

Munday et al. (2013)

Female Swiss albino mice received a single oral gavage exposure to STX (> 98% pure). The authors did not explicitly state the doses (i.e., expressed in mass of STX per body weight) to which the mice were exposed nor the number of animals per dose group. After dosing, the mice were observed for neurological effects including grip strength, exploratory behavior, abdominal breathing, and lethargy. Based on lethargy and decreases in grip strength and exploratory behavior, the authors identified a NOAEL of 544 nmol/kg (163 µg/kg)³.

This study affirms the neurotoxicity of STX. However, a number of factors render this study problematic for RfD development. As noted above, some of the specific doses employed in this study were not reported by the authors. Additionally, the authors did not provide a detailed methodological description of the neurotoxicity tests conducted, the number of animals per dose

² The USEPA defines subchronic exposure as occurring for “more than 30 days up to approximately 90 days in typically used laboratory animal species”.
https://iaspub.epa.gov/sor_internet/registry/termreg/searchandretrieve/glossariesandkeywordlists/search.do?details=&vocabName=IRIS%20Glossary#formTop

³ All conversions herein from nmol/kg to µg/kg are based on the molecular weight of 299 grams/mole for STX.

group, or quantitative data and the statistical analyses used to detect differences in neurotoxic effects between dose groups.

Finch et al. (2018)

Female Swiss albino mice received a single dietary exposure (via cream cheese) to STX (> 99% purity). The authors did not explicitly state the doses (i.e., expressed in mass of STX per body weight) to which the mice were exposed. Although not explicitly stated, it appeared that there were 3 animals per dose group. After dosing, the mice were continuously monitored for 3 hours for signs of neurotoxicity including any change in posture, respiratory rate, or movement. The authors identified a NOAEL of 1270 nmol/kg (379 µg/kg), although effects were observed in 1 of 3 mice in that dose group. However, 3 of 3 mice showed no effects with exposure to 1140 nmol/kg (341 µg/kg). In the 14 days following exposure, the authors reported that the mice appeared and behaved normally, gained weight, and showed no abnormalities at necropsy.

This study also affirms the neurotoxicity of STX. However, a number of factors render this study problematic for RfD development. As noted above, some of the specific doses employed in this study were not reported by the authors. The authors did not provide a detailed methodological description of the neurotoxicity tests conducted nor the quantitative data and the statistical analyses used to detect differences in neurotoxic effects between dose groups.

Ramos et al. (2014)

Female Wistar rats (5 to 10 per dose group) were orally exposed for 30 days via drinking water contaminated with cyanobacterial (*Cylindrospermopsis raciborskii*) cultures producing STX and its analogues at final concentrations of 3 or 9 µg STX eq/L. Rats in the control group were exposed to drinking water with culture medium but no cyanobacteria. Based on these concentrations, the authors estimated the doses to be 0.24 or 0.72 µg STX eq/day⁴. After the 30 days of exposure, the rats were killed and various subclinical biochemical parameters were assessed in brain (prefrontal cortex, hippocampus) and liver tissues. Specifically, the authors measured the following: concentration of reactive oxygen species (ROS), total antioxidant capacity (ACAP), glutathione (GSH) concentration and glutamate cysteine ligase activity (GCL), glutathione-S-transferase (GST) activity, and lipid peroxidation via the ferrous oxidation-xylenol orange (FOX) assay and the thiobarbituric acid reactive substances (TBARS) assay.

Exposed rats showed no clinical signs of toxicity (not specified by the study authors) and did not have deviations in body weight gain compared to controls. Some changes in biochemical parameters were observed relative to the control group. Although the authors found a decrease in ROS only in the hippocampus of the 3 µg/L group, they also observed a lower ACAP in this group, while ACAP was higher in the cortex of the 9 µg/L group. GCL activity was decreased in the cortex of the 3 µg/L group but increased in the cortex and hippocampus of the 9 µg/L group. GSH levels were increased in the hippocampus and liver of the 3 µg/L group. GST activity was increased in the hippocampus but decreased in the liver of the 9 µg/L group. While lipid peroxidation was increased (FOX assay) in the liver of the both dose groups, no change in lipid peroxidation was observed with the TBARS assay.

⁴ Authors reported that each rat drank 0.08 L of contaminated drinking water per day.

This study provides mechanistic information demonstrating the ability of STX and its analogues to affect various parameters associated with oxidative stress in the brains and livers of rats. These changes may precede more serious effects in these tissues such as overt neurotoxicity or liver damage. Nevertheless, the changes in subclinical biochemical parameters assessed in this study are not considered to be adequate to serve as the basis of an RfD (i.e., these endpoints are not specific indicators of an adverse clinical effect or disease). Although this study provided sufficient methodological and statistical details, the use of drinking water contaminated with cyanobacteria raises the possibility that endotoxins produced by the bacteria may confound effects purported to be from STX and its analogues.

Diehl et al. (2016)

Female Wistar rats were orally exposed for 30 days via drinking water contaminated with cyanobacterial (*Cylindrospermopsis raciborskii*) cultures producing STX and its analogues at final concentrations of 3 or 9 µg STX eq/L. Based on these concentrations, the authors estimated the exposure to be 0.24 or 0.72 µg STX eq/day for each rat. The authors checked the *C. raciborskii* cultures for the presence of other cyanobacteria toxins, specifically cylindrospermopsin and microcystin, and found no positive results for their production. A negative control group was exposed to drinking water contaminated with a culture of the cyanobacteria *Aphanothece* sp.⁵, which did not produce the toxins listed above. Between 10 and 15 rats were assigned to each dose group. After the 30 days of exposure, the rats were subjected to the following behavioral tests: open field habituation (OFH) task, elevated plus maze anxiety (EPM) task, inhibitory avoidance (IA) task, and Morris water maze (MWM).

Compared to controls (i.e., rats exposed to drinking water with culture medium but no *C. raciborskii*), exposed rats showed no clinical signs of toxicity (not specified by the study authors) and did not have deviations in body weight gain. The following behavioral results were observed relative to the control group. Exposure to STX had no effect on the performance of rats in the OFH and EPM tasks. However, performance was affected in the IA task in rats exposed to 9 µg STX eq/L. Additionally, performance was also affected for certain aspects of the MWM task, such as an increased time to find a hidden platform and time spent within certain quadrants of the test chamber, although only the 9 µg STX eq/L exposure group was tested. Based on the affect in the IA task, a NOAEL of 3 µg STX eq/L is identified, which is converted to approximately 0.8 to 1.1 µg STX eq/kg/day, based on the initial body weight range (210 to 300 g) and drinking water volume (0.08 L/day) of the rats in this study.

Diehl et al. (2016) demonstrates that short-term STX exposure through drinking water contaminated with cyanobacteria can cause memory impairment in rats, an effect not observed or assessed in other studies. In an earlier study by these authors, oxidative stress was reported to occur in the brain of rats exposed to similar conditions (Ramos et al., 2014). This earlier study provides mechanistic support to the observation of memory impairment. However, Diehl et al (2016) is not judged to be adequate for deriving an RfD. Although this study provided sufficient methodological and statistical details, the use of drinking water contaminated with cyanobacteria raises the possibility that endotoxins produced by the bacteria may confound results purported to

⁵ Within the context of the Diehl et al. (2016) study, "sp." is referring to the fact that the *Aphanothece* used in this study was a non-toxin producing cyanobacteria that was not taxonomically defined.

be from STX and its analogues. The ability of endotoxin to affect memory in laboratory rodents is reviewed elsewhere (Zakaria et al., 2017; Batista et al., 2019). For some behavioral tests, only one dose group was tested. Additionally, Diehl et al. (2016) do not provide details about how they estimated STX eq in drinking water and do not provide quantitative information for other STX analogues they measured (Vilarinho et al., 2018).

Human epidemiology studies

No studies of any duration that investigated the effect of STX-only exposure on human health were identified. However, a number of case reports exist describing PSP in humans, which is caused by STX and its analogues (EFSA, 2009). DSR did not individually assess these case reports as a number of previous assessments have compiled such studies for the derivation of RfDs for STX (Fitzgerald et al., 1999; FAO, 2004; EFSA, 2009; Arnich and Thébault, 2018). As mentioned below, the RfDs from some of these assessments have served as the basis for guidance values used by other US states and some countries.

Four previous assessments were identified that have compiled available case reports for PSP and either identified a POD (Arnich and Thébault, 2018) or actually derived an STX RfD (Fitzgerald et al., 1999; FAO, 2004; EFSA, 2009). These four assessments are summarized below to inform their potential use as the basis for the NJDEP STX RfD. Each of these assessments typically used a similar collection of PSP case reports for deriving an RfD, and the specific case reports considered can be found within each assessment. As PSP results from acute exposure to STX and its analogues, acute RfDs are derived by these assessments. Additionally, as the case reports that informed these RfDs did not differentiate between STX and its analogues causing PSP, the acute RfDs are expressed in $\mu\text{g STX eq/kg}$. As presented below in the “Discussion” section, a number of uncertainties exist with these case reports.

Fitzgerald et al. (1999)

This assessment, which is published in a peer-reviewed journal, is based on 11 studies reviewing case reports published between the 1950s and 1990s describing PSP in Asia, Europe, North America, and South America. This collection of case reports included 999 exposed individuals (880 with symptoms, 119 without symptoms). Although not completely characterized by Fitzgerald et al. (1999), ages of individuals likely ranged from 2 to >27 years old. Fitzgerald et al. (1999) considers the largest number of individuals compared to the other assessments reviewed herein. However, this sample size is based on the inclusion of a study by Fu et al. (1982), which is not considered by the other assessments but also does not report any human exposure data.

Of these case reports, nine provide human dose information for outcomes (i.e., unaffected, ill, death). However, Fitzgerald et al. (1999) does not report on the methods (e.g., the mouse bioassay assay [MBA]) used to determine the human doses. Table 1 below summarizes outcome and human dose information as reported in Fitzgerald et al. (1999). There is considerable overlap between outcome groups and human doses. For example, the human dose range that caused mortality falls within the dose ranges for unaffected and ill individuals. Such dose ranges demonstrate either a wide range of human susceptibility to PSP, differences in exposure and outcome assessment, or a combination of both.

Table 1. Summary of case report data from Fitzgerald et al. (1999) ^a	
Outcome	Human Dose (µg STX eq) [Human dose in µg STX eq/kg body weight] ^b
Unaffected (n = 119)	17 to 36,580 [0.28 to 610]
Ill (n = 828)	13 to 123,457 [0.22 to 2058]
Deaths (n = 52)	456 to 6300 [7.6 to 105]
a = Adapted from Table 1 of Fitzgerald et al. (1999) b = For a rough comparison with results from other European assessments reported herein (e.g., EFSA, 2009), a body weight of 60 kg was assumed for all individuals regardless of age, as Fitzgerald et al. (1999) did not provide a breakdown of the number of individuals in each age group.	

Based on nonfatal illness, Fitzgerald et al. (1999) identified 4 individuals with the lowest reported toxin doses as candidates for the basis of their RfD: an adult (age not specified) exposed to 13 µg toxin, a 2-year old child exposed to 114 µg toxin, a 12-year old male exposed to 124 µg toxin, and a 27-year old female exposed to 124 µg toxin. Fitzgerald et al. (1999) considered the first case (adult exposed to 13 µg toxin) to be an outlier and selected the dose of 124 µg toxin in the adult female as the LOAEL for STX. This selection was based on the fact that when normalizing the total doses (i.e., µg toxin/person) based on age-appropriate body weights (60 kg for an adult) the LOAEL on a body weight basis in the adult female (2.1 µg/kg) was lower than in the 2-year old and 12-year old children.

For UFs, Fitzgerald et al. (1999) applied a factor of 10 to extrapolate from the LOAEL of 2.1 µg/kg identified above to a NOAEL. No UF was applied for human variation as the authors noted that case reports were from several countries, and included both males and females, and adults and children. No additional UFs were applied. The resulting acute RfD is 0.21 µg STX eq/kg.

Using the basis of this LOAEL (i.e., observed health effects with 124 µg of toxin exposure) and recognizing that there were insufficient data to derive a drinking water guideline, Australia's National Health and Medical Research Council (NHMRC, 2011) developed a drinking water health alert value (3 µg/L) for STX (based on 50% of STX exposure coming from drinking water, a daily water consumption rate of 2 L/day, and an uncertainty factor of 10 for use of a LOAEL rather than a NOAEL).

Food and Agriculture Organization of the United Nations (FAO, 2004)

This terse assessment is based on 20 incidents of PSP in Canada between 1970 and 1990 involving about 60 individuals with ages between 3 and 72 years. FAO (2004) does not describe

the methods used to estimate human STX dose, but reports that individuals with mild cases had consumed between 2 and 30 µg/kg while more severe cases consumed > 10 to 300 µg/kg. Based on these data, FAO (2004) identified a LOAEL of 2.0 µg/kg.

For UFs, FAO (2004) applied a factor of 3 to extrapolate from the LOAEL of 2.0 µg/kg to a NOAEL. No UF was applied for human variation as FAO (2004) noted that the cases of PSP involved a spectrum of people in terms of occupation, age, and sex and that mild symptoms were reversible. No other UFs were applied. The resulting acute RfD is 0.7 µg STX eq/kg.

European Food Safety Authority (EFSA, 2009)

This assessment is based on 14 studies reviewing case reports published between the 1940s and 2000s describing PSP in Africa, Europe, North America, and South America. This collection of case reports included over 600 individuals (roughly 574 with symptoms and 80 without symptoms). Although not completely characterized by EFSA (2009), ages of individuals likely ranged from < 6 years old to adults.

EFSA (2009) reported toxin concentrations in shellfish as well as analytical methods and assumptions used to determine human dose. Table 2 below summarizes outcome and human dose information as reported in EFSA (2009). The overlap between outcomes and human doses may be due to the wide range of human susceptibility to PSP, differences in exposure and outcome assessment, or a combination of both.

Table 2. Summary of case report data from EFSA (2009) ^a	
Outcome	Human Dose ^b (µg STX eq/kg body weight)
No symptoms	0.3 to 610
Mild symptoms	0.7 to 70
Moderate symptoms	1.5 to 150
Severe symptoms	1.5 to 300
Respiratory arrest/failure	53 to 2058
Death	7 to 225
a = Adapted from Table 16 of EFSA (2009); number of individuals in each outcome category not provided for all studies	
b = As reported in EFSA (2009)	

Based on these PSP data, EFSA (2009) identified a LOAEL “in the region of 1.5 µg STX equivalents/kg b.w.” (i.e., they qualitatively identified the LOAEL). To support this LOAEL, EFSA (2009) stated that “many individuals did not suffer adverse reactions at much higher intakes and therefore it is expected that this LOAEL is very close to the threshold for effects in the most sensitive individuals.” This conclusion, however, does not appear to be clearly supported in EFSA (2009), as there is a lack of individual data (e.g., dose and outcome) for the entire study population, including a lack of data on STX levels that caused effects in children versus adults.

For UFs, EFSA (2009) applied a factor of 3 to extrapolate from the LOAEL of 1.5 µg/kg identified above to a NOAEL. No UF was applied for human variation as EFSA noted that “data were from reports of a large number of affected consumers, including the most sensitive individuals.” No additional UFs were applied. The resulting acute RfD is 0.5 µg STX eq/kg.

As noted above, five US states (CO, OH, OR, PA, WA) have used this acute RfD and exposure factors, which differed among states, to derive recreational water guideline levels for STX (ranging from 0.8 to 75 µg/L). In addition to these states, the WHO (2020) developed its recreational water guideline value of 30 µg /L for STX based on the LOAEL derived by EFSA (2009).

Arnich and Thébault (2018)

This assessment, which is published in a peer-reviewed journal, developed a quantitative approach (1) to model the dose-response relationship between human exposure to paralytic shellfish toxins (i.e., STX and its analogues) and the severity of PSP symptoms, and (2) to identify a threshold dose for PSP symptoms. In doing so, the authors conducted a systematic review, an investigative process aimed at minimizing bias and maximizing transparency of their assessment. As part of this process, the authors identified all existing published studies on this topic and assessed the quality of each study for use in statistical analysis.

Although Arnich and Thébault (2018) identified 30 studies reviewing case reports of PSP published through February 2018 that reported on 329 exposed individuals, the authors excluded a number of studies due to missing information (e.g., amount of shellfish ingested, temporality between when contaminated shellfish was ingested and collected for analysis). When possible, assumptions were made for missing data (e.g., body weight). Based on this screening step, the authors based subsequent statistical analyses on 191 exposed individuals (149 with symptoms, 42 without symptoms) from 16 studies.

For these analyses, the authors used an ordinal scale (i.e., data were placed into categories of increasing rank) for PSP symptoms based on EFSA (2009):

- 0, no symptoms
- 1, mild symptoms (e.g., dizziness, headache, nausea, numbness, tingling, vomiting)
- 2, moderate symptoms (e.g., incoherent speech, lack of voluntary movement, rapid pulse, shortness of breath)
- 3, severe symptoms (e.g., difficulty swallowing, muscular paralysis, respiratory arrest without death)
- 4, death

In attempting to describe the relationship between STX dose and PSP symptoms, the authors found it necessary to determine whether additional studies should be excluded from dose-response analysis. For example, one study with 7 exposed individuals (5 with symptoms, 2 without symptoms) was excluded from further analysis because toxin exposure for individuals without symptoms was higher than exposure for individuals with symptoms.

Using the 15 remaining studies, Arnich and Thébault (2018) found no clear dose-response relationship between category of symptoms and toxins ingested (in µg STX eq/kg body weight) when displayed graphically on a log₁₀ scale.

With the intent of using the highest quality studies available for dose-response analysis, the authors then assigned a level of confidence (low, medium, or high) to each of the 15 studies. High confidence studies used few assumptions to estimate dose, analyzed toxins in shellfish leftover from the meal consumed by the subject, and reported the amount of shellfish consumed. In contrast, low confidence studies used many assumptions to estimate dose, analyzed other shellfish (i.e., those not consumed by the exposed individual), and were ambiguous about the amount of shellfish consumed. Studies not easily classified into the high or low confidence level were assigned a medium level. Of the 15 studies, the authors assessed that 6 had a low level of confidence, 7 had a medium level, and 2 a high level. Due to small sample size, the authors could not establish a dose-response relationship from a graphical presentation of the data from only the high-level studies. When high and medium level studies were considered, Arnich and Thébault (2018) found that the dose-response results were no better than when using studies with all levels of confidence.

As a further attempt to identify and exclude studies with anomalous data, Arnich and Thébault (2018) conducted a rough sensitivity analysis by determining to what extent the exclusion of a given study affected the R^2 (coefficient of determination) for the entire dataset of all 15 studies. Based on this approach (Figures 6 and 7 in Arnich and Thébault, 2018), the authors found that excluding 2 studies, both of which reported exposure data far from the mean exposure values (for all studies) for some symptom categories, improved the R^2 value from 0.0074 to 0.299. The remaining 13 studies yielded a linear dose-response relationship (p -value < 0.001).

Based on data from the remaining 13 studies of 143 exposed individuals (113 with symptoms, 30 without symptoms), Arnich and Thébault (2018) conducted a dose-response analysis to identify a threshold for PSP symptoms. Although benchmark dose (BMD) modeling is recommended for dose-response analysis by the USEPA (2012), BMD modeling of ordinal data was not available when the Arnich and Thébault (2018) study was conducted. Therefore, the authors developed an approach based on a cumulative link mixed model, which is a standard choice for modeling ordinal data.

To identify the best fitting model, the authors tested whether different fixed effects⁶ (e.g., age, dose, sex) and random effects (e.g., publication bias) predictor/explanatory variables were necessary for inclusion in the model. Additionally, the authors explored the use of different link functions (logistic versus probit) for using the actual response data (i.e., the categories of symptoms) from the human case reports to ultimately predict the probability of a given symptom based on STX exposure. Based on this approach and selection of the model with the lowest Akaike Information Criterion (AIC)⁷, the authors conducted subsequent analyses using a probit model, with Log10 (dose) and the random effect of publication bias removed.

Using this probit model, Arnich and Thébault (2018) generated prediction curves with 95% confidence intervals. From these curves, the authors identified critical doses (CDs) estimated for

⁶ Fixed effect variables are factors assumed to be either constant or to change at a constant rate over time. Random effect variables are assumed to be unpredictable.

⁷ Akaike's Information Criterion (AIC) is a statistical measure used to compare how well different nested models (i.e., different combinations of the explanatory variables) predict the response variable. In practice, the model with the lowest AIC is considered the best fit (USEPA, 2012).

a 10%, 5%, and 1% probability of showing symptoms. For each CD, the authors estimated lower and upper critical doses (LCD and UCD) from the 95% lower- or upper-bound of the 95% confidence interval of each CD. This approach is comparable to the identification of the lower- and upper-bound of the BMD (i.e., the BMDL and BMDU) in USEPA's approach to BMD modeling (USEPA, 2012). Table 3 reports the results of these predictions. Based on these predictions, the LCD with a greater than 10% probability of showing any symptom is 0.37 µg STX eq/kg. At this dose, 10% of individuals would have some symptoms of PSP, without consideration of severity of symptoms. The rationale for selecting a 10% risk level, as opposed to a 5% or 1% level, is presented in the "Selection of principal study" section. Additionally, as discussed below, 0.37 µg STX eq/kg can serve as the POD for the derivation of an STX RfD.

Selection of principal study

Both laboratory animal and epidemiology studies that could potentially inform the derivation of a short-term RfD for STX were reviewed. When epidemiology studies that provide appropriate data are available, they are preferable to laboratory animal studies for the derivation of an RfD. Therefore, information on human cases of PSP are considered for deriving the short-term RfD. In addition, the available animal studies were judged not appropriate for the derivation of a short-term STX RfD for reasons mentioned above (e.g., inadequate study design or data reporting, confounding by other bacterial toxins, assessed only sub-clinical endpoints).

The human case reports of PSP from STX exposure have been summarized in four assessments. All of these assessments identified PODs that were in many cases then used to derive acute RfDs for STX (Fitzgerald et al., 1999; FAO, 2004; EFSA, 2009; Arnich and Thébault, 2018). Table 4 summarizes the acute RfDs derived by these assessments. Unlike the other three assessments, Arnich and Thébault (2018) did not derive an RfD from their POD (0.37 µg STX eq/kg). As discussed in more detail below, a POD of 0.37 µg STX eq/kg, based on a 10% risk of any symptom from exposure to STX is judged to be appropriate for use as a POD. This approach is consistent with the USEPA's BMD modeling, in which 10% excess risk (i.e., a 10% response rate over controls or non-exposed individuals) is the default response level (i.e., the benchmark response [BMR]), particularly for data that are not continuous (USEPA, 2012). For the purposes of comparison with the other assessments in Table 4, the POD from Arnich and Thébault (2018) is simply used as the acute RfD. The acute RfDs derived from information in the four

Table 3. Predicted critical doses (in µg STX eq/kg) for each symptom category at different levels of risk			
Level of risk	LCD	CD	UCD
Category of symptoms > 0 (no symptoms)			
10%	0.37	0.88	2.6
5%	0.20	0.47	1.8
1%	0.06	0.14	1.2
Category of symptoms > 1 (mild symptoms)			
10%	1.9	3.7	7.9
5%	0.94	2.0	5.3
1%	0.28	0.60	3.1
Category of symptoms > 2 (moderate symptoms)			
10%	5.2	9.2	17
5%	2.6	4.9	11
1%	0.74	1.5	5.7
Category of symptoms > 3 (severe symptoms)			
10%	82	140	340
5%	43	73	180
1%	13	25	69
Adapted from Table 4 of Arnich and Thébault (2018) with critical doses rounded to two significant digits. CD = critical dose. LCD = lower critical dose. UCD = upper critical dose.			

Table 4. Summary of acute RfDs				
	Fitzgerald et al. (1999)	FAO (2004)	EFSA (2009)	Arnich and Thébault (2018) ^a
Point of Departure (µg STX eq/kg)	2.1 (LOAEL)	2.0 (LOAEL)	1.5 (LOAEL)	0.37 (modeled) ^b
UF _{Animal}	<i>1</i>	<i>1</i>	<i>1</i>	--- ^c
UF _{Human}	<i>1</i>	<i>1</i>	<i>1</i>	---
UF _{Duration}	<i>1</i>	<i>1</i>	<i>1</i>	---
UF _{LOAEL}	10	3	3	---
UF _{Database}	<i>1</i>	<i>1</i>	<i>1</i>	---
UF _{Comp}	10	3	3	---
Acute RfD (µg STX eq/kg)	0.21	0.67	0.5	0.37
<p>a = Arnich and Thébault (2018) did not derive an acute RfD. For comparative purposes, the modeled POD was used as the acute RfD.</p> <p>b = lower confidence level on modeled dose for 10% probability of symptoms</p> <p>c = Dashed lines indicate that Arnich and Thébault (2018) did not apply UFs to their POD.</p> <p>Note: For some assessments in this table, not all UFs (e.g., database) were considered by that assessment. In such cases, DSR applied a 1 (see italics). In no instance did this application change the published acute RfD from that assessment.</p>				

assessments are all within a factor of 3 of each other, with the lowest being 0.21 µg STX eq/kg (Fitzgerald et al., 1999) and the highest 0.67 µg STX eq/kg (FAO, 2004). This is not surprising as many of the same case studies are used in each assessment. Additionally, the composite uncertainty (i.e., the UF_{Comp}) among the assessments is within a factor of 10.

As NJDEP recreational advisories are intended to protect for repeated daily exposures during the duration of a cyanoHAB event (NJDEP, 2020), short-term RfDs are derived in Table 5 from the same four assessments included in Table 4 to account for this exposure duration (i.e., extrapolating from acute to short-term exposure).

None of the acute RfDs shown in Table 4 accounted for deficiencies in the STX database (e.g., lack of systemic, developmental, and reproductive studies). As discussed below, DSR concludes that factors of 3 for human variability (UF_{Human}) and duration ($UF_{Duration}$) as well as a factor of 10 for database deficiencies ($UF_{Database}$) to be appropriate for deriving a short-term RfD for STX. Accordingly, the short-term RfDs in Table 5 are 100-fold lower than their respective acute RfDs in Table 4.

Table 5. Summary of assigned UFs and short-term RfDs derived by DSR from PODs developed by other investigators				
	Fitzgerald et al. (1999)	FAO (2004)	EFSA (2009)	Arnich and Thébault (2018)
Point of Departure (µg STX eq/kg)	2.1 (LOAEL)	2.0 (LOAEL)	1.5 (LOAEL)	0.37 (modeled) ^a
UF_{Animal}	1	1	1	1
UF_{Human}	3	3	3	3
$UF_{Duration}$	3	3	3	3
UF_{LOAEL}	10	3	3	1
$UF_{Database}$	10	10	10	10
UF_{Comp}	1000	300	300	100
Short-term RfD (µg STX eq/kg/day)	0.0021	0.0066	0.005	0.0037
a = lower confidence level on modeled dose for 10% probability of symptoms				

As with the acute RfDs in Table 4, the short-term RfDs are within a factor of 3 of each other, with the lowest being 0.0021 µg STX eq/kg (Fitzgerald et al., 1999) and the highest 0.0066 µg STX eq/kg (FAO, 2004). The composite uncertainty (i.e., the UF_{Comp}) among the assessments is within a factor of 10.

With the exception of Arnich and Thébault (2018), the other assessments qualitatively (i.e., not through modeling the data) determined the POD (in each case a LOAEL) for deriving an RfD. While yielding the lowest short-term RfD, Fitzgerald et al. (1999) based their POD on a single individual with non-fatal PSP. FAO (2004) identified their POD on the lowest dose causing mild PSP symptoms in the case reports they reviewed. Similarly, EFSA (2009) identified their POD

based on the lowest dose causing moderate symptoms. In contrast, Arnich and Thébault (2018) modeled data from 143 exposed individuals to predict a dose with a 10% chance of causing any PSP symptom. Because of the systematic review approach used to identify and assess relevant data, subsequent quantitative modeling of PSP data, and peer-review, the POD derived by Arnich and Thébault (2018) is deemed most scientifically appropriate for deriving a short-term RfD for STX. Therefore, Arnich and Thébault (2018) is selected as the principal study for the derivation of an STX short-term RfD and recreational guidance value.

Although Arnich and Thébault (2018) did not use USEPA BMD modeling software for determining the POD of 0.37 µg STX eq/kg, their modeling approach is judged to be scientifically appropriate. Overall, the Arnich and Thébault (2018) approach closely resembles the modeling performed by the USEPA BMD modeling software. Arnich and Thébault (2018) selected risk levels (i.e., 10%, 5%, and 1%) for PSP symptoms and then identified doses (CDs) corresponding to those levels of risk with LCDs and UCDs indicating the statistical confidence limits (i.e., 95%) of the CDs. This selection of risk level(s) and identification of doses with confidence limits are analogous to the BMRs, BMDs, and BMDLs and BMDUs employed in BMD modeling recommended by USEPA (2012). With BMD modeling, the BMDL serves as the POD as it accounts for experimental variability and ensures that the BMR is not exceeded (USEPA, 2012). Analogously, the LCD determined in Arnich and Thébault (2018) serves as the POD.

The POD of 0.37 µg STX eq/kg determined in Arnich and Thébault (2018), based on a 10% risk level for any symptom from exposure to STX, is judged to be appropriate, as 10% excess risk (i.e., a 10% response rate over controls or non-exposed individuals) is the default response level (i.e., the BMR) used for BMD modeling, particularly for data that are not continuous (USEPA, 2012). Basing the POD on a lower risk level (e.g., 5% or 1% of showing symptoms) is deemed to be not necessary, as lower risk levels are meant to protect against frank (i.e., more severe) effects. The POD determined in Arnich and Thébault (2018), based on the LCD for a 10% probability of showing any PSP symptom (mild, moderate, severe, death) is 0.37 µg STX eq/kg. This value is far lower than the LCD (1.9 µg/kg) for a 10% probability of even mild symptoms (Table 3). Additionally, a 10% risk level is also judged appropriate because the PSP symptoms (i.e., mild, moderate, and severe) are reversible. Arnich and Thébault (2018, Table 3 therein) estimate that at a dose of 1 µg STX eq/kg (which is over 2.5-fold higher than the POD of 0.37 µg STX eq/kg), the probability of experiencing moderate symptoms, severe symptoms, or death was 1.57%, 0.526%, and 0.002%, respectively. Therefore, the vast majority of individuals exposed to 0.37 µg STX eq/kg could likely experience no or mild symptoms. Individuals who survive PSP for 24 hours have a high probability of a rapid and full recovery (EFSA, 2009).

Selection of uncertainty factors and derivation of the short-term RfD for STX

Based on USEPA guidance (USEPA, 2002), five individual UFs were considered for deriving a short-term RfD for STX. In deriving the short-term RfD, a UF_{Comp} of 100 is applied to the POD of 0.37 µg STX eq/kg from Arnich and Thébault (2018). The specific UFs are as follows:

$UF_{Animal} = 1$ (i.e., no adjustment is made). The POD is based on human data.

$UF_{Human} = 3$. The case reports used to inform the POD are based on human data including 143 individuals from both sexes, different life stages (individuals aged 2 to 69 years old), and from various geographical locations. Although this study population includes this diversity, the complete range of human sensitivity to STX may not have been captured thoroughly, particularly for children. The short-term oral RfD and recreational advisory for STX derived by NJDEP is intended to be protective for oral exposure on multiple days of swimming during the swimming season for children, who receive higher exposures via incidental ingestion of water during swimming than adults (see “Exposure factors and derivation of the STX recreational guidance value” section). As reviewed in WHO (2020), children also appear to be more intrinsically sensitive to STX than adults. In Arnich and Thébault (2018), only about 7% of the study population were known to be under 18 years old⁸, and the percent of children age 6-11 (the most highly exposed age group during swimming, see below) would have been even lower. In comparison, the percentages of children under 18 years old in the US and NJ populations are 24% and 22%, respectively⁹. This comparison suggests that the Arnich and Thébault (2018) population only partially represents the effects of STX on children.

Aside from children, other individuals may be sensitive to STX. As discussed in the “Mode of Action” section, there are inter-individual differences in isoforms of the VGSCs that bind STX. These isoforms may differ in their distribution, expression, and sensitivity, potentially explaining the higher sensitivity of some individuals to this toxin. Within the Arnich and Thébault (2018) population, 32% of individuals experienced severe effects from STX exposure, while 6% died. While these individuals may have been exposed to higher doses of STX or the doses may not have been accurately determined (see “Discussion” section), it is also possible that these individuals may truly be more sensitive to STX. In support of this possibility, Table 7 of Arnich and Thébault (2018) shows overlap between the category of symptoms experienced and STX dose for the individuals in the study. Specifically, some individuals with severe symptoms or who died were reported to be exposed to a STX dose that caused less severe symptoms in other individuals.

Finally, although this study population does include some sensitive individuals (e.g., children), the total number of individuals is relatively small (n=143) and other potential sensitive populations may be underrepresented.

Because of these considerations discussed above, a factor of 3 is applied to account for human variability.

⁸ The percentage of children is based on individual data reported in Appendix A (table A2) of Arnich and Thébault (2018). Individuals with an age less than 18 years old were considered children. For individuals where the age was not available, Arnich and Thébault (2018) considered them to be adults, as the authors assigned these individuals an estimated adult body weight for dose-response analysis. Based on this approach, the Arnich and Thébault (2018) study population was considered to have 10 children and 133 adults.

⁹ The percentage of children is based on the number of children aged less than 18 years old compared to the total population for the US in 2010 (<https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf>) and as estimated in NJ in 2019 (https://www.nj.gov/labor/lpa/dmograph/est/nj_agesex2019.xlsx).

UF_{Duration} = 3. The POD is based on PSP in humans following a single (i.e., acute) exposure to STX-contaminated shellfish during a meal. A single exposure is shorter than the intended exposure scenario for the STX recreational value, which is multiple days of swimming during the swimming season. Therefore, in deriving the short-term RfD, the POD based on acute information needs to be adjusted downward to account for a longer period of exposure, in particular to account for the accumulation of STX in the body, for which a human half-life of 10 to 20.4 hours has been reported (Gessner et al., 1997; Wharton et al., 2017). While a swimming season may last many months, it is unlikely that an individual would swim every day during that season. Swimming may more likely occur on consecutive days on a weekly basis, which is consistent with a short-term exposure of between 24 hours and 30 days. Therefore, a factor of 3 is applied to account for duration of exposure.

UF_{LOAEL} = 1. The POD derived from the LCD identified by Arnich and Thébault (2018) (a 10% probability of showing any PSP symptom) is analogous to a BMDL identified through USEPA's BMD modeling. Based on USEPA practice, a factor of 1 is applied to the UF_{LOAEL} when a BMDL is identified and used as the POD. This is based on the assumption that the BMR selected for a critical effect represents a minimal, biologically significant change (USEPA, 2018). Accordingly, a factor of 1 is judged appropriate.

UF_{Database} = 10. The lack of developmental, reproductive, and immune studies identified for this assessment and in recent reviews (Testai et al., 2016; WHO, 2020) gives an indication of the limited extent of the mammalian toxicological database for STX. Therefore, a factor of 10 is judged appropriate to account for the lack of these types of studies.

$$\text{Short-term RfD} = \text{POD} / \text{UF}_{\text{Comp}} = (0.37 \mu\text{g STX eq/kg/day}) / 100 = 0.0037 \mu\text{g/kg/day}.$$

Although based on a POD expressed in $\mu\text{g STX eq/kg/day}$ due to the likely presence of multiple STX analogues present in the underlying PSP data, the resulting short-term RfD is simply expressed hereafter in $\mu\text{g/kg/day}$. In practice, this short-term RfD assumes that STX is the most prevalent and toxic of the STX analogues present in a sample (e.g., a surface water sample).

Exposure factors and derivation of the STX recreational guidance value

Recreational guidance values for cyanotoxins, such as STX, are based on exposure through incidental ingestion during swimming. Exposure through incidental ingestion is higher in children than in adults. Factors relevant to incidental ingestion are the incidental ingestion rate (L/h), daily exposure duration (h/day), and body weight (kg). The exposure factors used by NJDEP (2018) and USEPA (2019) are discussed below.

The incidental ingestion rate of 0.12 L/h previously used by NJDEP (2018) in recreational advisories for other cyanotoxins was based on Dufour et al. (2006), which is cited in the USEPA (2011) Exposure Factors Handbook. In this study, the upper percentile (97th percentile) ingestion rate in children less than 18 years old was 0.09 L for a 45-minute swimming event, equivalent to 0.12 L/h. The duration of swimming each day was assumed to be 1 hour by

NJDEP, but this assumption was not based on empirical data. Based on this incidental ingestion rate and swimming duration, daily incidental ingestion during swimming was assumed to be 0.12 L/day.

USEPA (2019) provided additional data on incidental ingestion of children during swimming subsequent to the development of the NJDEP (2018) recreational guidance values for other cyanotoxins. USEPA (2019) developed distributions of incidental ingestion rates (L/h) for different age groups (6-10 years, 11-17 years, 18 and over) based on data from seven studies collected and analyzed by Dufour et al. (2017). This dataset includes 10 times more participants than Dufour et al. (2006), the study cited in the USEPA (2011) Exposures Factors Handbook that was used by NJDEP (2018). Incidental ingestion rates were highest for children age 6-10 years.

Duration of exposure was estimated from data in the USEPA (2011) Exposure Factors Handbook. The data show that children age 5-11 spend more time in the water than younger children, older children, or adults. These data are depicted in a graph (Figure 4-4) in USEPA (2019), where mean, median, and 90th percentiles for daily durations for age 5-11 (who swam at home in the outdoor pool or spa) are about 2.75 h, 2.35 h, and 5 h, respectively.

The distribution of daily incidental ingestion (L/day) was developed by USEPA using Monte Carlo simulations that combined the distributions for incidental ingestion rate (L/h) and duration of exposure (h/day). Daily incidental ingestion (L/day) was higher for age 6-10 than in older age groups. The daily incidental ingestion rate used by USEPA (2019) is 0.21 L/day, which is the 90th percentile of the combined distribution for age 6-10.

DSR has reviewed the basis of the USEPA (2019) exposure assumptions and has concluded that they are more technically sound than the assumptions used by NJDEP (2018). A major difference between the 0.21 L/day ingestion rate from USEPA (2019) and the 0.12 L/day rate from NJDEP (2018) is that the NJDEP (2018) exposure duration of 1 hour was an assumption that was not based on empirical data. The USEPA (2019) daily incidental ingestion rate of 0.21 L/day is the overall 90th percentile ingestion rate for children 6-11 years of age, based on the distributions of both hourly incidental ingestion rate and daily swimming exposure durations. Based on these data, the NJDEP (2018) assumption of a 1-hour exposure duration does not sufficiently represent the daily duration of swimming for children in this age group. Therefore, the NJDEP recreational guidance level for STX is based on a daily incidental ingestion rate of 0.21 L/day.

The equation for deriving the STX recreational guidance value is given as:

$$\text{Recreational guidance value } (\mu\text{g/L, ppb}) = (\text{RfD} \times \text{BW}) \div \text{I}$$

Where:

RfD = the Reference Dose for STX (0.0037 $\mu\text{g/kg/day}$)

BW = the assumed body weight of a child (31.8 kg; based on a mean body weight of children 6 to < 11 years old from USEPA [2011])

I = the daily incidental ingestion rate of swimming water (0.21 L/day)

Based on the equation above, the proposed recreational guidance value for STX is 0.6 µg/L (rounded from 0.56 µg/L).

Discussion

There are numerous uncertainties related to the STX short-term RfD used to derive the recreational guidance value. The literature relevant to the derivation of a short-term RfD for STX is limited, particularly for studies in laboratory animals. In contrast, a number of case reports for human PSP exist and were ultimately used as the basis for the STX short-term RfD. However, as discussed below, a number of uncertainties exist with these case reports.

As discussed elsewhere (FAO, 2004; EFSA, 2009; FAO, 2011; Arnich and Thébault, 2018; WHO, 2020), uncertainties are associated with the available case reports for PSP. Perhaps the biggest concern with these reports is determining the dose of STX that caused PSP symptoms. For example, in determining the concentrations of STX and its analogues present in the implicated food, some reports sampled leftover shellfish consumed at the meal prior to the onset of symptoms, whereas other reports sampled uncooked shellfish from the same batch that was consumed or obtained from the same source (harvesting area, store, restaurant). Other reports may have sampled shellfish harvested on a different day. Compounding the issue of shellfish sampling is accurate determination of the amounts of shellfish consumed and whether cooking affected toxin levels. Additional contributions to the uncertainties of these studies include the body weight of the affected individual (e.g., measured or often assumed to be 60 kg by European assessments), the aptitude of medical staff diagnosing PSP, and the variation in susceptibility within the human population.

Further uncertainties arise from the analytic approach used to determine the amount of STX and its analogues in shellfish. Although chemical approaches exist for measuring the levels of STX and its analogues in shellfish (e.g., high-pressure liquid chromatography coupled with fluorescent detection; reviewed in FAO, 2011), the majority of case reports of PSP relied on the mouse bioassay (MBA) for determining the concentration of toxin present in the food. Historically, the MBA has been the primary method for detecting the presence of STX and its analogues in shellfish around the world, including in New Jersey (FDA, 2012; NJDEP, 2016). In short, this assay involves extracting toxins from a homogenate of the suspected shellfish, exposing mice to the extract by intraperitoneal injection, and monitoring the time it takes for the mice to die. Extracts can be diluted so that death occurs within 5 to 7 minutes, and the amount of dilution needed provides a quantitative metric (i.e., mouse units) that can be converted to µg of STX. As the MBA cannot distinguish between the STX analogues in a sample, the result of the assay is expressed as STX eq (EFSA, 2009; FAO, 2011). Inter-laboratory variability with the MBA adds to the uncertainty with assessing human STX exposure from PSP, as animal characteristics (e.g., strain, sex, general health) and toxin extraction protocols can differ between laboratories (EFSA, 2009). The conversion of mouse units to µg of STX eq is another source of uncertainty.

An important limitation to the use of the human PSP data, not only for Arnich and Thébault (2018) but also the other assessments relying on these data (Fitzgerald et al., 1999; FAO, 2004;

EFSA, 2009), is publication bias. Specifically, the case reports used to inform these assessments were primarily of exposed individuals with symptoms of PSP (i.e., sample selection was biased because it did not follow a randomized sampling design). Exposed individuals without symptoms of PSP are likely underrepresented in the dataset, as only symptomatic individuals are likely to seek medical attention and be included in case reports. Arnich and Thébault (2018) address this limitation by stating “Data on exposure of individual who ate some shellfish but had no symptoms are also very important, in order to better model the dose-response relationship at low doses and get a more accurate estimate of the dose without symptoms. Even if low doses are included in our dataset (Figure 2) from different outbreaks, there is a publication bias on no (sic) symptomatic individuals, and it is possible that our dose-response could over-estimate the risk.” Additionally, there is the potential underrepresentation of individuals with mild to moderate symptoms who were exposed to lower levels of STX. Had such individuals been included in the PSP dataset (i.e., they sought medical attention due to their symptoms resulting in a case report), their information (STX dose and symptom category) could have helped inform the lower portion of the dose-response curve. Nevertheless, given these multiple uncertainties, the short-term RfD derived here is intended to be protective and is probably highly conservative (i.e., protective) for the most likely exposures.

Notwithstanding these uncertainties and limitations in the human PSP data, a short-term RfD for STX based on the human data, specifically as analyzed by Arnich and Thébault (2018), is supported by the toxicology data in laboratory animals with acute STX-only exposure. Specifically, studies by Munday et al. (2013) and Finch et al. (2018) exposed female mice to relatively pure STX and reported neurotoxicity. While epidemiological data are preferred over animal data for deriving toxicity values, short-term RfDs could be derived for comparative purposes using these two animal studies. As summarized in Appendix B, short-term RfDs derived from acute STX-only animal studies range from 0.054 µg/kg/day (Munday et al., 2013) to 0.13 µg/kg/day (Finch et al., 2018). These short-term RfDs based on rodent data are more than an order of magnitude higher than the short-term RfD of 0.0037 µg/kg/day based on the analysis of human PSP data by Arnich and Thébault (2018).

It should be noted that multiple analogues of STX are produced by cyanobacteria, and that the analytical assay used by the Bureau of Freshwater and Biological Monitoring measures the total concentration of multiple STX analogues (i.e., it does not measure individual analogues). The short-term RfD is based on the toxicity of STX, as it is considered more prevalent and toxic than most of its analogues. The toxicological database for the STX analogues is insufficient to develop an RfD for any of them. Therefore, it is recommended that the guidance value based on STX cover the whole spectrum on STX analogues present in a given sample.

Comparison with other state recreational guidance value

Five US states (CO, OH, OR, PA, WA) are reported to have recreational water guideline levels for STX (USEPA, 2019). Although all are based on symptoms of PSP from the same principal study (EFSA, 2009), these recreational values range from 0.8 to 75 µg/L (Appendix A). This range in values reflects their intended application to acute (OH, OR, PA, WA) versus short-term exposures (CO), and use of different UFs and exposure factors among these states. OH EPA

(2016) has the lowest recreational value of 0.8 µg/L, and this value is also used by PA DEP (2017). Table 6 compares the basis of the NJDEP and OH EPA (2016) recreational guidance values.

Table 6. Comparison of the basis of the NJDEP and OH EPA recreational guidance values for STX		
	NJDEP (2021)	OH EPA (2016)
Critical effect (Principal study)	Symptoms of PSP (Arnich and Thébault, 2018)	Symptoms of PSP (EFSA, 2009)
Point of departure (µg STX eq/kg)	0.37 (modeled)	0.5 (NOAEL) ^a
UF _{Animal}	1	1
UF _{Human}	3	10
UF _{Duration}	3	1
UF _{LOAEL}	1	1
UF _{Database}	10	10
UF _{Comp}	100	100
RfD (µg/kg/day)	0.0037 Short-term	0.005 Acute
Body weight (kg)	31.8	15
Daily incidental ingestion of swimming water (L/day)	0.21	0.1
Incidental ingestion rate (L/kg/day)	0.006 L/kg/day	0.006 L/kg/day
Recreational value (µg/L)	0.6	0.8
a = The NOAEL of 0.5 µg STX eq/kg was derived by EFSA (2009) based on a LOAEL of 1.5 µg STX eq/kg and the application of a factor of 3.		

Although based on an acute RfD, the OH EPA (2016) value is virtually identical to the NJDEP value. However, the basis of the OH EPA value (i.e., EFSA, 2009) is judged to be not as scientifically robust as the basis for the NJDEP value (i.e., Arnich and Thébault, 2018). In short, EFSA (2009) identified a LOAEL “in the region of 1.5 µg STX equivalents/kg b.w.” (i.e., the LOAEL was identified qualitatively), which EFSA (2009) then converted to a NOAEL that was used as the POD for the OH EPA value. In contrast, the POD from Arnich and Thébault (2018) is based on a systematic review approach to identify and assess data, statistical modeling, and it underwent peer review.

A notable difference between the OH EPA (2016) and NJDEP recreational values is the application of a factor of 10 to account for human variability. OH EPA applied a full factor of 10, whereas NJDEP applied a partial factor of 3 as the study population in Arnich and Thébault (2018) partially informed the spectrum of human variability by including individuals of both sexes, different life stages (individuals aged 2 to 69 years old), and from various geographical locations. Unlike OH EPA (2016) and NJDEP, other states using EFSA (2009) as the basis for their STX recreational values (WA DOH, 2011; OHA, 2019) applied a factor of 1 for human

variability. Additionally, EFSA (2009) did not apply a factor stating that “No additional factor for variation among humans was deemed necessary because the data covered a large number of affected consumers, including sensitive individuals.”

Aside from differences in UFs, derivation of the OH EPA (2016) and NJDEP recreational values differ in terms of exposure factors, specifically body weight of children and incidental water ingestion rate. While these exposure factors are numerically different, the difference between the two states is negated as the ratio between the daily ingestion rate to body weight, which is the incidental ingestion rate (L/kg/day), is virtually identical for OH EPA (2016) and NJDEP.

The only other state to derive an STX recreational value based on a short-term RfD was CO (CDPHE, ND; Appendix A). The CDPHE derived a value of 4 µg/L based on EFSA (2009), which is over 6 times higher than the NJDEP recreational value. The higher values developed by OR (8 µg/L) and WA (75 µg/L) are for acute exposure.

Conclusion

Based on the modeling of human PSP data, a short-term RfD of 0.0037 µg/kg/day for STX was derived. Using the assumed body weight of a child (31.8 kg) and the daily incidental ingestion rate of swimming water (0.21 L/day) from the USEPA (2019), an STX recreational guidance value of 0.6 µg/L was derived and is recommended for use during New Jersey cyanoHAB events.

Acknowledgments

This assessment was reviewed by members of the Division of Science and Research including Drs. Josephine Bonventre, Gary Buchanan, Mingzhu Fang, and Gloria Post. Dr. Lori Lester provided statistical consultation. The constructive comments of three external peer-reviewers are acknowledged.

References

- Arnich N, Thébault A. 2018. Dose-Response Modelling of Paralytic Shellfish Poisoning (PSP) in Humans. *Toxins*. 10: E141.
- Batista CRA, Gomes GF, Candelario-Jalil E, Fiebich BL, de Oliveira ACP. 2019. Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration. *Int J Mol Sci*. 20:2293-2323.
- CDPHE. N.D. Colorado Department of Public Health and Environment. Algae bloom risk-management toolkit. For recreational waters.
<https://drive.google.com/file/d/0B0tmPQ67k3NVczRwQkc3Q2dOXzA/view>
- Diehl F, Ramos PB, Dos Santos JM, Barros DM, Yunes JS. 2016. Behavioral alterations induced by repeated saxitoxin exposure in drinking water. *J Venom Anim Toxins Incl Trop Dis*. 22:18.

- Donovan CJ, Ku JC, Quilliam MA, Gill TA. 2008. Bacterial degradation of paralytic shellfish toxins. *Toxicon*. 52:91-100.
- Dufour AP, Evans O, Behymer TD, Cantú R. 2006. Water ingestion during swimming activities in a pool: a pilot study. *J Water Health* 4:425-30.
- Dufour AP, Behymer TD, Cantú R, Magnuson M, and Wymer LJ. 2017. Ingestion of swimming pool water by recreational swimmers. *Journal of Water and Health*, 15(3), 429-437. (Cited in USEPA, 2019).
- EFSA. 2009. European Food Safety Authority. Scientific Opinion of the Panel on Contaminants in the Food Chain on a request from the European Commission on Marine Biotoxins in Shellfish – Saxitoxin Group. *The EFSA Journal*. 1019:1-76.
<https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2009.1019>
- FAO. 2004. Report of the Joint FAO/IOC/WHO ad hoc Expert. Consultation on Biotoxins in Bivalve Molluscs. Advance pre-publication copy.
https://www.who.int/foodsafety/publications/chem/biotoxin_report_en.pdf
- FAO. 2011. Food and Agriculture Organization of the United Nations. Assessment and management of biotoxin risks in bivalve molluscs. <http://www.fao.org/3/i2356e/i2356e.pdf>
- FDA. 2012. United States Food and Drug Administration. Bad Bug Book. Handbook of Foodborne Pathogenic Microorganisms and Natural Toxins.
<https://www.fda.gov/media/83271/download>
- Finch SC, Boundy MJ, Harwood DT. 2018. The acute toxicity of tetrodotoxin and tetrodotoxin-saxitoxin mixtures to mice by various routes of administration. *Toxins*.10.E423.
- Fitzgerald DJ, Cunliffe DA, Burch MD. 1999. Development of health alerts for cyanobacteria and related toxins in drinking water in South Australia. *Environmental Toxicology*. 14:203-207.
- Fu XC. 1982. Food poisoning caused by eating snails. *Zhonghua Yu Fang Yi Xue Za Zhi* [Chinese journal of preventive medicine]. 16:140-3.
- Gessner BD, Bell P, Doucette GJ, Moczydlowski E, Poli MA, Van Dolah F, Hall S. 1997. Hypertension and identification of toxin in human urine and serum following a cluster of mussel-associated paralytic shellfish poisoning outbreaks. *Toxicon*. 35:711-722.
- Lima-Filho CM, Nogaroli L, Hedin-Pereira C, Azevedo SMFO, Soares RM. 2020. Effects of saxitoxins exposure on oligodendrocyte development in mouse neonates. *Toxicon*. 188:89-94.
- Munday R, Thomas K, Gibbs R, Murphy C, Quilliam MA. 2013. Acute toxicities of saxitoxin, neosaxitoxin, decarbamoyl saxitoxin and gonyautoxins 1&4 and 2&3 to mice by various routes of administration. *Toxicon*. 76:77-83.
- NHMRC. 2011. National Health and Medical Research Council. National Water Quality Management Strategy. Australian Drinking Water Guidelines 6.
<https://www.nhmrc.gov.au/file/14288/download?token=I0abH9A>

- NJDEP. 2016. New Jersey Department of Environmental Protection. State of New Jersey Contingency Plan for the Control of Shellfish Potentially Contaminated by Marine Biotoxin. <https://www.nj.gov/dep/bmw/docs/BiotoxinContingency2016.pdf>
- NJDEP. 2018. New Jersey Department of Environmental Protection. Cyanobacterial Harmful Algal Bloom (HABs) Freshwater Recreational Response Strategy. Revision 1.0 June 2018. <https://www.state.nj.us/dep/wms/bfbm/download/NJHABResponseStrategy2018.pdf>
- NJDEP. 2020. 2020 Cyanobacterial Harmful Algal Bloom (HAB) Freshwater Recreational Response Strategy. June 2020. <https://www.nj.gov/dep/hab/download/NJHABResponseStrategy.pdf>
- OH EPA. 2016. Ohio Environmental Protection Agency. Harmful Algal Bloom Response Strategy for Recreational Waters. <https://epa.ohio.gov/portals/35/hab/HABResponseStrategy.pdf>
- OHA. 2019. Oregon Health Authority. Oregon Harmful Algae Bloom Surveillance (HABS) Program. Recreational Use Public Health Advisory Guidelines Cyanobacterial Blooms in Freshwater Bodies. <https://www.oregon.gov/oha/PH/HEALTHYENVIRONMENTS/RECREATION/HARMFULALGAEBLOOMS/Documents/2019%20Advisory%20Guidelines%20for%20Harmful%20Cyanobacterial%20Blooms%20in%20Recreational%20Waters.pdf>
- PA DEP. 2017. Pennsylvania Department of Protection. Lake Erie Harmful Algal Bloom Monitoring and Response Strategy https://seagrant.psu.edu/sites/default/files/PA%20Lake%20Erie%20HAB%20Response%20Strategy%207-24-2017_0.pdf
- O'Neill K, Musgrave IF, Humpage A. 2016. Low dose extended exposure to saxitoxin and its potential neurodevelopmental effects: A review. *Environ Toxicol Pharmacol.* 48:7-16.
- Ramos PB, Diehl F, Dos Santos JM, Monserrat JM, Yunes JS. 2014. Oxidative stress in rats induced by consumption of saxitoxin contaminated drink water. *Harmful Algae.* 37:68-74.
- Smith EA, Grant F, Ferguson CM, Gallacher S. 2001. Biotransformations of paralytic shellfish toxins by bacteria isolated from bivalve molluscs. *Appl Environ Microbiol.* 67:2345-53.
- Testai E, Scardala S, Vichi S, Buratti FM, Funari E. 2016. Risk to human health associated with the environmental occurrence of cyanobacterial neurotoxic alkaloids anatoxins and saxitoxins. *Crit Rev Toxicol.* 46:385-419.
- USEPA. 2002. United State Environmental Protection Agency. A Review of the Reference Dose and Reference Concentration Processes. <https://www.epa.gov/sites/production/files/2014-12/documents/rfd-final.pdf>
- USEPA. 2009. United State Environmental Protection Agency. 2009 Edition of the Drinking Water Standards and Health Advisories. <https://nepis.epa.gov/Exe/ZyPDF.cgi/P1005P2B.PDF?Dockkey=P1005P2B.PDF>
- USEPA. 2011. United State Environmental Protection Agency. Exposure Factors Handbook 2011 Edition (Final). http://ofmpub.epa.gov/eims/eimscomm.getfile?p_download_id=522996

USEPA. 2012. United State Environmental Protection Agency. Benchmark Dose Technical Guidance. https://www.epa.gov/sites/production/files/2015-01/documents/benchmark_dose_guidance.pdf

USEPA. 2016. United States Environmental Protection Agency. Draft Human Health Recreational Ambient Water Quality Criteria or Swimming Advisories for Microcystins and Cylindrospermopsin. <https://www.epa.gov/sites/production/files/2016-12/documents/draft-hh-rec-ambient-water-swimming-document.pdf>

USEPA. 2018. United States Environmental Protection Agency. Integrated Risk Information System. Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0313tr.pdf

USEPA. 2019. United States Environmental Protection Agency. Recommended Human Health Recreational Ambient Water Quality Criteria or Swimming Advisories for Microcystins and Cylindrospermopsin. <https://www.epa.gov/sites/production/files/2019-05/documents/hh-rec-criteria-habs-document-2019.pdf>

Vilariño N, Louzao MC, Abal P, Cagide E, Carrera C, Vieytes MR, Botana LM. 2018. Human Poisoning from Marine Toxins: Unknowns for Optimal Consumer Protection. *Toxins*. 10ii: E324.

WA DOH. 2011. Washington State Department of Health. Washington State Provisional Recreational Guidance for Cylindrospermopsin and Saxitoxin. <https://www.doh.wa.gov/Portals/1/Documents/4400/332-118-CylindroSax%20Report.pdf>

Wharton RE, Feyereisen MC, Gonzalez AL, Abbott NL, Hamelin EI, Johnson RC. 2017. Quantification of saxitoxin in human blood by ELISA. *Toxicon*. 133:110-115.

WHO. 2003. Guidelines for safe recreational water environments. Volume 1. Coastal and fresh waters. <https://apps.who.int/iris/bitstream/handle/10665/42591/9241545801.pdf;jsessionid=4CFA13A82BB554A640A530118D60F8B8?sequence=1>

WHO. 2020. Cyanobacterial toxins: Saxitoxins. Background document for development of WHO Guidelines for Drinking-water Quality and Guidelines for Safe Recreational Water Environments. <https://apps.who.int/iris/bitstream/handle/10665/338069/WHO-HEP-ECH-WSH-2020.8-eng.pdf?sequence=1&isAllowed=y>

Zakaria R, Wan Yaacob WM, Othman Z, Long I, Ahmad AH, Al-Rahbi B. 2017. Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer's disease. *Physiol Res*. 66:553-565.

Zepeda RJ, Candiracci M, Lobos N, Lux S, Miranda HF. 2014. Chronic toxicity study of neosaxitoxin in rats. *Mar Drugs*. 12:5055-5071.

Appendix A: Comparison of state recreational water guideline levels for STX

State	Colorado	Ohio, Pennsylvania	Oregon	Washington
Citation(s)	CDPHE (ND)	OH EPA (2016), PA DEP (2017)	OHA (2019)	WA DOH (2011)
Critical effect (principal study)	Neurological effects from paralytic shellfish poisoning (EFSA, 2009)			
Point of departure	0.5 µg/kg/day ^a (NOAEL)			
Uncertainty factors used by the state (rationale provided by the state)	10 (not specified)	100 (10 for human variability; 10 for lack of chronic, developmental, and reproductive studies)	10 (limitations in database, other studies may find lower RfD)	None (study population was large and included sensitive individuals)
Reference Dose (duration)	0.05 µg/kg/day (short-term)	0.005 µg/kg/day (acute)	0.05 µg/kg/day (acute)	0.5 µg/kg/day (acute)
Body weight (kg) ^b	31.8	15	31.8	15
Incidental water ingestion rate (L/d) ^c	0.33	0.1	0.21	0.1
Relative source contribution factor	0.8	Not applied	1.0	Not applied
Recreational value (µg/L)	4	0.8	8	75
<p>a = EFSA (2009) identified a LOAEL of 1.5 µg/kg/day and applied an uncertainty factor of 3 to derive the NOAEL of 0.5 µg/kg/day</p> <p>b = 31.8 kg from USEPA (2011, 2016); 15 kg from WHO (2003)</p> <p>c = 0.33 L/d from USEPA (2016); for OH EPA (2016) and PA DEP (2017), 0.1 L/d based on assumptions for children of an incidental ingestion of 0.1 L of water per event and an ingestion rate of 1 L of water per day (USEPA, 2009); for WA DOH (2011), 0.1 L/d based on the assumptions that 0.05 L of water ingested per hour and that exposure lasts for 2 hours per day; 0.21 L/d from USEPA (2011) and Dufour et al. (2017)</p> <p>ND = no data provided</p>				

Appendix B: Derivation of short-term RfDs from laboratory animal studies for comparative purposes

Four laboratory animal studies were identified for consideration as being the basis of a short-term RfD for STX (Munday et al. 2013; Ramos et al., 2014, Diehl et al., 2016; Finch et al., 2018). As human data exist for PSP, which is caused by STX, animal studies were not used as the basis for the short-term RfD. For comparison purposes, short-term RfDs were derived from relevant animal studies to determine whether the short-term RfD based on human data was overly protective of human exposure to STX. Only studies by Munday et al. (2013) and Finch et al. (2018) were relevant, as these studies used STX-only exposure. As reviewed above, studies by Ramos et al. (2014) and Diehl et al. (2016) exposed rats to drinking water containing cyanobacteria capable of producing STX and its analogues, as well as other toxins. Table B1 reports the derivation of short-term RfDs using information from Munday et al. (2013) and Finch et al. (2018).

Table B1. Summary of short-term RfDs derived from relevant laboratory animal studies			
	Munday et al. (2013)	Finch et al. (2018)	Rationale
Point of Departure ($\mu\text{g}/\text{kg}$)	163	379	NOAEL for neurotoxicity in mice
$\text{UF}_{\text{Animal}}$	10	10	Animal to human extrapolation
UF_{Human}	10	10	To protect sensitive human subpopulations
$\text{UF}_{\text{Duration}}$	3	3	Extrapolation from acute to short-term exposure
UF_{LOAEL}	1	1	NOAEL used as point of departure
$\text{UF}_{\text{Database}}$	10	10	To account for a lack of developmental, reproductive, and immune studies
UF_{Comp}	3000	3000	
Short-term RfD ($\mu\text{g}/\text{kg}/\text{day}$)	0.054	0.13 (rounded from 0.126)	

Background Information on Microcystin “Warning” and “Danger” Threshold Values

**NJDEP Division of Science and Research
April 29, 2020**

Summary

NJDEP is aware of several states, including California, Ohio, Kansas, and Utah, that have “Danger” (or similar) threshold values for microcystin (shown in table at the end of this document). All of these states also have one (UT) or two (CA, OH, KA) lower tiers of threshold values (e.g. “Advisory”, “Warning”).

This document provides information to support New Jersey “Warning” and “Danger” threshold values for recreational exposure to microcystin. These higher threshold values will be used along with the lower “Advisory” threshold value to provide tiered advice on recreational exposure to microcystin. These threshold values are summarized in the Table 1 below:

Table 1. Tiered recreational threshold values recreational for microcystin

<i>Recreational Threshold Value</i>	<i>Microcystin Concentration</i>
Advisory	3 µg/L
Warning	20 µg/L <i>7 times NJ Advisory level based on child exposure.</i>
Danger	2000 µg/L <i>Child dose would be ~750 times the NJ Reference Dose and ~5 times below NJ LOAEL.</i> <i>USEPA (based on WHO) – “very high relative probability of acute health effects.”</i>

NJDEP Microcystin “Warning” Threshold Value

The information below provides support for a microcystin “Warning” threshold value of 20 µg/L.

WHO

WHO (2003) states that an adult (60 kg) who ingests 100 ml of water containing 20 µg/L microcystin while swimming will receive a dose close to the WHO (1998) Tolerable Daily Intake (TDI; equivalent to a Reference Dose) of 0.04 µg/kg/day, and that the health risk would be higher in a susceptible person (e.g. someone with chronic hepatitis B). WHO (2003) also states that a 15 kg child who ingest 250 ml of water during “extensive playing” could be exposed to 10 times the TDI.

The WHO (1998) TDI, 0.04 µg/kg/day, is based on the same mouse study (Fawell et al., 1994) as the NJDEP Reference Dose (0.01 µg/kg/day), but uses an uncertainty factor of 1000 instead of the uncertainty factor of 3000 used by NJDEP. This is because the Point of Departure of 40 µg/kg/day was considered to be a No Observed Adverse Effect Level (NOAEL) by WHO (1998), but it was considered to be a minimal Lowest Observed Adverse Effect Level (LOAEL) by NJDEP based on significant decrease in body weight gain in males, as well as non-statistically significant changes in other parameters (total blood protein, albumin, chronic liver inflammation) that are predictive of significant effects at higher doses. As such, NJDEP included an uncertainty factor of 3 for extrapolation from a minimal LOAEL to a NOAEL that was not included by WHO.

USEPA

Based on information provided by WHO (2003), USEPA (2019a) states that there is a high relative probability of acute health effects from a cyanobacterial bloom capable of producing 20-2000 µg/L microcystin.

Other States

As shown in Table 2 below, two states (CA, OH) use 20 µg/L as a “Danger” threshold value for recreational exposure. Additionally, New York (NYDEC, undated) classifies a HAB with microcystin levels of 10-20 µg/L as “Confirmed with High Toxins Bloom.”

Relationship to New Jersey microcystin Reference Dose

WHO (2003) states that a 15 kg child “extensively playing” in water containing 20 µg/L would receive a dose 10 times the WHO (1998) TDI.

Using current NJDEP child recreational exposure assumptions that are based on professional judgement, recreational exposure of a child to water with a microcystin concentration of 20 µg/L would result in a dose 7 times the NJ Reference Dose of 0.01 µg/kg/day.

NJDEP Microcystin “Danger” Threshold Value

The information below provides support for a potential microcystin “Danger” threshold value of 2000 µg/L.

WHO

WHO (2003) states that, when there is a cell count of 100,000 cells/ml, cells can concentrate 100-fold at the surface due to buoyancy to form a “high risk level scum” in the top 4 cm of water that could contain 2000 µg/L microcystin.

USEPA

Based on information provided by WHO (2003), USEPA (2019b) states that there is a very high relative probability of acute health effects from a cyanobacterial bloom capable of producing >2000 µg/L microcystin.

Furthermore, USEPA (2019a) developed a screening analysis for estimation of inhalation exposure near a waterbody contaminated with microcystin, while noting that the estimated exposures are associated with considerable uncertainty. The estimates are based on upper percentile values for daily time spent at a pool, river, or lake from the USEPA Exposure Factors Handbook (USEPA, 2011). Based on the USEPA screening analysis, daily doses from inhalation exposure near a lake with 2000 µg/L microcystin are estimated to be several-fold higher than the NJDEP Reference Dose of 0.01 µg/kg/day.

Other States

As shown in Table 2 below, two states (KA, UT) use 2000 µg/L as a “Danger” threshold value for recreational exposure.

Relationship to New Jersey microcystin Reference Dose

Recreational exposure of a child to water with a microcystin concentration of 2000 µg/L would result in a dose ~750 times higher than the NJ Reference Dose of 0.01 µg/kg/day and only about 5-fold below the minimal LOAEL of 40 µg/kg/day.

Table 2. Other states’ Danger (or similar) recreational threshold values for microcystin

State	Advisory	Toxin Level (µg/L)	Cell Count (cells/ml)	Recommended Actions	Basis
California	Danger (Also 2 lower level advisory tiers)	Microcystin >20 Anatoxin-a >90 Cylindro-spermopsin >17	---	Post sign stating that: <ul style="list-style-type: none">• There is a present danger.• People, pets and livestock should stay out of the water and away from water spray.	California Cyanobacteria and Harmful Algal Bloom (CCHAB) Network (2016) states: “based on risk management objectives rather than a purely health-based conservative approach” “suggested as a warning level by the World Health

					Organization (WHO 1999)" https://drive.google.com/file/d/13RQyEJ0MB46D6TNN9KpsdFW8pZBZ-Eou/view
Ohio	Danger (Also 2 lower level advisory tiers)	Microcystin >20 Anatoxin-a >300 Cylindrospermopsin >20	---	<ul style="list-style-type: none"> Elevated Recreational Public Health Advisory Avoid all contact with the water. Algal Toxins at Unsafe Levels Have Been Detected. 	Not provided https://epa.ohio.gov/portals/35/hab/HABResponseStrategy.pdf
Kansas	Waterbody is closed (Also 2 lower level advisory tiers)	Microcystin >2000	>10,000,000	<ul style="list-style-type: none"> Recommend that either portions of the lake, the entire lake, or zone, be closed. If necessary – close adjacent land up to 100 ft from shoreline Post signage* Notify health dept., doctors, vets, health providers, etc. Post on website* Issue media release* Notify public water suppliers* <i>*These actions are also recommended at a less restrictive advisory level.</i>	Not stated but consistent with 100-fold accumulation in high risk level scum in WHO (1999, 2003) Kansas: https://www.kdheks.gov/algae-illness/index.htm
Utah	Danger – High Relative Probability of Acute Health Risks (Also 1 lower level tier)	Microcystin >2000	>10,000,000	<ul style="list-style-type: none"> Lake closed Keep out of the water 	Utah: https://deq.utah.gov/water-quality/harmful-algal-blooms-home

Links to cited documents:

NJDEP (2016) <https://www.state.nj.us/dep/wms/bfbm/download/NJHABResponseStrategy.pdf>

NYDEC (undated) http://www.dec.ny.gov/docs/water_pdf/habsprogramguide.pdf

USEPA (2019a) <https://www.epa.gov/sites/production/files/2019-09/documents/recommend-cyano-rec-water-2019-update.pdf>

USEPA (2019b) <https://www.epa.gov/sites/production/files/2019-05/documents/hh-rec-criteria-habs-document-2019.pdf>

WHO (2003) https://www.who.int/water_sanitation_health/publications/srwe1/en/